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Abstract 
Nearly 300,000 Australians and 200 million people throughout the world have been 
exposed to the hepatitis C virus (HCV). Furthermore, over 10,000 new infections are 
reported on an annual basis. HCV is associated with chronic disease leading to hepatic 
fibrosis that may progress to liver failure and cancer, and is a leading cause of chronic 
hepatitis, cirrhosis and hepatocellular carcinoma. Standard therapy using Pegylated 
interferon (PEG-IFN) and ribavirin leads to virus eradication in just ~50% of cases and is 
associated with significant toxicity; as such, more effective therapies are urgently required. 
Recently, licensed protease inhibitors that target viral proteins have been revealed to 
increase response rates to ~70%; however, a major challenge associated with the use of 
these inhibitors is that the fidelity of the viral replication machinery is notoriously low, 
thus enabling the virus to quickly develop resistant mutations. Strategies that target the 
host factors that support viral replication can potentially reduce the risk of these resistant 
mutations emerging. However, a major limitation associated with the design and 
development of such therapies is our limited understanding of the role the hepatocyte plays 
in virus replication. Understanding the molecular and biochemical pathways that are 
activated in infected cells will, therefore, provide a means of developing targets that can 
interrupt virus replication and thus ensure treatments are effective on a long-term basis. 
The process by which HCV modulates the global intracellular metabolism to create an 
environment that aids RNA replication and the production of progeny particles is currently 
unknown, especially at sub-cellular levels. Changes in the host lipoprotein expression 
levels can result in dramatic differences in the various fractions of the cells. The 
endoplasmic reticulum (ER) plays a central role in HCV replication: following infection, 
viral RNA is translated at the ER, where viral proteins induce membrane modifications, 
giving rise to the ‗membranous web‘. This web acts as a platform for the synthesis of HCV 
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RNA. Additionally, lipid droplets (LDs) have recently attracted a considerable amount of 
attention because a link has been established between the accumulation of LDs and human 
diseases such as obesity, atherosclerosis and HCV-associated liver malfunctions. Thus, 
understanding the interaction of HCV/host lipoproteins at ER and LD levels can provide 
more enhanced insights than simply studying the whole infected cells. 
 The data described in this paper describes global changes in lipid abundance that 
can potentially impact the HCV life cycle and pathogenesis. These changes were more 
predominant at the ER. These efforts have led to several novel observations that have a 
potential translational application in hepatology research. This paper describes, for the first 
time, how PEMT pathways can have therapeutic efficacy in both inhibiting the replication 
of HCV and increasing interferon sensitivity. HP-TLC showed increased amounts of 
phosphatidylcholine (PC) in lipid extracts from whole cells and ER fractions. PC was the 
only phospholipid species detected in purified LDs and was significantly increased in 
infected cells. PCYT (CTP:phosphocholine cytidylyltransferase) is the rate-limiting 
enzyme of the major pathway of PC biosynthesis in hepatocytes and PEMT 
(phosphatidylethanolamine N-methyltransferase) is the rate-limiting enzyme in the minor 
PC pathway. Silencing PCYT by siRNA had no effect on HCV replication or infectivity. 
However, when PEMT was silenced, both viral replication and infectivity were decreased 
by more than 50%. 
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ISRE                       Interferon-stimulated response element 
JFH1                       Japanese fulfillment hepatitis-1 
KO                          Knockout 
LC-MS/MS          Liquid chromatography and tandem mass spectrometry 
LD                          linkage disequilibrium 
LDL                       Low-density lipoprotein 
LDs                        Lipid droplets 
LPS                        Lipopolysaccharides 
LVPs                      Lipo-viro particles  
MAG                     Monoacylglycerol 
 XXI 
 
MAPK                   Mitogen-activated protein (MAP) kinase 
MBS                      Modified Barth's saline 
MHC                     Major Histocompatibility Complex class  
MTP                      Microsomal triglyceride transfer protein 
MW                       Membranous web 
Mx1                      Myxovirus (influenza virus) resistance 1 
NAFLD                 Non-alcoholic fatty liver disease 
NASH                   Non-alcoholic steatohepatitis 
NKC                      Natural killer cells 
OCLN                    Occluding 
ORF                      Open reading frame 
PA                        Phosphatic acid 
PAMT1                Protein arginine methyl transferase 1 
PBS                      Phosphate buffer saline 
PC                       Phosphatidylcholine 
PCYTCTP:phosphocholine cytidylyltransferase 
PE                       Phosphatidylethanolamine 
PEMT                  PhosphatidylethanolamineN-methyltransferase 
PI                        Phosphatidylinositol 
PI3K                   Phosphatidylinositol-3-kinase 
PMSF                 Phenylmethanesulfonylfluoride 
PPARα               Peroxisome proliferator-activated receptor alpha 
PS                      Phosphatidylserine 
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RIG-I                  Retonic acid-inducible gene I 
RIPA                  Radio-immunoprecipitation assay 
ROS                    Reactive oxygen species 
 XXII 
 
SAMe                 S-Adenosyl-Methionine 
SDS                    Sodium dodecyl sulfate 
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SOCS                   Suppressor of cytokine signal 
SR-BI                   Scavenger receptor B type I 
SREBP-1c            Sterol regulatory element-binding protein1-c 
STAT 1/2             Signal Transducers and Activators of Transcription 
SVR                     Sustained virology response 
T2DM                  Type 2 diabetes mellitus 
TAG                     Triacylglycerol 
TBST                   Tris-buffered saline and Tween 
TCA                     Trichloroacetic acid 
TCID50                Tissue culture infectious dose 50 
TCID50                Tissue Culture Infective Dose 
TEMED                Tetramethylethylenediamine 
TG                         Triglyceride 
TLRs                     Toll-like receptors 
VLDL                    Very-low-density lipoprotein 
Δ9-THC                Δ9-tetrahydrocannabinol  
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1. INTRODUCTION 
1.1 Hepatitis C Virus 
1.1.1 History of hepatitis C  
In the mid-1970s, Harvey J. Alter et al., demonstrated that most post-transfusion 
hepatitis cases were not the result of hepatitis A or B viruses. Despite this discovery, 
international research efforts to identify the virus that caused so-called non-A, non-B 
hepatitis (NANBH), failed over the course of the following decade. In 1988, the presence 
of a virus was confirmed by Alter in a panel of NANBH specimens (Alter & Prince 1988). 
In April 1989, the virus was cloned and characterised, and named hepatitis C virus (HCV) 
(Choo et al. 1989; Kuo et al. 1989). Significantly, it was the first virus to be identified by 
molecular means alone, rather than by virus culture. 
It is estimated that HCV has been associated with humans for over 1,000 years; 
however, there is little definitive evidence to support these claims. The estimated age of 
the most recent common ancestors of HCV was 1,500 years (95% CI: 1350-1700), 
suggesting that HCV was originally endemic in Central Africa, before spreading to other 
regions (Smith et al. 1997; Simmonds 2004; Ndjomou et al. 2003).          
1.1.2 Epidemiology  
HCV is recognized as a major threat to global public health. An estimated 170 
million people worldwide have been infected, most of whom are chronically diseased and 
at risk of liver cirrhosis and hepatocellular carcinoma (HCC) (World Health Organization 
2010). To be successful, HCV treatment, prevention and vaccination strategies must be 
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based on a sound understanding of the evolutionary and epidemiological behaviour of the 
virus, especially in those geographic regions that are most seriously affected (Figure 1.1). 
Nearly 300,000 Australians and 200 million people worldwide have been exposed 
to HCV, and over 10,000 new infections are reported on an annual basis. Chronic disease 
can lead to hepatic fibrosis that may progress to liver failure and cancer (Centre for 
Epidemiology and Research PHD, Hepatitis C 2009). 
 
Figure 1.1 Estimated prevalence of HCV infection around the world (World Health 
Organization 2010). 
 
1.1.3 Natural history of hepatitis C virus 
In people with chronic HCV infection, disease progression is variable; it leads to a 
slow but progressive deterioration of liver function in as many as 70% of affected 
individuals. Over time, 20% will develop cirrhosis and its related complications, and about 
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1% to 2% of subjects may develop hepatocellular carcinoma (HCC), after 2 to 3 decades 
of infection (Afdhal 2004; Alter et al. 1992; Seeff 2002)(Figure 1.2). 
 
Figure 1.2  Natural history of hepatitis C virus (Lauer & Walker 2001) 
 
The course of disease, either resolution or chronic infection, with varying degrees 
of hepatitis, seems to be controlled at the level of the host immune response to virus-
infected hepatocytes. The hallmark of HCV infection is the establishment of persistent 
viral infection, but the mechanisms of how this occurs remain unclear. 
Understanding how HCV establishes persistent infection is crucial for future 
strategies of controlling this disease. The mechanism of how this occurs remains unclear, 
but over the past decade, many mechanisms by which HCV may establish chronicity have 
been proposed (Bowen & Walker 2005). These mechanisms include virus-encoded anti-
host immune strategies, virus-induced immunologic tolerance, viral escape mutations, 
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molecular mimicry, and decreased effectiveness of antiviral cytokines. In recent years, 
experimental evidence suggests that virus-encoded, anti-host strategies play an essential 
role in establishment of persistent viral infection (Bowen & Walker 2005). 
Factors associated with development of chronicity: 
The factors most consistently associated with development of chronicity are age at 
time of infection and immune status at time of exposure (Bowen & Walker 2005). 
Regarding mode of transmission, earlier studies of blood donors, transfusion recipients, 
and adults acquiring infection through injection drug use reported chronicity rates of 76% 
to 86%.  In contrast, only 55% to 71% of children infected through contaminated blood 
were persistently infected 15 to 20 years later (Alter 1997; Bialek & Terrault 2006). 
Neither size of inoculum nor modes of HCV acquisition have been linked consistently with 
likelihood of achieving viral clearance after exposure or severity of chronic disease. 
Racial differences in rate of spontaneous clearance of HCV are suggested by 
studies showing higher rates of HCV RNA positivity in anti-HCV-positive African 
Americans and Asian Americans than in white Americans (Busch et al. 2006; Piasecki et 
al. 2004). Recent findings indicate that polymorphisms near the interleukin-28B (IL28B) 
gene explains approximately half of the observed differences in spontaneous clearance 
rates and treatment response between African American and white patients (Thomas et al. 
2009). 
Studies investigating the impact of HCV genotype on the progression of chronic 
hepatitis C (CHC) have yielded conflicting results. Most investigators failed to identify 
genotype as an indicator of likely progression (Roffi et al. 1998; De Moliner et al. 1998), 
but a few reports suggest a possible association between genotype 1b and rapid disease 
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progression (Harris et al. 2007). These conflicting results reflect the difficulty in 
conducting long-term prospective or prospective/retrospective studies, using well-
characterized cohorts, to assess the natural history of HCV infection, given the protracted 
course of disease progression. 
Recent genome wide array studies (GWAS) have examined the influence of human genetic 
variations on clearance of HCV infection. These studies identified several polymorphisms 
near the IL28B gene that affected both natural and treatment-induced clearance of HCV 
infection. The two most commonly reported polymorphisms are rs12979860 and 
rs8099917 (Suppiah et al. 2009; Ge et al. 2009; Tanaka et al. 2009). These single 
nucleopeptide (SNPs) were in strong linkage disequilibrium (LD) with each other, that is, 
genotypes based on these SNPs were highly correlated and, as a result, provided very 
similar genetic associations. Subsequent reports confirmed these findings and showed  
that these SNP markers were also associated with the likelihood of spontaneous HCV 
clearance (Thomas et al. 2009; Rauch et al. 2010). A similar effect of the same genetic 
marker (rs8099917, located near the IL28B gene) for The lowest carriage frequency of the 
risk allele (24%) was observed among persons with spontaneous clearance and increased 
to 32% among chronically infected patients who responded to treatment and to 58% 
among chronically infected patients who failed to respond (Thomas et al. 2009; Rauch et 
al. 2010; Ge et al. 2009). Although both are probably really markers of the IFNL4 
polymorphism (Prokunina-Olsson et al. 2013). The rs12979860 polymorphism is the most 
commonly used clinically (O‘Brien et al. 2014), is known as the ―Duke‖ SNP as it was 
identified in Ge et al paper. 
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1.1.4 Modes of transmission of HCV 
1.1.4.1 Injecting drug use  
Injection drug use is the most common mode of HCV transmission in the USA; the 
proportion of acute cases who reported injecting drug use increased from 31% in 1994 to 
38% in 1999 to 45% in 2003 (Armstrong et al. 2006). The prevalence of HCV infection 
among injection drug users (IDUs) has been shown to be nearly 88% (Mateu-Gelabert et 
al. 2014). A recent meta analysis suggests that for patients who contracted HCV through 
injecting drug use, prognosis is poor (John-Baptiste et al. 2010). The key factors associated 
with an decreased rate of progression were the high proportion of male patients among 
IDU and the high proportion with excessive alcohol consumption (John-Baptiste et al. 
2010). 
1.1.4.2 Transfusion of blood and blood products 
Historically, transfusion of blood and blood products played an important role in 
epidemiology of HCV infection. Transfusion associated hepatitis declined as a result of 
deferral of high risk blood donors and testing donated blood for anti-HCV antibodies 
(Alter et al. 1992). In many countries HCV RNA is also tested for, further increasing the 
sensitivity of blood supply screening. 
1.1.4.3 Sexual transmission  
Medical opinion varies considerably regarding the likelihood of transmitting HCV 
through sexual contact; based on the study design, representativeness of the study 
population, and the methods used for case ascertainment. A recent review analyzed 80 
qualifying reports regarding the evidence for or against sexual transmission (Terrault et al. 
2013); regarding heterosexual transmission, the weight of evidence is that there is no 
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increased risk of sexual transmission of HCV among heterosexual couples in regular 
relationships. This risk increases among persons with multiple sexual partners (adjusted 
odds ratio [aOR] 2.2-2.9), however, this association may be confounded by increased 
likelihood of injection drug use with increased number of partners (Tohme & Holmberg 
2010). Additionally, there is good evidence that HCV can be transmitted sexually among 
men who have sex with men (MSM) (Nguyen et al. 2010; L et al. 2013), and even higher 
rates in those who are HIV positive (Kouyos et al. 2014). 
1.1.4.4 Perinatal transmission 
The risk of HCV transmission to infants born to a high titer HCV RNA–positive 
mothers range from 4.6 to 10%. The risk increase two to seven fold for infants born to 
HCV-HIV coinfected mothers than for children born to mothers infected with HCV alone. 
Because maternal antibodies may remain detectable in the uninfected infant for more than 
1 year, anti-HCV testing is not recommended before age of 18 months (Mast et al. 2005; 
Indolfi & Resti 2009). 
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Figure 1.3  Mode of transmissionof hepatitis C virus (Aceijas & Rhodes 2007).However, 
the route of transmission varies from country to country, for example in some Middle East 
countries nosocomial spread is higher. 
 
 
1.1.5 Virology 
1.1.5.1 HCV genome organization 
HCV was first isolated in 1989 and belongs to the Hepacivirus genus of the 
Flaviviridae family. The HCV genome is 9.6 kb of single-stranded positive sense RNA, 
which is packaged into an enveloped virus particle.. Its genome encodes one open reading 
frame flanked at each end by conserved untranslated regions (UTRs) (Choo et al. 1991). 
These UTRs are highly structured and critically important for viral replication (Moradpour 
et al. 2007).The 5‘ untranslated region (UTR) harbors an internal ribosome entry site 
(IRES) where translation of a 3000 amino acid precursor polyprotein of HCV coding 
region is initiated; which is both co- and post-transnationally cleaved at the endoplasmic 
reticulum (ER) membrane by host and viral proteases into 3 structural (core, E1, and E2) 
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and 7 nonstructural proteins (p7, NS2, NS3, NS4A, NS4B, NS5A, NS5B) (Figure 1.4) 
(Otto & Puglisi 2004; Lindenbach & Rice 2005). Discussing the role of core protein is of 
relevance, as it is particularly interferes with cellular lipid distribution and metabolism. 
The core protein is a small protein of 21 kDa which is converted into its mature form by 
successive cleavages (Kato, Miyamoto, et al. 2003; McLauchlan et al. 2002). This process 
occurs by removal of Domain 3 by signal peptide peptidase (Kato, Miyamoto, et al. 2003); 
the mature core protein is thus composed of only two domains (1 and 2). The N-terminal 
region of the core (Domain 1) is highly basic and probably contributes to viral genome 
encapsidation, through interaction with the 3'-UTR (Ivanyi-Nagy et al. 2008).  
Domain 2 targets the core protein to the cellular membrane and cytoplasmic lipid droplets 
(McLauchlan 2009). Domain 2 is organised into two amphipathic alpha-helices (Boulant et 
al. 2005) and contains a cysteine that is palmitoylated, leading to membrane targeting 
(Majeau et al. 2009).   
The core protein also seems to be involved in HCV-induced liver dysfunction, 
through a series of molecular events (Giannini & Bréchot 2003). The core protein interacts 
with a variety of proteins implicated in signal transduction (e.g. NF-κB may be involved in 
the control of cell viability) (Giannini & Bréchot 2003; Rui & Goodnow 2006). 
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Figure 1.4  The HCV genome and expressed polyprotein. 
The HCV genome is composed of an open reading frame (ORF) flanked by 5‘ and3‘ 
untranslated regions (UTRs). IRES-mediated translation of the ORF leads to the formation 
of a polyprotein that is processed into 10 viral proteins. Cleavage of the core protein from 
E1 involves cellular signal peptidases, which also cleave E1, E2, and p7 from the 
polyprotein (pink arrows). The NS2–NS3 protease auto-cleaves itself (green arrow). The 
NS3 protease located in the first one-third of NS3, assisted by its membrane-bound 
cofactor, NS4A, cleaves the remaining proteins NS3, NS4A, NS4B, NS5A,  and NS5B 
(violet arrows). ( adapted from: Abdel-Hakeem & Shoukry 2014). 
 
 
1.1.5.2 Hepatitis C Virus Genotypes 
Based on genome analysis HCV is divided among six genotypes with numerous 
subtypes (Figure 1.5)(Pawlotsky & Gretch 1998; National Institutes of Health Consensus 
Development Conference Statement 2002).These genotypes can differ up to 30% from 
each other in nucleotides(Sy & Jamal 2006). Within HCV genotypes, several subtypes 
(designated a, b, c and so on) that differ in their nucleotide sequence by 20–
25%(Simmonds et al. 2005). Although HCV is endemic worldwide, there is a large degree 
of geographic variability in genotypes distribution (Table 1.1). Even though infection with 
all HCV genotypes can progress to chronic liver disease, genotype-specific differences in 
the natural history of the disease may exist. For example, type 2 diabetes mellitus is 
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strongly associated with HCV genotypes 1 (Douglas & George 2009) and genotype 3 have 
been found to induce steatosis (Cross et al. 2010; Hui, Kench, Farrell, Lin, D. E. V 
Samarasinghe, et al. 2002). Moreover the efficacy of the standard treatment with ribavirin 
and pegylated interferon depends on the genotype, with infection with either genotype 1 or 
4 leading generally to a poorer treatment response than infection with genotype 2 or 3 
(Eriksen et al. 2010). 
 
Table 1.1: Geographic locations HCV genotypes.  
Genotype Location 
Genotypes 1, 2 and 3 Australia, North America and Western Europe 
Genotype 4 Africa, Egypt and the Middle East, but is increasingly seen 
in some parts of Europe 
Genotype 5 Africa and the Middle East 
Genotype 6 Southeast Asia 
Genotype 7 Central Africa 
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Figure 1.5  Phylogenetic tree of HCV types (Great Heterogeneity Is Now Appreciated) 
(Simmonds et al. 2005). 
 
 
1.1.5.3 HCV life cycle 
For a long time, it has been difficult to study HCV life cycle because of the 
difficulties in propagating this virus in cell culture. However, the development of a cell 
culture system that enables a relatively efficient amplification of HCV provides a powerful 
new tool for researching HCV (Kato, Date, et al. 2003; Zhong et al. 2005; Wakita, 
Pietschmann, Kato, Date, Zhao, et al. 2005). This system is based on the transfection of the 
human hepatoma cell line Huh-7 with genomic HCV RNA derived from a cloned viral 
genome of a HCV isolate from a Japanese patient with fulminant hepatitis (JFH). Data 
obtained with the culture system begin to shed light on the HCV life cycle. 
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The HCV structural proteins and the receptor molecules at the surface of target 
cells are involved in the early entry of viral particles. E1 and E2 glycoprotein are necessary 
for viral entry and fusion (B. Bartosch et al. 2003). Viral attachment is thought to be 
initiated via E2 interaction with one or more components of the receptor complex (Flint & 
McKeating 2000). In the other hand cell surface receptors like cell surface 
Glycosaminoglycans, Human CD81, Low density lipoprotein (LDL) receptors, Scavenger 
receptor B type I (SR-BI ), Claudin-1, and  different co-receptors  molecules have been 
showed to mediate HCV binding to host cell (Barth et al. 2006; J. M. Pawlotsky et al. 
2007).  
Up on the infection of the host cell, HCV particles are taken up by receptor-
mediated endocytosis and trafficked in endosomes, where the low pH of these 
compartments induces fusion of the viral envelope and pounding endosomal membrane. 
The nucleocapsid is then uncoated to release the virus genome into the cytoplasm to serve 
as a mRNA for syntheses of the viral proteins, where it can be directly translated into 
structural and non-structural proteins. In an early step of viral replication the IRES located 
in the 5‘ UTR of the viral genome regulates translation of HCV open reading frame that 
encodes a unique polyprotein by recruiting both cellular and viral proteins (Otto & Puglisi 
2004), the post translated protein is targeted to the endoplasmic reticulum (ER) membrane 
where it is further processed by host and viral peptidases to yield out a 10 structural and 
non-structural proteins. Viral non-structural proteins and host factors assemble in 
cytoplasmic membrane-bound RNA replicase, which then recruits the HCV genome out of 
translation into replication (Pawlotsky et al. 2007). After RNA synthesis, new viral 
genome can be recycled back into translation and replication or packed by viral structural 
proteins into nascent viral particles. A hallmark of the HCV replication cycle is its 
extraordinary dependence on host cell lipids. Several studies have shown that viral RNA 
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replication is tightly linked to lipid synthesis pathways and sensitive to pharmacological 
intervention with statins and certain fatty acids (Figure 1.6)(Kapadia & Chisari 2005). 
 
 
 
Figure 1.6 HCV life cycle. 
Following initial binding of the hepatitis C virus (HCV) particle to scavenger receptor 
class B member 1 (SRB1) and CD81, the particle engages in further interactions with the 
tight junction proteins claudin 1 (CLDN1) and occludin (OCLN) and finally enters cells by 
receptor-mediated endocytosis (step 1). The viral RNA genome is released into the 
cytoplasm and translated at the rough ER (step 2). Viral proteins, in conjunction with host 
cell factors, induce the formation of a membranous web (MW)) composed of single-, 
double- and multi-membraned vesicles as well as lipid droplets (LDs) (step 3). RNA 
replication occurs at an unspecified site within the membranous web (step 4). Assembly of 
HCV particles probably initiates in close proximity to the ER and lipid droplets, where 
core protein and viral RNA accumulate. The viral envelope is acquired by budding through 
the ER membrane in a process that is linked to lipoprotein synthesis (step 5). HCV 
particles are released via the constitutive secretory pathway (step 6). CYPA, cyclophilin A; 
PtdIns4KIIIα,_phosphatidylinositol 4-kinase IIIα ( adabted from: Bartenschlager et al. 
2013). 
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1.2 Role of lipids in the HCV life cycle 
There is increasing evidence that cellular lipid pathways are fundamentally 
involved in the replication cycle of HCV:  
1- HCV circulates in plasma with lipoproteins as an infectious complex. 
2- Lipoprotein hepatocyte receptors are involved in HCV entry. 
3- Replication of HCV RNA in hepatic cells is inhibited by inhibitors of lipid 
metabolism. 
4- HCV is released from hepatocytes with lipoproteins.   
1.2.1 HCV circulates in plasma with lipoprotein as an infectious complex 
HCV exhibits molecular heterogeneity and the characterization of HCV particles 
from the plasma of infected patients shows a highly heterogeneous population of viruses 
(buoyant density <1.03-1.25 g/ml). HCV circulates in the bloodstream in different forms; 
either free or in a complex with immunoglobulin or lipoprotein to form the so-called lipo-
viro particles (LVPs). Implicated lipoproteins by density are very-low-density lipoprotein 
(VLDL), intermediate-density lipoprotein (IDL), or low-density lipoprotein (LDL) 
(Monazahian et al. 2000). HCV RNA is always found in at least one of these fractions and 
represents 40% of the total plasma HCV RNA, but can reach up to 95% in some patients 
(Andre et al. 2002). 
The low-density infectious particles are roughly spherical with a heterogeneous 
diameter of 50-150 nm. Their structure is rich in triglycerides, apolipoprotein B-100 
(APOB), and apolipoprotein E (APOE), and physio-chemically resemble VLDL particles 
(André et al. 2002). The association of ApoC1 with infectious particles in the serum of 
experimentally infected chimpanzees has also been documented (Meunier et al. 2008).  
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Interestingly, these particles typically contain ApoB100 (Fisher & Ginsberg 2002), which 
is of hepatic origin and an integral part of VLDL (Zannis et al. 2001). However, the 
presence of ApoB48, normally produced by enterocytes, suggests that a proportion of 
circulating LVPs may originate not only from the liver but also from the intestine (Diaz et 
al. 2006). 
 
The first report of an association between HCV core protein and lipid structures 
was made using an inducible expression system (Moradpour et al. 1996). Now, multiple 
studies have suggested that lipoproteins play a critical role in the infectivity of natural 
HCV, and also that apolipoproteins may be efficient regulators of HCV infectivity:  
a) Most circulating HCV particles are of low density due to association with B-lipoproteins 
(Thomssen et al. 1992; Thomssen et al. 1993). Only the very low density fraction of 
serum-derived HCV (sHCV) was highly infectious in chimpanzees (Beach et al. 1992), 
tissue culture (Lindenbach et al. 2006), and in natural human infections (Diaz et al. 2008), 
in contrast to high-density populations of HCV which are poorly infectious (Agnello et al. 
1999). Measurement of low density apolipoprotein B associated LVP in HCV genotype 1 
infection was better correlated with more advanced fibrosis and poorer treatment response 
than total viral load. In these patients; insulin resistance and associated dyslipidaemia were 
the major determinants of low-density apoB-associated LVP in fasting plasma (Bridge et 
al. 2011). 
b)In 2006 data by Lindenbach et alprovided evidence that the specific infectivity of cell 
culture-produced HCV (HCVcc) produced in vitro and recovered from experimentally 
infected chimpanzees or uPA-SCID mice with human liver grafts was higher and buoyant 
density was lower than those of the same virus strain produced in cell culture (Lindenbach 
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et al. 2006). Thus, the association between virus particles and lipoproteins may confer 
higher viral infectivity (Lindenbach et al. 2006).  
c) HCVcc infection in vitro could be efficiently inhibited not only by antibodies directed 
against the HCV envelope but also by antibodies against ApoB-containing lipoproteins 
(Andréo et al. 2007). 
 
1.2.2 Lipoprotein hepatocyte receptors are involved in HCV entry 
Two lipoprotein receptors on hepatocytes are known to be of the receptors 
components that mediate viral entry: SR-B1 and LDL-R (Scarselli et al. 2002). SR-B1 is a 
lipoprotein receptor, with the highest levels found in the liver and adrenal glands, which is 
responsible for the selective uptake of cholesteryl ester from high-density lipoprotein 
(HDL) (Out et al. 2004). As HCV particles have been reported to be complexed with 
lipoproteins, it is possible that HDL interacts with HCV particles, via protein/protein or 
lipid/protein interactions (Bartosch et al. 2005), suggesting an indirect interaction of virus 
with lipoprotein receptors (Maillard et al. 2006; Nielsen et al. 2006). Previous observations 
implicated SR-B1 as an important receptor for infection by different HCV subtypes and 
supporting this hypothesis is the fact that the same SR-B1 protein element is responsible 
for the recognition of different HCV E2 glycoproteins, despite the high level of variability 
in their amino acid sequences, especially in the hyper-variable region 1 (HVR1) previously 
shown to interact with SR-B1 (Birke Bartosch et al. 2003). 
HCV appears to use SR-BI during cell entry not merely as an additional site for 
viral particle binding, but also by exploiting its physiological activity, i.e. the capacity to 
mediate lipid transfer from HDL, which is known to facilitate the entry of many different 
viruses, including influenza virus, HIV, and HCV (Voisset et al. 2005; Rhainds &Brissette 
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2004). However, HCV is many times more sensitive to HDL-mediated infection 
enhancement than other cholesterol-sensitive viruses (Voisset et al. 2005). Therefore, 
enhancement of HCV infection might be dependent on the lipid exchange activity of SR-
B1 (Bartosch et al., 2005). Recently, a novel function of SR-B1 for viral antigen uptake 
and recognition has been suggested; SR-B1 may represent a cell-surface receptor for the 
recognition of viral antigens and has been implicated in trafficking exogenous viral 
antigens toward the Major Histocompatibility Complex (MHC) presentation pathway. The 
SR-B1-viral antigen interaction may represent a novel target for therapeutic or preventive 
strategies, aiming to induce an efficient antiviral immune response (Barth et al. 
2008).Moreover, HDL with SR-B1 is the predominant enhancing factor in infectivity and 
the presence of HVR1 with HDL protects HCV from neutralizing antibodies as HDL can 
reduce the neutralizing effect of anti-HCV antibodies (Dreux et al. 2006; Voisset et al. 
2006).This phenomenon might be responsible, at least in part, for the limited ability of the 
humoral immune response to control HCV infection in vivo, which raises concerns about 
the potential for using anti-HCV antibodies for active or passive immunotherapy (Dustin 
& Rice 2007). 
Thus, as an alternative to the development of anti- HCV antibodies, one could 
consider anti-SR-B1 human monoclonal antibodies capable of interfering with HCV 
infection as potential therapeutic leads (Catanese et al. 2007). Agents involved in 
modulating the normal hepatocellular processes of lipid transport have been reported to 
have pleiotropic effects on HCV infectivity. Antibodies to ApoB have been shown to have 
antiviral activity (Maillard et al. 2006; Andréo et al. 2007; Dreux & Cosset 2007).  
1.2.3 Cellular Lipids and HCV replication  
Replication of HCV, like all positive-strand RNA viruses, occurs in association 
with cytoplasmic membranous vesicles (Miller & Krijnse-Locker 2008). Proteomic 
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analysis of these membrane vesicles recently showed that they are enriched in several 
proteins involved in lipid metabolism and lipoprotein generation (i.e., apoB-100, 
Microsomal triglyceride transfer protein (MTP), apoE and Acyl-coA synthetase 3 
(ACSL3) (Huang et al. 2007).  
Acute HCV infection in chimpanzees is associated with an increased intrahepatic 
expression of genes involved in lipogenesis (Su et al. 2002) such as the ATP citrate lyase, 
an enzyme activated by the transcription factor sterol-responsive element binding protein 
(SREBP) (Su et al. 2002). This suggests possible links between viral replication and 
lipobiogenesis.  
 
Cholesterol: 
Viral RNA replication has been shown to be dependent on cholesterol, 
sphingomyelin and fatty acid synthetic pathways, which promote the formation of lipid 
rafts on which replicase complexes assemble (Kapadia & Chisari 2005; Amemiya et al. 
2008; Tai et al. 2009). Cholesterol metabolism pathways are now known to impact on 
HCV replication, secretion, and entry (Ye 2007). 
Cholesterol can be synthesized from acetyl-CoA via the mevalonate pathway (Goldstein & 
Brown 1990), which also generates several isoprenoids, including farnesyl and 
geranylgeranyl lipids that are covalently attached to the COOH-terminus of certain 
proteins (Zhang & Casey 1996). Cells can also acquire LDL–associated cholesterol in 
serum through LDL-receptor–mediated endocytosis (Goldstein et al. 1985). 
The first clue that the mevalonate pathway is involved in HCV RNA replication 
was the finding that treatment of cultured cells with lovastatin inhibited HCV RNA 
replication (Ye et al. 2003). Lovastatin is a cholesterol-lowering drug that inhibits 3-
hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, the rate-limiting enzyme in 
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the entire mevalonate pathway (Goldstein & Brown 1990). These results were 
subsequently confirmed by others (Kapadia & Chisari 2005; Ikeda et al. 2006; S. S. Kim et 
al. 2007). 
Geranylgeranyl lipid was found to be the essential product of the mevalonate 
pathway required for HCV RNA replication, as inhibition of HCV RNA replication by 
lovastatin was overcome by the addition of geranylgeraniol, but not farnesol or cholesterol 
(Kapadia & Chisari 2005; Ye et al. 2003). Geranylgeranyl lipid serves as a lipid substrate 
for protein geranylgeranylation, a post-translational modification that covalently attaches 
geranylgeranyl to various cellular proteins to facilitate their membrane association (Zhang 
& Casey 1996). Thus, it appears that one or more geranylgeranylated proteins are required 
for HCV RNA replication. 
Recently; F-box and leucine-rich repeat-containing protein 2 (FBL2), which 
contains an F-box domain and a COOH-terminal Cys-A-A-X sequence (CAAX box) motif 
was identified as a cellular partner for the HCV nonstructural protein NS5A (Wang et al. 
2005). FBL2 is localised to cellular membranes through geranylgeranylation by the 
geranylgeranyl transferase I; which is an enzyme of the mevalonate pathway, which 
governs cholesterol synthesis. This concept is further supported by the observation that 
HCV replication could be blocked by an inhibitor of geranylgeranyl transferase I (Ye et al. 
2003), an enzyme that transfers geranylgeranyl groups to cellular proteins (Zhang & Casey 
1996). Therefore, FBL2 could indirectly influence VLDL formation and promote the LVPs 
release. It should be noted that all of the aforementioned studies used genotype 1 HCV 
replicons. It is not known whether geranylgeranylation of host proteins is required for 
replication of other genotypes of HCV. 
 
Chapter 1: General Introduction 
 
21 
 
Unlike geranylgeranyl, the requirement of cholesterol per se for HCV RNA 
replication is still an area of debate due to the controversial available data. The observation 
that addition of cholesterol failed to rescue HCV RNA replication in the presence of 
lovastatin argues against cholesterol being directly involved in HCV RNA replication (Ye 
et al. 2003). On the other hand, inconsistent findings were obtained when cells were 
depleted of cholesterol by treatment with methyl-β-cyclodextrin, which directly extracts 
cholesterol from cell membranes (Kilsdonk et al. 1995). Under these conditions, HCV 
RNA replication is either not affected (Kapadia et al. 2007) or reduced by 50% (Aizaki et 
al. 2004). The inconsistency in these results could arise from a secondary effect of general 
cellular toxicity that occurs when cells are depleted of cholesterol, or from a difference in 
the HCV genotype used in these studies. 
 
Fatty Acids: 
In addition to being cholesterol precursors, fatty acids can also directly modulate 
(stimulate or inhibit) HCV replication. HCV infection takes control of cellular metabolism 
and drives, among other things, marked increases in fatty acid synthesis. Fatty acids can be 
used as prosthetic groups in exactly the same way as cholesterol intermediates. These 
prosthetic groups may facilitate viral non-structural protein anchoring to the specialised 
membrane structures that serve as the platform for HCV RNA replication and assembly. 
For example, Yu et al, have provided evidence that NS4B under goes a double 
palmitoylation on two cysteine residues (cysteines 257 and 261) located at the C-terminal 
end (Yu et al. 2006). Site-specific mutagenesis has shown that these lipid modifications, 
especially of the last cysteine residue (Cys261) have an additive effect on HCV replication 
and protein-protein interactions (Yu et al. 2006). Thus, palmitoylation may be a kind of 
post-translational modification essential to the HCV life cycle and may also play a role in 
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HCV pathogenesis. Moreover; inhibitors of palmitoylation also inhibited HCV replication 
(Yu et al. 2006). 
Interestingly, the effect of fatty acids seems to depend on their degree of saturation 
(Kapadia & Chisari 2005). Saturated and monounsaturated fatty acids stimulate HCV 
replication (Kapadia & Chisari 2005). In contrast, polyunsaturated fatty acids, including 
arachidonic acid, docosahexaenoic acid and eicosapentaenoic acid, inhibit it (Leu et al. 
2004). Inhibition of fatty acid synthase (FAS) by cerulenin (Su et al. 2002) or C75 (Yang 
et al. 2008) blocks HCV replication in a subgenomic replicon system and the secretion of 
virions in the JFH1 infectious system.  
In patients with CHC even though there are many circumstances where the uptake 
of fatty acids by hepatocytes may be pathologically increased, such as in the insulin-
resistant state (Browning & Horton 2004), there is clear experimental evidence that HCV 
can directly perturb lipid metabolism. Diamond and co-workers in a recent global 
proteomic and metabolomics profiling study provide important evidence that HCV directly 
reprograms numerous metabolic pathways and modulates accumulation of select lipid 
species in the infected human hepatocytes (Diamond et al. 2010). Specifically, they 
identified two novel proteins essential for HCV-induced metabolic reprogramming, the 
mitochondrial fatty acid oxidation enzymes dodecenoyl-CoA delta isomerase (DCI) and 
hydroxyacyl-CoA dehydrogenase beta subunit (HADHB) (Diamond et al. 2010). 
Interestingly, an altered abundance of these enzymes has also been observed in liver 
biopsies from CHC patients, suggesting that beta-oxidation, the major process by which 
fatty acids are oxidized influences HCV persistence not in the experimental level only but 
in the clinical setting, as well (Diamond et al. 2010). Recent studies have examined the 
mechanisms by which enzymes involved in fatty acid oxidation influence HCV replication 
in hepatocytes, either by targeted gene silencing or pharmacologic inhibitors. These studies 
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have confirmed that impairing fatty acid oxidation adversely impacts HCV growth 
(Rasmussen et al. 2011), providing a stimulus for new approaches to targeting host 
metabolic factors (Rasmussen et al. 2011).  
In another evidence, during early stages of primary infection in chimpanzees, HCV 
activates genes involved in lipid metabolism, via SREBP (Su et al. 2002). Further, using a 
cell culture based model, Kim and coworkers (K. H. Kim et al. 2007) have shown that 
HCV is able to induce transcriptional activation, proteolytic processing and 
phosphorylation of SREBP-1, thereby causing the increase of fatty acid synthesis. Waris et 
al show that in vitro, in addition to SREBP-1c, HCV induces transcriptional activation of 
SREBP-2. SREBP-1c and SREBP-2 are, responsible for the transactivation of enzymes 
involved in the synthesis of fatty acids and cholesterol, respectively (Waris et al. 2007a).  
SREBP activity is stimulated in vitro by several viral proteins including the HCV core 
protein (Rasmussen et al. 2011; K. H. Kim et al. 2007) and the non-structural proteins 2 
(Oem et al. 2008), 5A (Xiang et al. 2010) and 4B (Waris et al. 2007a; Park et al. 2009). 
Activation of SREBP and numerous enzymes implicated in lipidogenesis has also been 
reported in transgenic mice expressing various HCV proteins (Chang et al. 2008; Lerat et 
al. 2009). 
It worth mention that in the subgenomic HCV replicon system it was shown that 
25-hydroxycholesterol, which inhibits SREBP cleavage/translocation, causes not only a 
decrease in fatty acid biosynthesis but also in HCV replication (Su et al. 2002). In contrast 
to these findings, activation of the SREBP pathway by nystatin, which acts through 
cholesterol sequestration, caused a dose-dependent increase in replication levels by nearly 
100% (Su et al. 2002).  
Our group previously made the novel observation that cannabinoid receptor 1 
(CB1) is widely expressed in the livers of patients with CHC and is associated with 
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advanced fibrosis and steatosis, providing another important link between HCV and lipids 
(van der Poorten et al. 2010). CB1 is an important regulator of lipid metabolism in the 
liver, and it has been show that treating mice with a CB1 agonist induces de novo fatty 
acid synthesis, via increased hepatic expression of SREBP-1c and its downstream targets 
fatty acid synthase and acetyl coenzyme-A carboxylase-1 (ACC1) (Osei-Hyiaman et al. 
2005). We have now shown that CB1 antagonists inhibit HCV replication in the liver 
(Shahidi et al. 2014).  
In contrast to the in vitro data, there is very little data available on the expression 
level of SREBP in the liver of CHC patients and liver histology. The available data suggest 
an association between the activation of SREBP-1c and the severity of inflammation and 
fibrosis, but not steatosis (McPherson et al. 2008). Similarly, intrahepatic levels of FAS 
mRNA were not correlated with steatosis (McPherson et al. 2008). However, in two more 
recent studies FAS mRNA has been reported to be increased (Diamond et al. 2010; 
Nakamuta et al. 2009). Further well designed large-scale studies are required, before we 
can elucidate a final conclusion.  
Beside activating SREBP, the HCV core protein may also bind to and activate the 
DNA-binding domain of the retinoid receptor α, a transcriptional regulator that controls 
many cellular functions including cellular lipid synthesis (Fukasawa et al. 2006). Enzymes 
responsible for fatty acid synthesis such as acetyl-coA carboxylase and FAS are, indeed, 
strongly activated by the expression of viral proteins in vitro (Jackel-Cram et al. 2007).  
 
1.2.4 Lipids and HCV Assembly and Secretion 
The development of a cell culture system that supports not only HCV replication 
but also the production of infectious virus has revealed additional roles for lipid 
metabolism in viral particle assembly, secretion and infectivity. Circumstantial evidence 
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suggests that HCV virions and VLDL particles share a common route of secretion, and 
reagents that abrogate VLDL secretion also block HCV secretion. Triglyceride-rich 
VLDL, the main lipoprotein component of HCV in patient sera, is produced and secreted 
by hepatocytes. VLDL assembly occurs in two steps: the first step involves the co-
translational lipidation of APOB-100 by MTP in the lumen of the ER which transfers 
triglycerides to nascent ApoB-100 (Hussain et al. 2003). Unlipidated APOB-100 is 
targeted for degradation by the ubiquitin proteasome machinery (Hussain et al. 2003; 
Shelness & Ledford 2005). This ApoB-containing VLDL precursor (pre-VLDL) 
subsequently fuses with triglyceride droplets during the second maturation step, a process 
also mediated by MTP (Shelness & Ledford 2005; Sellers & Shelness 2001). Although the 
exact mechanism and intracellular location (ER, post-ER or Golgi) of this second 
lipidation event are still uncertain, it appears to be dependent on the GTP binding protein 
ARF-1 (ADP ribosylation factor-1) and phospholipase D (Workman 2004).  
Recent studies show that ApoB remains associated with infectious HCV particles after 
treatment of the virus with either deoxycholic acid or NP-40, providing evidence that 
HCV-associated lipoproteins are not simply adsorbed at the surface of virus particles 
circulating in patient sera, but that VLDLs are an integral part of HCV particles, with 
strong binding between HCV and ApoB-containing lipoproteins (Nielsen et al. 2006). 
In addition, reagents that impair VLDL assembly (such as MTP inhibitors or siRNA 
targeting ApoB or ApoE) also abrogate HCV secretion, but do not affect HCV RNA 
replication per se (Nahmias et al. 2008; Yao & Ye 2008; Huang et al. 2007). These data 
provide further evidence that functional components of VLDL assembly and secretion are 
required by HCV for its secretion (Huang et al. 2007). Consistent with these observations, 
the density of intracellular virus particles in the HCV cell culture model was much higher 
than that of secreted virus (Gastaminza et al. 2008). As well as inhibiting virion secretion, 
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disruption of ApoB biosynthesis also resulted in reduced accumulation of intracellular 
infectious virions, suggesting that intracellular ApoB levels function as a major 
determinant of HCV virion morphogenesis (Gastaminza et al. 2008). Colocalization of 
HCV replication and VLDL assembly components indicate close proximity between the 
intracellular regions involved in virus genome replication and virion assembly (Huang et 
al. 2007). The property that makes the virus unique is that the entire virion is not exposed 
to serum during circulation and virus particles have to escape from VLDL-derived 
lipoprotein particles in endocytic vesicles.  
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Figure 1.7Possible host factor sites to target as novel antiviral strategies 
(1) Inhibition of HCV entry by anti-receptor antibodies; (2) Interference with the host 
metabolic factors involved in HCV replication; (3) Modulation of nuclear receptors 
involved in HCV replication; (4) Inhibition of HCV release. LDL-R: Low density 
lipoprotein receptor; HDL: High density lipoprotein; VLDL: Very low density lipoprotein; 
SRB-1: Scavenger receptor B1; FXR: Farnesoid X receptor; ER: Estrogen receptors; MTP: 
Microsomal triglyceride protein; HMG-CoA: 3-hydroxy-3-methylglutaryl coenzyme A. 
(Khattab 2009). 
 
 
 
1.3 The role of the endoplasmic reticulum (ER) in HVC replication 
 The ER plays an essential role in multiple stages of HCV replication (Fig 1.8) 
including (I) initial translation of viral RNA; (II) formation of the membranous web; (III) 
production of lipid droplets on which virus is assembled and (IV) processing and export of 
mature virus. As with other positive strand RNA viruses (such as Dengue), HCV induces 
morphological membrane modifications to form double membrane vesicles (DMVs) that 
serve as the platform for virus replication (Shi et al. 2003; Hagemeijer et al. 2012). 
Although of crucial importance, little is known about how these vesicles are formed. HCV 
infection also induces lipid synthesis to produce larger lipid droplets, often leading to 
steatosis in patients with HCV infection (Kumar et al. 2005), and the ER is the primary 
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site for lipid synthesis. Hence, many of the factors involved in VLDL biogenesis and 
secretion through the ER pathway are also necessary for virus formation and export. 
Considering the importance of the ER in establishing the HCV replication complex and 
export of viral particles, we will quantitatively assess the changes induced in this organelle 
in response to HCV infection. Such information concerning these fundamental 
mechanisms is critical to the design of new therapeutic interventions.                                                                                     
 
 
Figure 1.8 Life cycle of HCV showing the involving the ER(Herker & Ott 2012). 
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1.4 HCV and lipid abnormalities 
1.4.1 HCV and fatty liver 
Disruption of lipid metabolism during chronic HCV infection could contribute to 
the initiation of steatosis, or fatty liver (Mori et al. 2008).The prevalence of steatosis in 
patients with CHC is reported to be between 40 and 80% depending on the features of the 
population studied in terms of alcohol consumption, prevalence of overweight/obesity, 
diabetes and other risk factors for fatty liver (Poynard et al. 2003; Lonardo et al. 2006). 
However, even after all common causes of steatosis have been excluded, the prevalence of 
steatosis in CHC remains about 40%. This figure represents an approximately 2-fold 
increase compared to the prevalence of steatosis in other common chronic liver diseases 
such as hepatitis B (20%) (Rubbia-Brandt et al. 2000; Thomopoulos et al. 2006). 
Furthermore, the composition of FAs that accumulate in the livers of transgenic mice 
expressing HCV core protein is different from that seen in fatty liver due to simple obesity. 
Carbon-18 monounsaturated fatty acids (C18: 1) such as oleic or vaccenic acids are 
significantly increased with core protein. A similar difference is seen when comparing of 
liver tissues from patients with CHC and those with nonalcoholic fatty liver disease 
(NAFLD) (Moriya et al. 2001).  This suggests that HCV may directly cause fatty liver, at 
least in subgroups of patients with CHC.  
Hepatic steatosis in patients with CHC assumes importance clinically because it: 
(1) negatively impacts the response to antiviral therapy (2) increases the rate of fibrosis 
progression (Asselah et al. 2006) and (3) influences the development of HCC (Patton et al. 
2004). The similarities between hepatitis C and NAFLD make it likely that these 
conditions often coexist. Thus, these conditions may both be present in many patients, and 
there is likely to be overlap in mechanisms.  
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1.4.2 Molecular mechanisms of hepatic steatosis in HCV patients 
Multiple mechanisms may account for the development of steatosis in persons with 
CHC, including effects of HCV core protein expression and comorbid metabolic 
conditions; these interactions are summarized in Figure 1.9. Virus-specific alterations in 
host metabolism can induce insulin resistance (IR) and type 2 diabetes mellitus 
(T2DM)(Cargnel et al. 1999; Shintani et al. 2004), leading to hepatic steatosis, which in 
turn can exacerbate IR (Asselah et al. 2006; Péres et al. 2013).  
Figure 1.9 Virus and host interactions leading to steatosis in patient with HCV and 
clinical implication of those interactions(Puri & Sanyal 2006). 
 
 
A recent Italian study looking at host genetics found that the PNPLA3 rs738409 
genotype promotes steatosis development in CHC patients, and is independently associated 
with advanced fibrosis, cirrhosis, reduced response to antiviral treatment and development 
of hepatocellular carcinoma (Valenti et al. 2011).  
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The effect of HCV infection on steatosis is mediated in large part by the HCV core 
protein, which has significant effects on the transcription of genes involved in lipid 
metabolism, including palmitoyl acyl-CoA transferase 1A (CPT1A) and MTP, which 
correlates well with steatosis (Conjeevaram et al. 2007)(Figure 1.10). The association of 
core protein with mitochondria has significant effects on lipid accumulation, including 
decreased fatty acid degradation, disproportional increases in fatty acid uptake and 
changes in Ca²
+
 influx at the mitochondrial outer membrane (Li et al. 2007). These 
mechanisms also appear to be contribute to core protein induced generation of reactive 
oxygen species (ROS), effects on lipid peroxidation and hepatocyte damage (Machida et 
al. 2006). Several genes have been shown to be essential for HCV-related steatosis, 
including PA28-γ (Moriishi et al. 2007) and peroxisome proliferator-activated receptors-α 
(PPARα) (Dharancy et al. 2005; Tanaka et al. 2008).  
 
Figure 1.10 HCV core inhibits VLDL secretion, promoting steatosis. 
It is postulated that HCV core protein inhibits microsomal triglyceride transfer protein 
(MTP) activity, thus inhibiting very low-density lipoprotein (VLDL) assembly and 
secretion(Puri & Sanyal 2006). 
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1.4.3 HCV Genotype-specific alterations in lipid metabolism  
A genotype-specific alteration in lipid metabolism has been demonstrated for 
HCV. In patients infected with genotype 3, steatosis is mostly virus-induced and often 
severe, correlates with intrahepatic viral load, and resolves after successful antiviral 
therapy (Rubbia-Brandt, Leandro, et al. 2001; Hui, Kench, Farrell, Lin, D. Samarasinghe, 
et al. 2002). In contrast, in patients infected with genotype 1 or 4, steatosis is mainly 
associated with host metabolic factors and correlates with body mass index (BMI) and 
central adiposity (Conjeevaram et al. 2007). 
In HCV genotype 3 infection, steatosis appears to be a direct consequence of viral protein 
expression, suggesting the presence of specific sequences across the genome of genotype 3 
that are involved in fat accumulation within hepatocytes (Negro 2010). This observation is 
supported by two supplementary findings. First, the severity of steatosis in patients with 
genotype 3correlates with the level of HCV RNA, both in liver (Rubbia-Brandt et al. 2000) 
and in serum (Adinolfi et al. 2001). Second, steatosis may significantly decrease, or even 
completely disappear, following eradication of HCV genotype 3 with antiviral agents, 
which is not typically seen with non-3 genotypes (Rubbia-Brandt et al. 2000; Poynard et 
al. 2003). A relapse of HCV genotype 3 after the end of therapy may even result in the 
reappearance of steatosis in patients in whom it had disappeared during treatment (Rubbia-
Brandt, Giostra, et al. 2001). 
Although the mechanism by which HCV-3 induces steatosis more efficiently than 
others genotypes is not completely understood, some potential mechanisms have been 
postulated.   
A) In hepatocytes, HCV interferes with cellular lipids through direct protein–protein or 
protein–lipid interactions, and also by influencing hepatic lipid metabolism. Indeed, it is 
important to recognize that HCV replication modifies fatty acid metabolism as well as the 
Chapter 1: General Introduction 
 
33 
 
cholesterol pathway. In general, HCV may interfere with lipid metabolism at three levels: 
impaired secretion, impaired degradation and increased neolipogenesis. (Syed et al. 2010). 
B) Impaired secretion of lipoproteins from the infected hepatocyte was the first proposed 
mechanism of HCV induced steatosis. HCV core protein may cause hepatic steatosis by 
inhibiting the activity of MTP (Perlemuter et al. 2002), an enzyme that plays a key rate-
limiting role in VLDL assembly, thereby inhibiting the secretion of VLDL from the liver. 
Although the effects of core on MTP were initially observed in transgenic mice, these 
findings have now been observed in humans. In a study of 58 HCV patients, a highly 
significant (P=0.0017) inverse correlation was found between liver MTP mRNA levels and 
the degree of hepatic steatosis, suggesting an important role for MTP in hepatic steatosis 
(Mirandola et al. 2006). 
C) HCV-3 may also cause steatosis by either stimulating de novo synthesis of fatty acids 
as discussed above, or by decreasing FA oxidation. HCV may decrease FA oxidation 
through impairment of the expression and transcriptional activity of PPARα which 
regulates several genes responsible for FA degradation (Cheng et al. 2005). Expression of 
PPARα appears to be impaired with HCV infection (Dharancy et al. 2005; de Gottardi et 
al. 2006).In patients with CHC, expression of the PPARα gene in the liver was reduced by 
86% compared with controls, and the expression of its target gene, CPT1A was 
coordinately reduced by 85%. Recent evidence of a direct role for PPARα activation in the 
pathogenesis of steatosis and HCC was obtained from studies that combined HCV core 
transgenic mice with PPARα knockout (KO) mice. These experiments found that PPARα 
KO mice expressing core protein had reduced expression of PPARα target genes, and only 
mild steatosis in the liver (Tanaka et al. 2008). In general, PPARα acts to ameliorate 
steatosis, but in the presence of mitochondrial dysfunction, induced by the core protein, 
core activated PPARα may exacerbate steatosis. Others have shown that PPARγ 
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expression is significantly lower in genotype 3 than genotype 1 HCV infection and that 
steatosis in genotype 1 HCV infection is also associated with decreased levels of PPARγ 
(de Gottardi et al. 2006). 
 
1.4.4 Lipid induces insulin resistance 
An additional mechanism leading to fatty liver may be related to the increased 
prevalence of IR among CHC patients. Insulin has a central role in lipid metabolism in the 
liver and IR increases the peripheral release and hepatic uptake of FAs, resulting in an 
accumulation of lipid in the liver (Browning & Horton 2004). In obesity, defects in insulin 
mediated lipid metabolism result in lipid metabolites being trafficked to the liver and 
skeletal muscle, instead of adipose tissue, producing ―lipotoxicity‖. Trafficking of lipid 
from overloaded adipocytes to key metabolic tissue has been shown to specifically induce 
IR (Muoio & Newgard 2008). HCV induces inflammatory cytokines which potently 
activates the novel group of PKC isoforms δ, ε, θ and η (Sedaghat et al. 2002). Activation 
of PKCε in the liver and PKCδ and θ in muscle has been shown to induce IR, by 
increasing phosphorylation of IRS1 and IRS2 at inhibitory serine residues, while 
decreasing phosphorylation of activating tyrosines (Aguirre et al. 2002; Greene et al. 
2006).  (Figures1.10 and 1.11). 
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Figure 1.11 The interaction of putative mediators leading to IR and hepatic steatosis in 
HCV infection. Increased levels of TNF- and suppressor of cytokine signalling-3 (SOCS-
3) in CHC induce IR by interfering with tyrosine phosphorylation of insulin receptor 
substrate 1 and 2 (IRS 1&2). This process is associated with reduced phosphatidylinositol-
3-hydroxykinase (PI3K) and downstream signals involving AKT-kinase and protein kinase 
C (PKC). SOCS-3 can also attenuate the activity of signal transducer and activator of 
transcripition-3 (STAT-3). This process can enhance SREBP-1c promoter activity, 
contributing to hepatic steatosis and IR (Quoted from: Buneet et al., 2006). 
 
 
1.4.5 Lipid abnormalities and response to antiviral treatment 
Many studies have reported a correlation between lipid profiles and virological 
response to antiviral treatment. A recent Japanese study of 44 patients with CHC found 
that high triglyceride (TG) content of VLDL was strongly predictive of a better response to 
treatment (Mawatari et al. 2010). In a large European cohort of 575 HCV genotype 1-
infected patients, a low baseline level of cholesterol, but not TG, was an independent 
predictor of not achieving sustained virology response (SVR) (P= 0.084),. Despite a drop 
in the cholesterol level of patients while receiving antiviral treatment, cholesterol 
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rebounded to above baseline in patients with SVR, and or to baseline in 
nonresponders/relapsers (P = 0.02). Significant differences of TG levels in patients with 
and without SVR were only observed at follow-up (136 and 117 mg/dl, respectively, 
P=0.028) (Lange et al. 2010). A large German observational study enrolled 10390 patients 
treated with PEG-interferon alfa-2a and ribavirin and evaluated for cardiovascular and 
metabolic risk markers. In a prospective analysis , the authors concluded that elevated total 
cholesterol levels predicted higher SVR, but the presence of diabetes mellitus was a 
negative predictor of SVR (Jaeckel et al. 2010). 
A recent study of the influence of race on the effect of lipid profiles on SVR 
analysed data from the Virahep-C study, a prospective study of treatment-naïve patients 
with genotype 1 HCV infection who received peginterferon (PEG-IN) alfa-2a plus 
ribavirin therapy for up to 48 weeks (Ramcharran et al. 2010). The study found that 
baseline TG levels were inversely correlated with SVR rate, but LDL-associated 
cholesterol (LDL-C) levels directly correlated with SVR. Albeit, baseline LDL-C was 
significantly higher in Caucasian Americans compared with African Americans, but the 
difference in these parameters did not explain the racial difference in treatment response 
(Ramcharran et al. 2010). In another study to provide a genetic analysis for the 
associations between serum lipid levels and hepatic steatosis in CHC patients.; Clark and 
co workers identified 4 SNPs in the IL28B gene region were significantly associated with 
pre-treatment LDL (top SNP rs12980275, P=10-17, good IFN response variant=higher 
LDL). In a logistic regression model, baseline LDL was strongly associated with SVR. 
The authors conclude that the poor response IL28B variant was strongly associated with 
lower pretreatment LDL levels and more hepatic steatosis (Clark et al. 2012). In 
accordance with these findings, in another recent trial from JapanSaito et al, show that the 
TT genotype of rs8099917 polymorphism near IL28B gene was associated with high LDL 
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cholesterol level this in addition to a high frequency of the mutations in interferon 
sensitivity determining region and a wild type of core aa 70 and high. Again; the 
rs8099917 polymorphism was the most significant factor to predict lack of the response for 
PEG-IFN-α/RBV in genotype 1b CHC patients with high viral load (Ito et al. 2011). These 
intriguing data may help to provide explanation to the series of clinical observations 
linking higher LDL, less steatosis and SVR. 
 
1.4.6 Lipid abnormalities and liver fibrosis 
The correlation between lipid profile and severity of liver fibrosis was assessed in 
some recent reports. In a recent study from Taiwan, the authors found advanced hepatic 
fibrosis was associated with an adjusted odds ratio of 0.03 (0.00–0.32) for total cholesterol 
level (Hsu et al. 2010). The same finding was elucidated by a retrospective analysis of the 
V ahep-C study; albeit, TG was significantly associated with steatosis (P=0.001). HDL 
(P=0.004) and total cholesterol (P=0.001) were significantly lower in those with fibrosis 
than in those without fibrosis (Ramcharran et al. 2011). 
1.4.7 Lipid abnormalities and hepatocarcinogensis  
A recent study tried to identify the signature genes involved in lipid metabolism, by 
characterizing normal liver vs. HCV infected liver vs. HCV associated HCC using gene 
microarray. Up regulation of gene-mediated FA de novo synthesis and down regulation 
gene-mediated FA oxidation were correlated with HCV associated HCC. Also, the down 
regulation of genes resulting in abnormal cholesterol metabolism in HCV infection was 
found to be intensified in the setting of HCC (Salomao et al. 2010).Steatosis and HCC 
developed in PPARα intact but not in PPARα heterozygous or PPARα null core gene 
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transgenic mice, indicating that not just the presence but the persistent activation of 
PPARα is important in hepatocarcinogenesis by HCV core protein.                                                                                                                   
1.5 HCV, interferon signalling and treatment response 
 
1.5.1 Goals of therapy: 
Primary goal: 
 Eradicate HCV infection. 
Secondary goal: 
 Slow disease progression. 
 Improve liver histology. 
 Reduce risk of hepatocellular carcinoma. 
 Improve health related quality of life. 
 
Current recommended therapy for HCV (AASLD guidelines, January 2014): 
Recommended regimen for treatment-naive patients with HCV genotype 1 who 
are eligible to receive IFN:Daily sofosbuvir (400 mg) and weight-based RBV (1000 
mg [<75 kg] to 1200 mg [≥75 kg]) plus weekly PEG for 12 weeks is recommended for 
IFN-eligible persons with HCV genotype 1 infection, regardless of subtype. 
Recommended regimen for treatment-naive patients with HCV genotype 1 who 
are not eligible to receive IFN: Daily sofosbuvir (400 mg) plus simeprevir (150 mg), 
with or without weight-based RBV (1000 mg [<75 kg] to 1200 mg [≥75 kg) for 12 
weeks is recommended for IFN-ineligible patients with HCV genotype 1 infection, 
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regardless of subtype. 
Recommended regimen for treatment-naive patients with HCV genotype 2, 
regardless of eligibility for IFN therapy: Daily sofosbuvir (400 mg) and weight-
based RBV (1000 mg [<75 kg] to 1200 mg [≥75 kg]) for 12 weeks is recommended 
for treatment-naive patients with HCV genotype 2 infection. 
Recommended regimen for treatment-naive patients with HCV genotype 3, 
regardless of eligibility for IFN therapy: Daily sofosbuvir (400 mg) and weight-
based RBV (1000 mg [<75 kg] to 1200 mg [≥75 kg]) for 24 weeks is recommended 
for treatment-naive patients with HCV genotype 3 infection. 
Recommended regimen for treatment-naive patients with HCV genotype 4 who 
are eligible to receive IFN: Daily sofosbuvir (400 mg) and weight-based RBV (1000 
mg [<75 kg] to 1200 mg [≥75 kg]) plus weekly PEG for 12 weeks is recommended for 
IFN-eligible persons with HCV genotype 4 infection. 
Recommended regimen for treatment-naive patients with genotype 4 who are not 
eligible to receive IFN. Daily sofosbuvir (400 mg) plus weight-based RBV (1000 mg 
[<75 kg] to 1200 mg [≥75 kg]) for 24 weeks is recommended for IFN-ineligible 
patients with HCV genotype 4 infection. 
 
Recommended regimen for treatment-naive patients with HCV genotype 5 or 6. 
Daily sofosbuvir (400 mg) and weight-based RBV (1000 mg [<75 kg] to 1200 mg 
[≥75 kg]) plus weekly PEG for 12 weeks is recommended for IFN-eligible persons 
with HCV genotype 5 or 6 infection. 
 
However, in Australia patients still have no access to either sofosbuvir or 
simeprevir. This will hopefully change soon, but it is not clear who will qualify for 
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sofosbuvir, given its high cost (US $84,000 for 12 week course). Generally, IFN is still the 
backbone of most recommended therapies for HCV; therefore IFN response is critical to 
treatment success. That will probably change in a few years as combination DAA 
treatment becomes available, but even then the host innate IFN response is important. 
 
1.5.2 Interferons 
Interferons (IFNs) are natural proteins produced by the cells of most vertebrates in 
response to challenges by foreign agents such as viruses, parasites and tumor cells. 
Interferons belong to the large class of glycoproteins known as cytokines. Interferons are 
produced by a wide variety of cells in response to the presence of double-stranded RNA, a 
key indicator of viral infection. Interferons assist the immune response by inhibiting viral 
replication within host cells (Figure 1.12), activating natural killer cells (NKC) and 
macrophages, increasing antigen presentation to lymphocytes, and inducing the resistance 
of host cells to viral infection. When the antigen is presented to matching T and B cells, 
those cells multiply and specifically eliminate the foreign substance, highlighting the 
importance of antigen presentation for the immune response (Liu 2005). 
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Figure 1.12. Cellular Events in the Action of Interferons. 
The binding of IFN to its receptor results in the transcription of a group of genes that code 
for antiviral proteins involved in preventing viral replication in that cell. As a consequence 
the cell will be protected from infection with a virus until the antiviral proteins are 
degraded, a process which takes several days. The antiviral state in IFN-treated cells 
results from the synthesis of enzymes that result in the inhibition of protein synthesis, 
including 2‘5‘ oligo A synthestase  (2‘5‘OAS) and protein kinase (PK) (modified from: 
Goodbourn et al. 2000). 
. 
 
1.5.2.1 Types of interferon  
Three major classes of interferons have been described in humans, based on the 
receptors through which they signal: 
1- Interferon type I: All type I IFNs bind to a specific cell surface receptor complex 
known as the IFN-α receptor (IFNAR) that consists of IFNAR1 and IFNAR2 chains. The 
type I interferons present in humans are IFN-α, IFN-β and IFN-ω(Liu 2005). 
2- Interferon type II: Binds to the IFN-γ receptor (IFNGR). In humans this is IFN-γ.  
3- Interferon type III: Signal through a receptor complex consisting of IFNLR1 and 
IL10R2. In humans four types of IFN- (IFNL1-4) have so far been recognised. 
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1.5.2.2 Natural function and synthesis 
Interferons in general have several effects in common. They are antiviral and 
possess antioncogenic properties, induce macrophage and natural killer lymphocyte 
activation, and increase expression of major histocompatibility complexglycoprotein 
classes I and II, thus enhancing presentation of foreign (microbial) peptides to T cells. In a 
majority of cases, the production of interferons is induced in response to microbes such as 
viruses or bacteria and their products (viral glycoproteins, viral RNA, bacterial endotoxin, 
bacterial flagella, CpG sites). Interferons can also be induced by mitogens or other 
cytokines, such as interleukin 1, interleukin 2, interleukin-12, tumor necrosis factor or 
colony-stimulating factor, which are synthesised in response to various antigens. 
Metabolism and excretion of interferons take place mainly in the liver and kidneys; they 
rarely cross the placenta but can cross the blood-brain barrier(Tanabe et al. 2004). 
 
!!
 
Figure 1.13. Intracellular signalling following the binding of interferon to cell surface 
receptors (modified from: Goodbourn et al. 2000). 
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1.5.2.3 Viral induction of interferons 
All classes of interferon play a role in fighting RNA virus infections, but their 
presence also accounts for many of the host symptoms, such as sore muscles and fever. 
Interferons are secreted when abnormally large amounts of dsRNA are detected in a cell 
.dsRNA is normally present in very low quantities, but increased amounts are present in 
infected cells, due to replication of viral RNA. Retonic acid-inducible gene I (RIG-I) 
detects cytoplasmic dsRNA, while Toll Like Receptor 3 (TLR3) detects dsRNA in 
endosome(Yoneyama et al. 2004).The dsRNA acts like a trigger for the production of 
interferon via  RIG-I and TLR 3,, a pattern recognition receptor of the innate immune 
system which leads to activation of the transcription factor IRF3 and late phase NF ( kappa 
Beta) (Chang et al. 2006). The gene that codes for this cytokine is switched on in an 
infected cell, and the interferon synthesized and secreted to surrounding cells.  
When an infected cell dies, either because of a cytolytic RNA virus or immune 
lysis, thousands of viruses will be released that could infect nearby cells. However, if these 
cells have received interferon from the infected cell, this essentially warns the other cells 
that there's a wolf in the flock of sheep. They then start producing large amounts of a 
protein known as protein kinase R (or PKR). If a virus infects a cell that has been ―pre-
warned‖ by interferon, the PKR is indirectly activated by the dsRNA (actually by 2'-5' 
oligoadenylate, produced by 2'-5' oligoadenylate-synthetase which is induced following 
TLR3 activation), and begins transferring phosphate groups (phosphorylating) to a protein 
known as eIF-2, a eukaryotic translation initiation factor. After phosphorylation, eIF-2 has 
a reduced ability to initiate translation, the production of proteins coded by cellular 
mRNA. This impairs translation of viral proteins, preventing viral replication and 
inhibiting normal cell ribosome function, killing both the virus and the host cell if the 
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response is active for a sufficient amount of time. All RNA within the cell is also 
degraded, preventing the mRNA from being translated by eukaryotic initiation factor 
(eIF2), in case some if the eIF2 failed to be phosphorylated(Proud 2005; Jackson et al. 
2010).Furthermore, interferon causes up regulation of MHC Class I and therefore to 
increased presentation of viral peptides to cytotoxic CD8 T cells, as well as a change in the 
proteasome (exchange of some beta subunits by b1i, b2i, b5i - then known as the 
immunoproteasome), which leads to increased production of MHC I compatible peptides. 
Interferon can cause increased p53 activity in virus infected cells, by inducing 
increased production of the p53 gene product. This promotes apoptosis (programmed, non-
lytic cell death), limiting the ability of the virus to spread. Increased levels of p53 
transcription are observed even in cells which are not infected, but only infected cells show 
increased apoptosis. This increased transcription may serve to prepare susceptible cells so 
they can respond quickly in the case of infection. When p53 is induced by viral infection, 
it behaves differently than it usually does. Some p53 target genes are expressed under viral 
load, but others, especially those that respond to DNA damage, aren‘t. One of the genes 
that is not activated is p21, which can promote cell survival, so leaving this gene inactive 
would help to promote apoptosis. Interferon enhances the apoptotic effects of p53, but it is 
not strictly required. Normal cells exhibit a stronger apoptotic response than cells without 
p53 (Takaoka et al. 2003). 
 
1.5.3 Interferon resistance 
Both host and viral factors are likely involved in determining the antiviral efficacy 
of IFN. 
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A- Viral factors: 
HCV has evolved important interactions with IFN induction and signalling that allow it to 
evade host immune mechanisms, causing persistent virus infection and IFN resistance 
(Figure 1.14A and B). IFN is rapidly synthesized after virus infection, rapidly triggering 
intracellular signaling events. The subsequent expression of IFN-stimulated (ISGs) is 
central to these antiviral responses. Several HCV proteins are suggested to interact in the 
IFN signaling pathway (Rani & Ransohoff 2005). HCV NS3/4A serine protease blocks 
phosphorylation and the effecter action of IRF-3, a key cellular antiviral signaling 
molecule (Foy et al. 2003). RIG-I has been shown to bind to the secondary structured HCV 
RNA efficiently to confer IFN-β induction (Saito et al. 2007). HCV NS2 and NS3/4A 
proteins are potent inhibitors of host cell cytokine/chemokine gene expression (Kaukinen 
et al. 2006). Furthermore, Both the full polyprotein and the HCV core protein have been 
shown to inhibit the JAK–STAT pathway in cell culture and transgenic mice (Heim et al. 
1999; Blindenbacher et al. 2003). 
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Figure 1.14 HCV subversion of IFN activation and signal transduction. 
(A) HCV NS3-4A blocks IFN induction at multiple levels and (B) HCV blocks IFN signal 
transduction(modified from: Goodbourn et al. 2000).. 
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B- Host factors: 
Age, sex, race, body weight, hepatic steatosis, insulin resistance (Figure 1.15), hepatic 
fibrosis and other comorbidities influence interferon efficacy. For example, Body fat mass 
and hepatic steatosis have been recognized as independent risk factors for a poor response 
to IFN-α therapy(McCullough 2003), older individuals have a lower response to IFN-α 
treatment than younger individuals (Hayashi et al. 1998), and African American HCV 
patients respond poorly to IFN-α therapy (Reddy et al. 1999). Furthermore, Several 
inhibitory pathways are identified that negatively regulate IFN-α–activated signal 
cascades. The suppressor of cytokine signaling (SOCS) family has been studied the most 
extensively and also is the most notably important negative factor for IFN-α signaling 
(Krebs & Hilton 2000). Interaction between Insulin Resistance and SOCS3 is one, which 
interacts with body weight and steatosis (Douglas & George 2009b). 
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Figure 1.15 Interaction between insulin and interferon- signaling pathways (Khattab 
2009). 
 
 
1.5.4 Interferon preparations 
Several different types of interferon are now approved for use in humans. 
1- Conventional interferon: 
Conventional interferon-α2a (Roferon A) and 2b (intron-A) are given as subcutaneous 
injection of 3MU of INF-α 3 times/week combined with ribavirin 10.6mg/kg/day.  
 
2- Pegylated interferon: 
Pegylated interferon provides greatly improved pharmacokinetics over conventional 
interferon, and now forms the backbone for current standard of care treatments for CHC. 
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To make pegylated INF-, polyethylene glycol (PEG) is added to the IFN- molecule, 
reducing elimination from the body and increasing its serum half life (Manns et al. 2001). 
This allows pegylated interferon to be injected once weekly, rather than three times per 
week for conventional interferon-alpha, and provides more sustained serum levels. Two 
pegylated formulation of IFN are currently available: Pegylated interferon-alpha-2b (Peg-
Intron) (12 kd) was approved in January 2001; pegylated interferon-alpha-2a (Pegasys) (40 
kd) was approved in October 2002. The dose of peginterferon α-2b is weight-based: 
1.5μg/kg/wk, while the dose of peginterferon α--2a is fixed at 180 μg/wk.  
 
1.5.5.Adverse effects  
The most frequent adverse effects of interferon treatment are flu-like symptoms 
(increased body temperature, feeling ill, fatigue) headache, muscle pain, chills, dizziness, 
hair thinning, and depression. Erythema, pain and induration (hardness) at the injection site 
are also frequently observed. Paradoxically, interferon therapy also causes 
immunosuppression, in particular though neutropenia, and can result in some infections 
manifesting in unusual ways (Larrey et al. 2007). 
Most adverse effects are reversible and disappear a few days after the therapy has finished. 
 
1.6 Genetic markers and antiviral responses  
1.6.1 HCV genetic variability and antiviral responses 
The inherent genetic variability of HCV may have important clinical consequences. 
Comparisons of different HCV genomes have identified amino acids that differed 
consistently by response to treatment (Torres-Puente et al. 2008). However, it now seems 
that the outcome of antiviral treatment might depend not only on variations of one or a few 
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independent positions, but more likely on the combination of amino acid sequences at 
several positions along the HCV genome. 
Interferon sensitivity determining region (ISDR) is a 40 amino-acid section in the 
center of NS5A protein (aa2209-2248). It was the first position implicated in determining 
the response to IFN therapy for HCV-genotype 1b (Enomoto et al. 1995). In addition to the 
ISDR, hypervariable regions (HVR1, HVR2 and HVR3) of the E2 glycoprotein show 
tendency to be correlated with antiviral therapy outcome (Osei-Hyiaman et al. 2005) 
(Figure 1.16). More recently, a relationship has been found between poor response to peg-
INF plus ribavirin combination therapy and substitutions at amino acid 70 and 91 in the 
core protein (Enomoto & Maekawa 2010).  
 
 
 
Figure 1.16 HCV genetic Variability and antiviral responses. 
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1.6.2 Host genetic markers and antiviral responses 
Host genetic factors may play also a role in determining disease outcome and 
response to therapy in CHC. In 2009, three different studies showed that single nucleotide 
polymorphisms (SNPs) near the interferon lambda 3 [IFNL3] gene predict the response to 
interferon-based treatment of hepatitis C (at SNP rs12979860, CC connotes the responder 
genotype, CT or TT connotes the non responder genotype; at rs8099917, TT is the 
responder genotype, while GT or GG is the non-responder (Suppiah et al. 2009; Tanaka et 
al. 2009; Ge et al. 2009), an observation of major translational impact.  
 
1.6.3 Ribavirin (RBV) 
Ribavirin is a guanosine nucleoside analogue, first synthesized more than 35 years 
ago. Although it shows no direct antiviral activity against HCV when used alone, it is 
highly effective in treatment of CHC when used in combination with IFN-α, and remains 
an important part of triple therapies containing new protease or polymerase inhibitors.  
The molecular mechanisms by which RBV enhances early and sustained virological 
response rates during IFN-based antiviral therapy are still unknown. Several mechanisms 
have been proposed including:  
i. Immunomodulatory properties, altering the host immune response from Th2 to 
Th1. 
ii. Inhibition of the inosine monophosphate dehydrogenase (IMPDH), the NAD-
dependent enzyme that cintrols de novo synthesis of purine nucleotides (Pankiewicz & 
Goldstein 2003). Inhibition of IMPDH results in an interruption of DNA and RNA 
synthesis (Jayaram et al. 1982). 
iii. Direct inhibition of the HCV-encoded NS5B RNA polymerase. 
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iv. Induction of lethal mutagenesis (―error catastrophe‖). 
v. Modulation of ISGs expression (Feld et al. 2010).  
 The dose of RBV ranges from 800-1400 mg/day according to body weight (15 mg/kg 
body weight/day). 
RBV treatment is associated with many side effects, most commonly haemolytic 
anemia and rash. 
 
1.7. HCV Therapy: What will the future look like? 
1.7.1 Targeting anti-HCV therapies 
Advances in the understanding of HCV biology have identification of a large 
number of compounds, collectively known as Direct Acting Antivirals (DAAs), which 
target HCV proteins, or Host Targeting Agents. Boceprevir and telaprevir were approved 
in 2011 in many countries including Australia, and are now standard of care for HCV 
genotype 1. Sofosbuvir and simeprevir have been approved in USA, Europe and very 
recently in Australia, although still being finalised here. They are now standard of care in 
USA according AASLD guidelines. Pivotal studies in New England Journal of Medicine 
earlier this year showed extremely high cure rates with IFN-free treatment. Either 
sofosbuvir plus NS5A inhibitor (daclatasvir or ladipasvir), or multi-drug combinations in 
Abbvie study (Poordad et al. 2014). DAAs have been selected to target several critical 
steps in viral replication including cell infection, RNA transport to the endoplasmic 
reticulum, HCV translation, transcription, and assembly (Figure 1.17). 
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Figure 1.17 HCV life cycle and targets for Direct Acting Antivirals (DAAs)(Hahn et al. 
2011). 
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Table 1.2: Steps in HCV replication and potential mechanisms for inhibition   
 
 
1.7.2 Therapies that target host factors 
A major obstacle in combating HCV infection is that the fidelity of the viral 
replication machinery is low, enabling the virus to quickly develop mutations that resist 
compounds targeting viral enzymes (Bartenschlager et al. 2013). Targeting host factors 
essential for viral replication provides an alternative strategy that should minimise the risk 
of viral resistance and treat all HCV genotypes. [Most NS3 inhibitors and non-nucleos/tide 
NS5B inhibitors are relatively specific for genotype 1, with little or no activity against 
genotype 3 (Eltahla et al. 2014). However it is essential to identify treatments that have 
minimal side effects on patients. 
 
1.7.2.1 Antireceptor antibodies  
The rationale for antireceptor antibodies as antiviral drugs is based on: that is not 
being prone to the problems of viral variability and HDL attenuation of neutralizing 
Step of HCV replication (target) 
 
 Option for inhibition  
Transport of RNA to ER Ribozymes   
Antisense-oligonucleotides Short interfering 
RNAs 
Translation and post-translational 
processing 
Protease inhibitors 
RNA transcription Polymerase inhibitors 
Viral assembly  Glucosidase inhibitors 
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activity; we could consider anti-SR-B1 and anti-CD-81 antibodies capable of interfering 
with HCV infection an alternative to the development of anti-HCV antibodies (Drummer 
2014; Lacek et al. 2012).  
Recent data refer to the critical role of CD81 in HCV infection in vivo and offer a 
new perspective for the prevention of allograft reinfection after orthotopic liver 
transplantation in chronically infected HCV patients (Fofana et al. 2013). However, the 
efficacy of targeting CD81, SR-BI or CLDN1 may be limited by receptor-independent 
modes of virus transmission. 
 
1.7.2.2 Targeting host metabolism  
1.7.2.2.1 Cyclophilin B inhibitors  
A key host cell factor involved in HCV RNA replication is the human protein 
cyclophilin B, which interacts with the C-terminal region of NS5B and appears to 
stimulate its RNA binding activity. The cyclophilin B inhibitor Debio-025 potently 
suppresses genotype 1 HCV replication in vivo (Quarato et al. 2012), but its development 
is currently suspended due to concerns about possible toxicity. 
 
1.7.2.2.2 Insulin sensitizers 
Insulin resistance has emerged as a new target for treatment of CHC patients. The 
rationale for increasing insulin sensitivity in patients with CHC is that the insulin resistant 
state 1) directly or indirectly inhibits the antiviral action of IFN; 2) increases viral fitness, 
making it more resistant to therapy, or both (Serfaty et al. 2012). Interestingly, intracellular 
factors deregulated by HCV and responsible for the insulin resistant phenotype may have 
promiscuous effects, as they are also involved in regulating IFN-α signaling (Irshad et al. 
2013).  
Chapter 1: General Introduction 
 
56 
 
The available clinical data on the use of insulin sensitisers reveals conflicting results 
(Cheng et al. 2014).  
 
1.7.2.2.3 Host lipid biosynthesis inhibitors 
HCV increases cellular lipids metabolism (Perlemuter et al. 2002). So, existing 
anti-obesity drugs may represent a safe way to block these metabolic changes and inhibit 
viral infection as one of the potential novel approaches that may improve response rates to 
treatment. There are at least 2 different molecular mechanisms providing novel targets for 
treatment of HCV: either through the modulation of cellular TG or cholesterol metabolism.  
In vitro data suggest that statins, the widely used cholesterol-lowering drugs, may 
inhibit HCV RNA replication by depletion of geranylgeranyl lipids (Kapadia & Chisari 
2005; Ye et al. 2003). It was demonstrated that dose-dependent strong antiviral effects 
exist for all the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-coA) reductase inhibitors, 
except for pravastatin, in vitro. Fluvastatin exhibited the strongest antiviral activity, 
followed by atorvastatin and simvastatin (Ikeda et al. 2006). Several clinical trials have 
used statins as monotherapy or in combination with the standard of care (SOC). O‘Leary et 
al. undertook a human pilot study and treated 10 CHC patients with hypercholesterolaemia 
with atorvastatin (at the conventional daily dose of 20 mg) for 12 weeks. They reported no 
statistically significant change in HCV RNA levels compared with pretreatment levels at 4 
and 12 weeks, despite improvement in lipid parameters (O‘Leary et al. 2007). Bader et al 
reported that fluvastatin inhibited HCV RNA replication in patients with CHC; fluvastatin 
(20-320 mg/day) was well tolerated in patients with CHC and was effective at relatively 
low doses (Bader et al. 2008). Milazzo et al reported disappointing results in a pilot trial of 
42 patients coinfected with HCV and HIV and receiving fluvastatin 80 mg daily, in whom 
the expected decrease in serum cholesterol and LDL was paralleled by a paradoxical 
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increase in HCV RNA levels (Milazzo et al. 2009). A more recent open label randomized 
controlled trial in HIV/HCV genotype 1 co-infected patients found that the addition of 
Fluvastatin (80 mg/day) to SOC therapy significantly improved the rate of rapid 
virological response (RVR, HCV PCR negative after 4 weeks), but did not significantly 
increase the SVR rate (Milazzo et al. 2010). In another small uncontrolled trial, 20 mg/day 
fluvastatin was added to pegylated IFN-/ribavirin in a group of 21 patients. Among the 
15 patients who received a 48-week course of therapy the SVR was 67% (Sezaki et al. 
2009). In a large retrospective trial Harrison et al (Harrison et al. 2010), showed that 
administration of a statin was associated with a significant increased rate of SVR; 
interestingly this effect was noted to be independent of the baseline lipid profile. In subset 
analysis, statin users had higher chances of SVR when aged >48 years, of non-African 
American ethnicity and female. These data were recently supported by a very large cohort 
of diabetic CHC patients, in which use of statin was associated with improved SVR (Rao 
& Pandya 2011).  
The mechanisms by which statins interfere with HCV replication are not 
completely understood.  Tiedemann et al recently suggested that statins my have 
multifactorial effect on chronic HCV infection. They may interfere with HCV replication 
by induction of the enzyme heme oxygenase 1 (HO-1), with subsequent reduction of 
cellular levels of ROS (Tiedemann et al. 2010). This effect was associated with induction 
of endogenous antiviral defense mechanisms by induced expression of IFN alpha 2 and 17 
and several IFN stimulated genes (e.g. OAS 1 and 2, PKR and HRI). 
All together, these findings suggest that statin use is safe in CHC patients and 
support ‗proof-of-concept‘ for trials combining statins with standard pegylated interferon 
plus ribavirin therapy. However, the choice of statin may be vital in order to achieve 
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antiviral effect, and further studies are needed to investigate the mechanism of action of 
statins against HCV. 
In addition to the antiviral effects of statins, HMG-CoA-reductase inhibitors(Fluva- 
and simvastatin) are able to selectively induce apoptosis of hepatoma cells. The underlying 
mechanism seems to include insufficient prenylation of Ras and Rho proteins, resulting in 
a lack of cellular integrity. Therefore HMG-CoA-reductase inhibitors, which have been 
shown to interfere with HCV replication, might also have beneficial effects in reducing the 
occurrence of HCC (Pathil et al. 2006).  
Other classes of drugs designed for treating hypercholesterolemia block the assembly 
and secretion of VLDL 
These drugs may also be effective in treating HCV infection because they inhibit 
release of HCV particles from infected cells (Huang et al. 2007).  In this regard, antisense 
RNA drugs targeting apoB and several microsomal triglyceride protein (MTP) inhibitors 
(Amemiya et al. 2008; Tai et al. 2009) have already been tested in clinical trials because of 
their ability to block VLDL secretion, thereby lowering the plasma levels of VLDL 
triglycerides and LDL cholesterol. Long-term treatment with MTP inhibitors led to the 
toxic accumulation of fat in livers (Amemiya et al. 2008; Tai et al. 2009), thus hampering 
the approval of these drugs for the treatment of hypercholesterolemia on a long-term basis. 
However, short-term treatment (up to several weeks) reduced the plasma level of VLDL 
with only minor adverse effects, which disappeared after drug discontinuation (Tai et al. 
2009). It will be interesting to examine whether short-term treatment with MTP inhibitors 
is beneficial in treating HCV infection (Khattab 2009). Furthermore, DGAT1 is required 
for the trafficking of core protein to lipid droplets. Inhibition of DGAT1 activity or RNAi-
mediated knockdown of DGAT1 severely impairs infectious virion production (Herker et 
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al. 2010). Lastly, a recent studies by our group showed that acyl-CoA cholesterol 
acyltransferase (ACAT) inhibitors and cannabinoid 1 (CB1) antagonist are an effective 
strategies against HCV (Read et al. 2014; Shahidi et al. 2014). 
 
1.8 Summary and Research Objectives 
Understanding the molecular and biochemical pathways activated in HCV-infected 
cells will provide targets to interrupt virus replication, and facilitate the development of 
more effective treatments. A unique aspect of HCV is that the entire viral life cycle is 
associated with host lipoproteins: (1) HCV circulates in plasma with lipoprotein as an 
infectious complex (lipoviral particle); (2) Hepatocyte lipoprotein receptors are involved in 
HCV entry; (3) Replication of HCV RNA in hepatic cells is inhibited by inhibitors of lipid 
metabolism; (4) HCV particles released from hepatocytes are attached to lipoproteins; and 
(5) Serum lipid profiles (LDL-C, HDL-C and triglycerides) are associated with rates of 
spontaneous or treatment-induced HCV clearance (Negro 2010). Despite the fact that the 
importance of cellular lipid for HCV infection has been proven (Diamond et al. 2010), the 
extent to which HCV modulates global cellular metabolism to create a favourable 
environment for RNA replication and the production of progeny particles is currently 
unknown, especially at the sub-cellular level. Changes in host lipoprotein expression can 
dramatically affect the lipid content of different sub-cellular compartments. As a result, 
measuring metabolite concentrations in different cellular fractions can identify changes in 
metabolic pathways more accurately than quantifying the relevant enzymes or mRNAs that 
encode them (Kell et al. 2005b; Tan et al. 2009). The endoplasmic reticulum (ER) plays a 
central role in HCV replication: following infection, viral RNA is translated at the ER, 
where viral proteins induce membrane modifications, giving rise to the ‗membranous 
web‘. This web acts as the platform for the synthesis of HCV RNA. Viral structural 
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proteins are then packaged with RNA, assembled into ‗lipoviral‘ particles and exported 
through the ER-Golgi pathway (Gastaminza et al. 2008b). Thus, understanding HCV/host 
lipoprotein interactions at the level of the ER should provide novel insights into the HCV 
life cycle that would be missed by studying the whole infected cell in isolation. 
 
Research objectives: 
1) Examine the effect of HCV infection on the hepatocyte lipidome by comparing 
global lipidomic profiles between HCV-infected (JFH1) and uninfected Huh-7 cells using 
a multi-analytical approach. 
2) Examine the effect of HCV infection on the lipid content of specific Huh7 cell 
fractions (LDs and ER), using the same multi-analytical approach, to determine the 
mechanism of HCV-induced ER membrane modifications. 
3) Investigate the potential translational applications of these findings for the 
development of novel HCV therapies. 
Some previous studies have performed fairly crude analysis of specific lipids, such 
as triacylglycerol using biochemical assays (Negro & Sanyal 2009), but have not examined 
all major lipid species in a true quantitative way. Nor have they analysed the FA 
composition of lipids. Other studies have performed global mass spectrometry analysis of 
whole lipid extracts (Diamond et al. 2010), but this approach provides limited quantitation 
and can be biased by strong signals from polar lipids.  
This study combined high performance thin layer chromatography (HPTLC) 
separation of lipids with automated multiple development (AMD) technology for the first 
time to analyse changes in the lipid content of HCV-infected cells (Figures 1.18 A and B). 
HPTLC-AMD technology provides consistent, optimized extraction and fractionation 
systems to fractionate lipid extracts before more detailed analysis is performed. The silica 
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gel plate is developed with a reproducible stepwise elution gradient from polar to unpolar, 
allowing separation over a wide range of polarity and making it possible to separate 
substances that exhibit few differences in polarity. Software-controlled gradient ensures a 
high reproducibility. The advantages of using HPLTC technology are as follows: 
1.  HPTLC identifies major lipid species and provides accurate, reproducible 
quantitation. This shows which lipid classes are increased or decreased in infected cells. 
2. Cell fractionation allows a more detailed analysis of the relative increase/decrease 
of lipids, as in point 1, but in individual sub-cellular compartments. 
3.  Lipid mass spectrometry can be used downstream to determine the individual FA 
composition of lipid species that are altered (up or down). The purpose of this approach is 
to identify which enzymes are responsible for the change. 
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Figure 1.18 HPTLC-AMD instruments. 
(A) Automatic thin layer chromatography (TLC) sampler. (B) high performance thin layer 
chromatography (HPTLC) development chamber  (http://www.camag.com). 
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2. Materials and Methodology 
2.1 Materials 
2.1.1 Chemical reagents  
Dulbecco‘s modified Eagle‘s medium (DMEM) and phosphate-buffered saline 
(PBS) were purchased from Lonza. Foetal calf serum (FCS), penicillin, Geneticin (G418), 
streptomycin, Opti-MEM media and GlutaMAX™ were purchased from Gibco BRL. An 
Ultraclean® tissue and cells RNA isolation kit was purchased from Mol Bio Laboratories. 
A RNeasy miniprep kit was purchased from Qiagen. A Superscript III First Strand cDNA 
Synthesis kit, RNAiMax™ transfection reagent, Taq DNA polymerase, random hexamers, 
deoxynucleotides, a SYBR green master mix and DTT were purchased from Invitrogen. 
MMLV reverse transcriptase and the T7 RiboMAX™ Express Large Scale RNA 
Production System were purchased from Promega. Real-time PCR buffer premix D was 
purchased from Epicentre. Primers were purchased from Geneworks, and TaqMan® 
primer probes were purchased from Applied Biosystems. 
Tween 20, tetramethylethylenediamine (TEMED), ammonium persulfate (APS), 
Triton X- 100, bovine serum albumin (BSA) and all horseradish peroxidise (HRP) 
conjugated secondary antibodies were purchased from Sigma-Aldrich. Nitrocellulose 
paper,a DC™ protein assay kit, and 30% acrylamidewere purchased from Bio-Rad. 
SuperSignal West pico-chemiluminescent and SuperSignal West femtochemiluminescent 
substrates and a PageRuler™ Plus pre-stained protein ladder were purchased from Thermo 
Scientific. 
Chloroform, hexane, isopropanol and ethylacetate were purchased from VWR 
BDH Prolabo. Ethanol, methanol, dichloromethane and copper (II) sulfate heptahydrate, 
cholesterol and cholesteryl oleatewere purchased from Sigma. Phospholipid standards, 
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including1,2-Dioleoyl-sn-Glycerol-3-[phosphor-L-Serine]1-Oleoyl-2-Hydroxy-sn-
Glycero-3-Phosphocholine; 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine; and 1,2-
Dioleoyl-sn-glycero-3-[Phospho-rac-(1-glycerol)], were purchased from Avanti Polar 
Lipids.All neutral lipid standards, including 1-Oleoyl-glycerol; 1,3Diolein; cardiolipin; 
cholesterol and cholesteryl linoleate, were purchased from Sigma. Silica gel 60 HPTLC 
plates and solvents were purchased from EMD Chemicals. 
HCV rabbit anti-core (308) and sheep anti-ADRP antibodies were kindly provided 
by Dr. John McLauchlan (University of Glasgow, UK). HCV sheep anti-NS5A was 
provided by Prof. Mark Harris (University of Leeds, UK). STAT1, phosphor-STAT1, eIF-
2α and Erlin 1 Rabbit polyclonal antibodies were purchased from Cell Signaling. Alexa 
488-conjugated Donkey-anti-Rabbit secondary antibody, Alexa 594-conjugated Donkey-
anti-sheep secondary antibody, BODIPY 493/503 (4,4-difluoro-1,3,5,7,8- pentamethyl-4-
bora-3a,4a-diaza-s-indacene; 10 μg/mL) and Prolong GOLD mounting medium were 
purchased from Invitrogen. Human S-Adenosyl-Methionine (SAMe) ELISA kit was 
purchased from MyBioSource. 
2.1.2 Immunological reagents 
The monoclonal antibodies (mAbs) and polyclonal antisera (pAbs) that were used 
in this study are detailed below. 
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Table 2.1: List of antibodies and Western blot conditions used for protein 
quantification. 
                         
1
°
 Antibody 
      
Raised in 
                   
Working 
dilution 
 
2
°
 Antibody 
                 
Working 
dilution 
PEMT 
(LSBio) 
Rabbit 
1:1000 in 5% 
skim milk/TBST 
Anti Rabbit-IgG 
(Sigma) 
1:10000 in 5% 
skim milk/TBST 
STAT1α   
(Santa Cruz) 
Rabbit 
1:1000 in 5% 
skim milk/TBST 
Anti Rabbit-IgG 
(Sigma) 
1:10000 in 5% 
skim milk/TBST 
pSTAT1 
(Cell 
signaling) 
Rabbit 
1:1000 in 5% 
skim milk/TBST 
Anti Rabbit-IgG 
(Sigma) 
1:10000 in 5% 
skim milk/TBST 
HCV NS5A Sheep 
1:1000 in 5% 
skim milk/TBST 
Anti Goat-IgG 
(Sigma) 
1:10000 in 5% 
skim milk/TBST 
HCV Core Rabbit 
1:1000 in 5% 
skim milk/TBST 
Anti Rabbit-IgG 
(Sigma) 
1:10000 in 5% 
skim milk/TBST 
DDX3X 
(Santa Cruz) 
Rabbit 
1:500 in 5% 
skim milk/TBST 
Anti Rabbit-IgG 
(Sigma) 
1:10000 in 5% 
skim milk/TBST 
Erlin-1 Rabbit 
1:500 in 5% 
skim milk/TBST 
Anti Rabbit-IgG 
(Sigma) 
1:10000 in 5% 
skim milk/TBST 
ADRP Sheep 
1:1000 in 5% 
skim milk/TBST 
Anti Goat-IgG 
(Sigma) 
1:10000 in 5% 
skim milk/TBST 
eIF2-α 
(Cell 
signaling) 
Rabbit 
1:1000 in 5% 
skim milk/TBST 
Anti Rabbit-IgG 
(Sigma) 
1:10000 in 5% 
skim milk/TBST 
NFKβ           
(Cell 
signaling) 
Rabbit 
1:1000 in 5% 
skim milk/TBST 
Anti Rabbit-IgG 
(Sigma) 
1:10000 in 5% 
skim milk/TBST 
AKT           
(Cell 
signaling) 
Rabbit 
1:1000 in 5% 
skim milk/TBST 
Anti Rabbit-IgG 
(Sigma) 
1:10000 in 5% 
skim milk/TBST 
Β-actin 
(Sigma), 
Mouse 
1:10000 in 5% 
skim milk/TBST 
Anti Mouse-IgG 
(Sigma) 
1:20000 in 5% 
skim milk/TBST 
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Table 2.2: Primary and secondary antibody dilutions and incubation times for 
immunofluorescence labelling 
1
°
 Antibody Raised in Working dilution 2
°
 Antibody Working dilution 
Anti HCV 
(core) 
 
Rabbit Core 1:1000 in 1% 
FBS/PBS 
Alexa Fluor 
488 
antiRabbit 
IgG 
1:1000 in % 
FBS/PBS 
Anti NS5A 
 
Sheep 1:1000 in 1% 
FBS/PBS 
Alexa Fluor 
594 antiSheep 
IgG 
1:2000 in 
1%FBS/PBS 
 
 
2.1.3 Cell lines  
All replicating viruses were grown in the Huh-7 hepatoma cell line that was 
originally extracted from a liver tumour found in a 57-year-old Japanese male. Huh-7 cells 
were the kind gift of Dr. John McLauchlan (University of Glasgow, UK). The cells were 
cultured in Dulbecco‘s minimal essential medium (DMEM) that contained 4.5 g/L D-
Glucose and L Glutamine (Walkersville MD USA) supplemented with 10% foetal bovine 
serum (FBS) and 100 U/ml penicillin/streptomycin (Gibco-Life Technologies). 
2.1.4 Plasmid 
Plasmid DNA encoding JFH1 (pJFH1) were the kind gift of Prof. Takaji Wakita 
(National Institute of Infectious Disease, Tokyo, Japan). HCV RNA was prepared 
according to the method described by Wakita et al. (Wakita, Pietschmann, Kato, Date, 
Zhao et al. 2005) (see Section 2.2.2.1).  
 
 
Chapter 2: Materials and Methodology 
67 
 
2.1.5 Solutions 
Table 2.3 Standard solutions used in this project. 
Solution  Contents 
SDS-PAGE sample loading buffer 100 mM Tris-HCl pH 6.9, 2 % SDS, 
10 % glycerol, 5 % β mercaptoethanol, 
1 µg/ml bromophenol blue 
SDS-PAGE running buffer (10X) 30.0 g of Tris base, 144.0 g of glycine, and 10.0 
g of SDS in 1000 ml of H2O 
Western blot transfer buffer 24 mM Tris, 194 mM glycine, 20% methanol, 
0.1% SDS 
Tris-buffered saline with Tween (TBST) 
buffer 
20mM Tris-HCl, pH 7.4, 500 mM NaCl and 
0.1% Tween 
 
Protease inhibitors solution 
20 mM AEBSF, 100 mM Benzamidine, 
50 mM EDTA, 100 µg/ml Apronitin, 
100 µg/ml Leupeptine 
 
Coomassie stain 
0.2 % Coomassie brilliant blue dye R200, 
50 % methanol, 7 % acetic acid 
 
Destain solution 
5 % (v/v) methanol, 7 % (v/v) acetic acid 
(in H20) 
 
MTE buffer 
10 mM Tris-base, 2 mM MgCl2, 1 mM 
DTT, 270 mM D-mannitol, 0.1 mM 
EDTA, protease inhibitor mixture, pH 
to7.5 with 6 M HCl 
Modified Barth's saline (MBS) buffer 0.15 M NaCl, 25 mM, Mes, pH 6.5 
Hypotonic lysis medium (HLM) buffer 40 mM Tris, pH 7.4, 2 mM EDTA, 20 mM 
NaF, protease inhibitors 
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2.2 Methods 
2.2.1 Molecular virology 
2.2.1.1 Tissue culture 
Cells were cultured in Dulbecco's modified Eagle's medium (DMEM) (Sigma) 
supplemented with 10% v/v foetal bovine serum (FBS), 100 U/ml penicillin, 100 g/ml 
streptomycin and 2 mM L-glutamine, and incubated at 37 °C in a humidified incubator 
with 5% CO2. Culture medium for Huh-7 cells was additionally supplemented with 1% v/v 
non-essential amino acids (Cambrex). 
Cells were passaged by washing in phosphate-buffered saline (PBS) pH 6.8 prior to 
incubation with trypsin-EDTA solution pH 8 (Sigma-Aldrich) to disassociate cells from 
the growth surface. Cells were mechanically resuspended in culture medium, quantified 
using a haemocytometer and seeded into fresh culture medium at the desired density. 
2.2.1.2 Transfection of cells with JFH1 RNA 
Huh-7 cells were grown in T150 flasks up to ~80% confluence. Cells were 
harvested by a process of trypsinisation. 4  106 cells were washed twice by centrifugation 
at 1500 rpm for five min in 40 ml of cold phosphate-buffered saline (PBS) and 
resuspended in 1.6 ml cold PBS. Cell suspension was then combined with 4 µl of 
transcribed JFH1 viral RNA, mixed gently and transferred in two electroporation cuvettes 
of 800 µl each. Electroporation was performed with a single pulse at 0.34 kV, 974 μF. 
Electroporated cells were mixed with 10 ml complete media (DMEM+ 10% FCS) in two 
T25 flasks. Cells were then incubated at 37 °C for 3-5 days. Viral protein expression was 
confirmed by immune fluorescence microscopy, using antibody against viral core or NS5A 
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proteins. JFH1 virus-infected cells were allowed to grow for no longer than six passages to 
limit viral mutations. 
2.2.1.3 Harvesting cells 
Following removal of supernatant, Huh-7 cells or JFH1-infected cells were washed 
once with PBS and then detached by trypsinisation. Identically treated cells were pooled 
from replicate flasks, if necessary, to obtain 2  107 total cells per time point, per 
condition. Cells were washed twice in PBS, pelleted and stored at −80 °C until sample 
preparation. 
2.2.2 Preparation, manipulation and analysis of HCV and cellular RNA 
2.2.2.1 pJFH1 plasmid linearization for in vitro transcription 
DNA plasmids encoding the HCV genotype 2a strain JFH1 (pJFH1-pUC) were 
linearized at the 3′ end of the HCV DNA with the restriction enzyme XbaI (Promega). 
According to the manufacturer‘s protocol, plasmids encoding the full-length of the JFH1 
isolate were linearized by XbaI digestion overnight at 37 °C. XbaI was heat-inactivated at 
65 °C for 20 minutes, after which samples were cooled to RT then incubated for 10 
minutes on ice. The four terminal nucleotides produced by linearization were removed by 
treating the samples with 1 μl Mung Bean Nuclease (New England Biolabs) for 45 min at 
30 °C, resulting in the correct 3‘-end of the HCV DNA. Mung Bean Nuclease was 
inactivated with the addition of 0.1 % w/v SDS and the DNA was purified by 
phenol/chloroform extraction and ethanol precipitation before being resuspended in 
RNase-free water.  
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2.2.2.2 In vitrotranscription of HCV RNA 
After precipitation and purification of the plasmid DNA, RNA transcription was 
performed using a T7 RiboMAX™ Express Large Scale RNA Production System kit 
(Promega). The reaction mixture, which consisted of 1x RiboMAX™ Express T7 buffer, 1 
μg of linearized template DNA and 2 μl of T7 express enzyme mix, was then increased to 
a volume of 20 μl using nuclease-free water. The mixture was made in accordance with the 
manufacturer's instructions. After combining the mixture gently, it was incubated at 30°C 
for 30 min. One unit of RQ 1 RNase-free DNase was added to the mixture and incubated 
for 15 min at 37 °C. To remove protein, an equal volume of phenol: chloroform: 
isoamylalcohol (125:24:1) pH 4.0 (Sigma) was added, the mixture was vortexed for one 
minute, followed by centrifugation at 16,100  g for two minutes. The aqueous phase of 
the extracted mixture was transferred to a new tube and then mixed with an equal quantity 
of chloroform, vortexed for one minute and then centrifuged for two more minutes at 
16,100  g. The aqueous phase was transferred to a new tube where the RNA was 
precipitated by adding 1/10th volume v/v of 3 M sodium acetate pH 5.2 and the same 
volume of isopropanol. The extracted samples were vortexed thoroughly, then incubated 
on ice for five min. The precipitated RNA was then converted into pellets through 
centrifugation. Centrifugation was performed at 16,100  g for 10 min. The pellets were 
washed with 70 % v/v ethanol, then pelleted again. The pellets were air-dried, then 
dissolved in 20 μl RNase-free water. RNA was quantified using a NanoDrop ND1000 
spectrophotometer and RNA integrity was checked by agarose gel electrophoresis.  
2.2.2.3 Extraction of total RNA from cells 
Total RNA was extracted from cell culture monolayers using the Qiagen RNeasy 
Kit, according to the manufacturer‘s instructions. In brief, cells in six-well plates were 
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lysed in 350 μl of RNeasy Lysis buffer and transferred to a new RNase-free tube. Next, 
350 μl of 70% ethanol was added to each cell lysate and mixed thoroughly. 700 μl of 
sample solution was applied to an RNeasy spin column in a collection tube and centrifuged 
for 30 seconds at 10,000 RPM. The flow-through was discarded, and 700 μl wash buffer 
RW1 was added to each spin column and centrifuged for 30 seconds at 10,000 RPM. After 
transferring the spin column to a clean tube, 500 μl of second wash buffer, RPE was 
applied to each column and the tubes centrifuged as per the process described above. This 
step was repeated, RNA was eluted from the spin column with 50 μl of RNase-free water 
and centrifuged for one minute at 10,000 RPM into a clean, RNase-free tube. Eluted RNA 
was quantified using a NanoDrop ND1000 spectrophotometer and stored at -80 °C for 
subsequent experiments. 
2.2.2.4 Extraction of RNA from extracellular HCV virions 
RNA was extracted using the FavoPrep
TM 
kit (Favorgen Biotech corp). In brief, 
140 μl of supernatant from JFH1-infected Huh-7 cells was mixed with 560 μl lysis buffer 
containing carrier RNA and incubated at room temperature for 10 minutes. After the 
addition of 100% ethanol, the mixture was transferred to QIAamp Mini columns and tubes 
were centrifuged at 8000 RPM for one minute. RNA was then washed twice using AW1 
and AW2 washing buffers and eluted from mini columns with 30 μl buffer AVE. The 
extracted RNA was stored at -80 °C for future experiments. 
2.2.2.5 First-strand cDNA synthesis 
cDNA was reverse transcribed from total RNA using M-MLV reverse transcriptase 
(Promega) according to the manufacturer‘s instructions. In brief, 0.5 μg RNA and 250 
ng/μl random hexamer primers (Invitrogen) were added to a sterile RNase-free 
microcentrifuge tube in a total volume of ≤ 15 μl water. The mixture was incubated at 70 
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°C for five minutes to melt the mRNA secondary structure. The tubes were immediately 
cooled on ice for at least one minute. A reaction mixture containing 1x MMLLV reaction 
buffer (Promega), 0.5 μM each dNTPs (Invitrogene), 40 units RNaseOUT™ Ribonuclease 
(RNase) Inhibitor (Invotrogen) and 200 units M-MLV RT was prepared and added to the 
primer/template tube. Samples were mixed gently and incubated for 60 minutes at 37 °C. 
The synthesized cDNA was stored at -20 °C for further experiments. 
2.2.2.6 Real-time PCR 
Real-time quantitative PCR (qPCR) was performed using the Rotor-Gene 6000 
(Corbett Research, Sydney, NSW, Australia) with SYBR Green or Taqman protocols. 
mRNA levels were normalized to 18S ribosomal RNA or GAPDH, which produced 
comparable results. Real-time qPCR reaction conditions comprised initial denaturation at 
95 °C for 10 min, followed by 45 cycles of 95 °C for 15 seconds and 60 °C for 45 seconds. 
A melt curve analysis was performed at the end of each run of the SYBR Green protocol to 
confirm the generation of specific PCR products. QPCR results were analysed using 
Rotor-gene 6000 Corbett software. The fold change of each gene was calculated using the 
Delta-delta threshold (ΔΔCt) data analysis method. 
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Table 2.4 List of primer sequences used for real-time qPCR. 
            
Gene Forward Reverse 
PEMT 5’GGATGAAGAGATCTGGGAACC3’ 5’ATGACGGCAGCCACAAAG3’ 
PYCT 1A 5’TCCCGAATTCATTGGAAG3’ 5’TGAAGCGACAGGTTTCTTCTG3’ 
ISG15 5’CGCAGATCACCCAGAAGATC 3’ 5’GCCCTTGTTATTCCTCACCA 3’ 
OAS3 5’GTCAAACCCAAGCCACAAGT 3’ 5’GGGCGAATGTTCACAAAGTT 3’ 
SREBP-
1c 
5’GCCATGGATTGCACTTT3’ 5’CAAGAGAGGAGCTCAATG3’ 
ABCA1 5'GCACTGAGGAAGATGCTGAAA 3’ 5'AGTTCCTGGAAGGTCTTGTTCAC 3’ 
GAPDH 5’CCATTCAATGACCCTTGTTG-3’ 5’CTGGGATTTCCATTGATGACAAG-3’ 
 
Table2.5 List of Taqman gene expression assays used for real-time qPCR. 
Gene symbol Gene name Supplier Gene ID 
HCV 5‘UTR PATHOGEN 
Applied Biosystems, 
Foster City,CA 
Pa03453408_s1 
18S 
 
Eukaryotic, 18S 
Applied Biosystems, 
Foster City,CA 
Hs03003631_ml 
MTP 
Microsomal 
triglyceride transfer 
protein 
Applied Biosystems, 
Foster City,CA 
Hs00165177_ml 
LDL-R 
Low density 
lipoprotein receptor 
Applied Biosystems, 
Foster City,CA 
Hs00181192_ml 
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Table 2.6 Real-time qPCR reactions content using forward and reverse Primers. 
Component Volume (μl) Final concentration 
Fast SYBER Green qPCR 
Master Mix (Invitrogen) 
10 1X 
Forward Primer (10 μM) 0.5 0.25 μM 
Reverse primer (10 μM) 0.5 0.25 μM 
Diluted cDNA Template 2  
RNase free H2O 7  
Total Reaction volume 20  
 
Table 2.7 Real-time qPCR reaction content using Taqman gene expression assay. 
Component Volume (μl) 
MasterAMPTM2X PCR 
PreMix D (Epicenter) 
10 
Taqman Gene expression 
assay 
0.5 
Taq DNA Polymerase 
Recombinant 5U/μl 
(Invitrogen) 
0.4 
Diluted cDNA Template 2 
RNase free H2O 7.1 
Total Reaction volume 20 
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2.2.2.7 siRNA knockdown 
PYCT1A and PEMT siRNA (Origene) were transfected into JFH1-infected Huh-7 
cells using Lipofectamine transfection. Transfections were carried out using the 
Lipofectamine RNAiMAX (Invitrogen, CA, USA) kits according to the manufacturer‘s 
guidelines. Briefly, JFH1-infected Huh-7 cells were seeded at 1105 cells per well into a 
12-well plate in P/S free media for one day before transfection. siRNA-RNAiMax complex 
was made up as follows: 10 nmol siRNA was added to 85 μl of Opti-MEM (Invitrogen) 
and mixed gently. 1.4 μl RNAiMAX was added to 80 μl of Opti-MEM and mixed gently. 
Diluted siRNA and diluted RNAiMAX were combined and incubated at room temperature 
for 30 min to allow the formation of complexes. Complexed RNAi was added to wells 
containing 1 ml of P/S free DMEM. Transfections were carried out at 37 °C. Expression 
efficiency was assessed 48 h post-transfection using qPCR.  
 
2.2.3 Concentration of JFH1 viruses (PEG precipitation)  
JFH1-infected Huh-7 cells were cultured in T150 tissue culture flasks, in 200 ml of 
DMEM media containing 10% FBS. After ten days, the culture media was removed and 
filtered through a 0.45 µm MillEX-HV (MILLIPORE) membrane to remove all cellular 
debris. 40 mL of 40% w/v polyethylene glycol (PEG) (PEG 8000, PROMEGA) was added 
to the culture media to produce an 8% w/v mixture. The mixture was incubated overnight 
at 4
o
C with gentle agitation. All the tubes were then centrifuged at 8000 x g for 20 minutes 
at 4 
o
C. Pellets were collected and resuspended, either in TNE buffer or complete medium, 
then processed for sucrose density analysis. 
 
2.2.4 Tissue culture infective dose (TCID50) 
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Tissue culture infectious dose assay (TCID50) was performed to determine the 
concentration of infectious particle in the culture media (Shavinskaya, Boulant et al., 
2007). Each well of a 96-well plate was seeded with 10
4
-Huh-7 cells and incubated 
overnight at 37 °C. Culture media was drained out of the wells, and 200 µl fresh DMEM 
was introduced in each well. Next, 50 µL of filtered culture media from JFH1-infected 
cells was added to each of the eight wells in the first row, diluting it by 1:5. A 
multichannel pipette was used for further serial dilutions: 50 µl was pipetted out from 
these wells, introduced into adjacent wells in the next row and mixed gently. This step was 
usually repeated six times (determined by the experiment requirements), to dilute 
infectious particles and provide accurate infectious titres.  
After 72 h incubation at 37 °C, cells were washed with PBS buffer, then fixed with 
100% methanol. PBS was supplemented with 2% FCS for antibody blocking, added to 
cells for 30 min at room temperature then washed two times with PBS. PBS containing 
0.3% hydrogen peroxide was added to the cells to inactivate endogenous peroxides. Cells 
were washed in PBS two more times then incubated with anti-NS5A primary antibody 
(1:10,000 dilution) in PBS buffer containing 2% FCS at room temperature for 2 hr. Cells 
were washed in PBS as per the process above, then secondary antibody conjugated to 
horseradish peroxidase was added, diluted 1:100 in PBS buffer containing 2% FCS and 
incubated for 1 hr at room temperature. After the antibody was removed, cells were 
washed thrice in PBS, then horseradish peroxidase substrate (50 µl) was added to the cells 
(VECTOR NovaRED
TM
 Substrate Kit) for 5 min at room temperature. Finally, the wells 
were examined with an inverted microscope at 10  magnification to detect JFH1 
infection. Infected cells were identified by the presence of a red stain surrounding the 
nucleus. Each well was scored as either positive (at least one infectious centre) or negative, 
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and the TCID50 was calculated using the formula described in the Spearman–Karber 
method (Carrère-Kremer et al. 2004). 
 
2.2.5 Immunofluorescence  
Viral infection was confirmed by growing cells on glass coverslips in 24-well 
plates after nearly two passages following electrophoresis of JFH1 RNA. PBS buffer was 
used to wash the cells, and the cells were fixed with 100% methanol at -20 °C for 20 min. 
Alternatively, cells were fixed with 4% paraformaldehyde/PFA along with 0.01% Triton 
-100 for 5 minutes. Next, as a blocking step, cells were incubated in PBS containing 2% 
FCS at room temperature for 1 hr. After washing, cells were next incubated for 1 h at room 
temperature with anti-core or anti-NS5A antibody (Table 2.2) at 10× Western blotting 
concentrations in 2% FCS (see Table 2.2). Cells were washed thrice with PBS and 
incubated with fluorescent secondary antibodies, diluted 1:2000 in 2% FCS. Coverslips 
were again washed thrice with PBS and examined at 40 x magnification using the Zeiss 
Axiovert 200 M live cell imaging microscope. 
 
2.2.6 Statistical analysis 
Raw data was first analysed using Microsoft Excel. Graphs were generated, and statistical 
analysis was performed using GraphPad Prism 5 (GraphPad Software Inc., CA, USA). 
Student‘s t-test was used as appropriate to determine statistical significance between 
groups, with p < 0.05 deemed significant (*), p < 0.01 very significant (**) and p < 0.001 
extremely significant (***). 
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2.3 Proteomics 
2.3.1 Cellular protein extraction 
Cellular protein was extracted from cell culture monolayers using RIPA (Radio 
Immunoprecipitation Assay) buffer (Sigma). First, DMEM media was removed from six-
well plates, and the cells were washed with ice-cold PBS. Cells in each well were scraped, 
and 600 μl of cell suspension in PBS transferred to Eppendorf tubes that were then 
centrifuged to pellet the cells. RIPA buffer containing a mix of Phosphatase Inhibitor 
Cocktail 2 (Sigma), Complete Protease Inhibitor Cocktail (Roche), Phenylmethanesulfonyl 
fluoride (PMSF) and sodium fluoride was added to the cell pellet in each tube. Cell pellets 
were resuspended in lysis buffer by pipetting, and incubated on ice for 30 minutes. The 
lysates were then centrifuged at 14,000 RPM for 10 minutes at 4 °C, and supernatant 
containing extracted protein was transferred to a clean tube. Protein samples were then 
aliquoted and stored at -80 °C for future experiments. 
 
2.3.2 Protein precipitation protocols 
2.3.2.1 Trichloroacetic acid (TCA) 
 One volume of TCA stock was added to four volumes of protein sample, incubated for 
10 min at 4 °C, centrifuged at 14,000 rpm for 5 min, then supernatant was removed, 
leaving the protein pellet intact. The pellet was washed twice with 200 μl cold acetone 
then dried by placing the tube in 95 °C heat block for 5-10 min to drive off acetone. For 
SDS-PAGE, 2 or 4 sample buffer was added (with or without -ME), and the sample 
was heated for 10 min at 95 °C before being loaded onto polyacrylamide gel.  
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2.3.2.2 Acetone precipitation 
Proteins from detergent-insoluble fractions were precipitated with acetone, 10% 
trichloroacetic acid, 0.07% β-mercaptoethanol for 1 h at −20 °C. Following centrifugation 
at 4000 × g for 10 min, pellets were washed with acetone, 0.07% β-mercaptoethanol. 
 
2.3.3 Protein quantification 
Protein concentrations were determined using the Bio-Rad DC assay kit with 
purified bovine serum albumin (Sigma) as standard. Briefly, 20 μl of reagent S was added 
to 1 ml of reagent A. Then, 5 μl of standard and samples were transferred to a clean 
microtitre plate, and 25 μl of reagent A+S was added to each well. Next, 200 μl reagent B 
was combined with the content of each well and, after 15 minutes incubation at room 
temperature, the absorbance was read at 750 nm using a Wallac Victor 1420 Multipliable 
Counter Microplate Reader. 
 
2.3.1 Cellular protein extraction 
Cellular protein was extracted from cell culture monolayers using RIPA (Radio 
Immunoprecipitation Assay) buffer (Sigma). First, DMEM media was removed from six 
well plates and cells were washed with ice-cold PBS. Cells in each well were scraped and 
600 μl of cell suspension in PBS transferred to Eppendorf tubes that were then centrifuged 
to pellet the cells. RIPA buffer containing a mix of Phosphatase Inhibitor Cocktail 2 
(Sigma), Complete Protease Inhibitor Cocktail (Roche), Phenylmethanesulfonyl fluoride 
(PMSF) and sodium fluoride was added to the cell pellet in each tube. Cell pellets were 
resuspended in lysis buffer by pipetting, and incubated on ice for 30 minutes. The lysates 
were then centrifuged at 14,000 RPM for 10 minutes at 4 °C, and supernatant containing 
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extracted protein was transferred to a clean tube. Protein samples were then aliquoted and 
stored at -80 °C for future experiments 
 
2.3.4 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
The concentrations of separating and stacking gels were 10% and 5% respectively, 
and gel casting was performed in a Bio-Rad Mini PROTEAN® Tetra Cell gel tank. The 
volume of protein sample that was introduced to each well was 20 to 50 µl, preparation 
was performed in a 4 SDS-PAGE sample buffer and the mixture was boiled for five 
minutes at 95 
o
C prior to separation by SDS-PAGE. Gels were placed in 1× running buffer 
and samples loaded into wells. A 100 V potential was used for electrophoresis. The protein 
size was estimated by comparing to commercial standards, PageRulerTM Plus Pre-stained 
Protein Ladder (Thermo Scientific). Gels were either stained with Coomassie Brilliant 
Blue G250 stain or proteins were transferred to membranes for Western blot analysis.  
 
2.3.5 Western Blot Protein Analysis 
Proteins separated on polyacrylamide gels were transferred to Nitrocellular (Bio-
Rad) or Polyvinylidene fluoride (Millipore) membrane using a BioRad Trans-Blot SD 
blotting device. Transfer was carried out at 35 V overnight at a temperature of 4 °C. Skim 
milk powder (10%) dissolved in TBST buffer (containing 20mM Tris-HCl, pH 7.4, 500 
mM NaCl and 0.1% Tween) was used to block membranes after protein transfer by 
incubating for 1 hr at room temp with gentle agitation. Membranes were incubated 
overnight with primary antibodies diluted in 5% skim milk/TBST at a temperature of 4 
o
C, 
then washed three times in TBST buffer. Secondary antibody conjugated to horseradish 
peroxidase, diluted in TBST/10% skim milk, was added for one hour at room temperature, 
Chapter 2: Materials and Methodology 
81 
 
with gentle agitation, then rinsed off as previously described. Visualisation of the bound 
antibody was facilitated by the use of a Super Signal West Pico Chemiluminescence Kit 
(Thermo Scientific) and membranes were exposed to Kodak BioMax Film for different 
time intervals. Table 2.6 lists the different primary and secondary antibodies used in the 
Western blot analysis. 
 
2.3.6 Densitometry analysis 
Autoradiographs of Western blots were scanned and analysed using ImageJ 
software. A boxed area of fixed size was selected around each band, images were colour 
inverted, then the band density for each protein species was calculated. Mean density 
values for each sample area were calculated and then the background density value for 
each box was subtracted.  
2.3.7 2-Dimension polyacrylamide gel electrophoresis (2-D PAGE) for proteomics 
The first dimension isoelectric focussing was carried out using 8 cm immobilized 
pH gradient dry strips (IPG) with a linear pH 4–7 gradient. For rehydration, the sample in 
an appropriate volume of rehydration buffer (Urea 7 M, Thiourea 2 M, Tris 30 mM and 
CHAPS 4%. up to 50 ml Milli-Q H2O) was passively rehydrated overnight at room 
temperature in IPGPhor cassettes. Proteins were separated by the Ettan IPGphor II using a 
programmed voltage gradient at 20 °C, under the following conditions: 4 h at 400 V, 8000 
V linear gradient 1 h, rapid 8000 V to 20000 V hrs. After IEF, the IPG strips were 
equilibrated in SDS equilibration buffer (50 mM Tris-HCl pH 8.8, 6 M urea, 30% glycerol, 
2% SDS and 1% DTT) and buffer two containing 2.5% iodoacetamide instead of DTT in 
each case for 20 minutes. 
Second dimension separation was performed using the PROTEAN® II (Bio-Rad) 
Cell system. The equilibrated strips were applied to the top of 12% SDS-PAGE gels and 
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sealed with 1% agarose prepared in SDS-Tris-glycine buffer, with traces of bromophenol 
blue as a tracking dye to monitor electrophoresis. Electrophoresis was performed at a 
constant voltage (150 V) at 20 °C until the dye front reached the bottom of the gel. 
Following electrophoresis, the gel was stained using Coomassie Brilliant Blue G250 stain. 
Briefly, gels were fixed in 10% methanol and 7% acetic acid for at least 20 minutes, and 
then immersed in colloidal staining solution overnight. To remove background staining, 
gels were washed in 1% methanol. 
 
2.3.8 In-gel trypsin digestion of gel bands 
Protein bands were excised, and gel pieces were destained using 35 mM 
ammonium bicarbonate, 40% (v/v) acetonitrile, before dehydrating with 100% acetonitrile. 
Dehydrated gel pieces were completely dried in a vacuum centrifuge then 15 µl trypsin (12 
ng/µl in 50 mM ammonium bicarbonate) was added. After being incubated on ice for 1 h, 
all excess trypsin was removed, and 15 µl of 50 mM ammonium bicarbonate was added 
before incubating the tubes overnight at 37 °C.  
 
2.3.9 Protein mass spectrometry 
Tryptic peptides were analysed on an AB SCIEX TOF/TOF 5800 (MALDI) mass 
spectrometer using alpha-cyano-4-hydroxycinnamic acid as matrix. Mass spectrometry 
data were processed with ProteinPilot software at The Biomedical Proteomics Facility and 
the Australian Cancer Research Foundation Centre for Kinomics (ACRF CFK), Children‘s 
Medical Research Institute, Westmead, Australia. 
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2.4 Lipidomics 
2.4.1 Cell fractionation 
A sonicator (Probe Sonicator) was used to homogenize the cell pellet. The lysate 
was also centrifuged at 800 × g for 5 min to remove nuclei. The cytosolic fraction 
(supernatant) and the membrane fraction (precipitate) were separated from the post-nuclear 
fraction by centrifugation at 14,000 × g for 20 min. BSA was used as the standard to 
determine the concentration of protein used in the preparation for normalisation. The 
concentration was set in accordance with BCA protein assay reagents (Pierce 
Biotechnology, Rockford, IL, USA). The membrane fractions used for the experiment 
were re-suspended in a buffer and purified again through a process of ultracentrifugation. 
 
2.4.2 Isolation of Endoplasmic Reticulum (ER) 
Virus infected and control Huh-7 cells were plated in 150 cm
2
 flacks until 90% 
confluent. They were then washed two times with PBS and harvested with 0.05% trypsin. 
The cells were pelleted by undergoing centrifugation at 1500 × g for 5 min. The cell pellet 
was resuspended in 1 ml of MTE buffer (10 mM Tris-base, 2 mM MgCl2, 1 mM DTT, 
270 mM D-mannitol, 0.1 mM EDTA, protease inhibitor mixture, pH to7.5 with 6 M HCl) 
and incubated at 0 °C for 5 min. Unless stated, the following procedures were performed 
on ice. The cells were disrupted using sonication at low power (3 × 5 sec, amplitude 10%), 
separated by 10-sec rest intervals. The lysate was clarified of unbroken cells by 10 min 
centrifugation at 8,000 x g. The supernatant was transferred on top of a three-step sucrose 
gradient: bottom to top, 1 mL 2M sucrose, 3 mL 1.5 M sucrose, and 5 ml 1.3 M sucrose. 
All sucrose gradients were prepared using an MTE buffer. The gradients were spun for 1 h 
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at 32000 rpm in a Beckman SW 41 rotor, and the large band (ER gradient) at the interface 
of the 1.3 M sucrose gradient was collected. The extracted band was transferred to 14 × 
89-mm ultra clear SW41 tubes and filled up to the top with ice-cold MET buffer, mixed 
and ultracentrifuged for 1 h at 32000 rpm. Supernatant was discarded, and the pellet was 
resuspended in 500 µl PBS, labelled as ER, and stored immediately at -80 
º
C. 
 
2.4.3 ER lipid rafts isolation using detergent-free purification  
To allow the purification of ER-lipid rafts without the use of detergent, Triton -
100 was replaced with sodium carbonate (Song et al. 1996). The pellet from ER isolation 
(Section 2.4.2) was resuspended in 2 ml of 0.5 M Na3CO, pH 11.0. The suspension was 
adjusted to 45% sucrose by adding 2 ml of 90% sucrose prepared in MBS (0.15 M NaCl, 
25 mM Mes, pH 6.5) and laid at the bottom of an ultracentrifuge tube. 5% and 35% 
sucrose solutions, both in MBS containing 250 mM Na3CO, were added carefully to form 
a 5-35% discontinuous sucrose gradient and centrifuged at 39,000 rpm for 18 h in an 
SW41 Ti Beckman rotor. ER-Lipid rafts were collected from the light scattering band 
confined to the 5-35% sucrose interface.  
2.4.4 Isolation of lipid droplets (LDs) 
LDs were isolated by subcellular fractionation following published protocols 
(Brasaemle & Wolins 2006). Cells were trypsinised from culture flasks, pelleted by 
centrifugation at 2000 RPM for 5 min and suspended in 1 ml hypotonic lysis medium 
(HLM) buffer (40 mM Tris, pH 7.4, 2 mM EDTA, 20 mM NaF, protease inhibitors). After 
incubation on ice for 10 min, the cells were sonicated (2 × 10 sec, amplitude 10%), then 
centrifuged at 4000 × g for 10 min, the resulting supernatant with the floating fatty layer 
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was collected as the non-nuclear fraction into a separate 13.2 ml ultracentrifuge tube for a 
SW41 Ti rotor. 1/3 volume of ice-cold HLM containing 60% sucrose was added and 
mixed by gentle pipetting (final 20% sucrose). To form discontinuous gradients, 2.5 ml 
ice-cold HLM containing 15% sucrose and 4 ml ice-cold HLM containing 5% sucrose 
consecutively were slowly layered over the sample, then 5 ml ice-cold HLM was layered 
over the gradients to fill the tube. Gradients were spun for 45 min at 28000 x g at 4 °C. 
Four discrete fractions were collected sequentially from top to bottom. The lipid droplet 
fraction was collected from the top layer (fraction 1). The protein content of each fraction 
was analysed using DC Protein Assay (Bio-Rad). A small aliquot of the lipid droplet 
fraction was removed and confirmed to contain LDs by SDS-PAGE separation and 
immunoblotting with antibody against the lipid droplet associated protein, adipocyte 
differentiation-related protein (ADRP). 
2.4.4.1 LDs protein extraction 
Lipid droplet fractions contain a large amount of neutral lipids, including 
triacylglycerols, cholesterol esters, and phospholipids, but a low relative amount of 
protein. The high lipid content of the samples interfered with the resolution of proteins by 
SDS-PAGE. To overcome this obstacle, fresh or frozen lipid droplet fractions were 
delipidated using solvents, and the precipitated proteins were solubilised in concentrated 
detergent solutions through warming and sonication (Brasaemle and Wolins, 2006). In a 
fume hood, 10 volumes of cold acetone that had been stored at −80 °C were added to the 
thawed or fresh lipid droplet fraction in 15 ml falcon tubes. Samples were mixed 
thoroughly by inversion and incubated overnight at −20 °C. The precipitated protein 
samples were pelleted by centrifugation at 4,300  g for 10 min at 4 °C, then acetone was 
carefully removed from the loose pellet with a glass pipette and discarded into a suitable 
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container. 50-100 µl of 2 × SDS sample buffer was added to the dry pellet, mixed, and 
incubated for 4 to 6 h at 60 °C in a sonicating water bath with vigorous agitation every 15 
min using a vortex mixer. After adding β-mercaptoethanol (10% final), the samples were 
loaded onto an SDS-PAGE gel in 2 × SDS sample buffer without dilution. 
 
2.4.5 Lipid extraction 
Cellular lipids were extracted using a Bligh-Dyer protocol (Bligh & Dyer 1959) 
with modifications (Pettitt et al. 2006). Fresh or frozen cell pellets were resuspended in 
PBS to achieve a final volume equal to five times the volume of the cell pellet (i.e., a 20% 
cell suspension). The cell suspensions were homogenized in a mixture of methanol and 
chloroform. The ratio of methanol, chloroform and saline solution in the mixture was 
2:1:0.8. One volume of 1M NaCl/ 50 mM HCl (1:1 v/v) was then added to the mixture, 
then one volume of chloroform was introduced to induce phase separation. The ratios of 
methanol, chloroform and water in the final mixture were 2:2:1.8 respectively. The extract 
was left for 5 min at room temperature and then centrifuged at 800  g for 10 min. The 
lower (chloroform) phase was collected and evaporated under a stream of gaseous 
nitrogen. Lipid extracts were stored under N2 (−80 °C) until required. 1 ml of the upper 
(aqueous) phase was collected in Eppendorf tubes and dried under a vacuum with heating 
for protein estimation. 
 
2.4.6 High-performance thin layer chromatography (HPTLC) 
Extracted lipids were dissolved into chloroform/methanol (2:1, v/v) then loaded 
onto HPTLC plates with a parallel dilution series of lipid standards. For neutral and 
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phospholipid separations, plates were pre-washed with methanol/ethyl acetate (6:4, v/v) 
and activated at 110 °C for at least 30 min before loading. Dilution series of both native 
extract and lipid standards in chloroform/methanol (2:1) were loaded onto HPTLC plates 
under N2 using the Automatic TLC Sampler 4 (ATS4) and developed in the CAMAG 
AMD2 (CAMAG, Wilmington, NC, USA) (Churchward, Brandman, Rogasevskaia & 
Coorssen 2008; Churchward, Rogasevskaia, Höfgen, Bau et al. 2005). For neutral lipids 
and sterols, HPTLC plates were developed twice with dichloromethane/ethyl 
acetate/acetone (80:16:4, v/v/v) to 40 and 55 mm, then sequentially three times with 
hexanes/ethyl acetate to 68 mm (90:10, v/v), 80 mm (95:5), and 90 mm. Phospholipids 
were developed according to Weerheim (Weerheim, Kolb, Sturk & Nieuwland 2002) with 
modifications (Churchward, Brandman, Rogasevskaia & Coorssen 2008), using two-step 
separation. HPTLC plates were first developed with dichloromethane/ethyl acetate/acetone 
(80:16:4, v/v/v) to 90 mm, dried under a vacuum for 6 min, then developed again to 90 
mm with chloroform/ethylacetate/acetone/isopropanol/ethanol/methanol/water/acetic acid 
(30:6:6:6:16:28:6:2, by volume). 
 
2.4.6.1 Chromatogram staining and visualization of HPTLC plates 
After development, plates were sprayed uniformly with 10% cupric sulfate in 8% 
aqueous phosphoric acid (Daugherty 1987; Churchward, Brandman, Rogasevskaia & 
Coorssen 2008), allowed to dry for 10 min at room temperature, and then heated in an 
oven at 145 °C for 10 min. 
Imaging of cupric-sulfate-charred plates was carried out using the Luminescent 
Image Analyser LAS-4000 (Fuji Film, Japan). All images were analysed using Multi 
Gauge V3.0 software. 
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2.4.7 Lipid mass spectrometry 
Samples were analysed using both positive and negative electrospray ionisation on 
a Thermo Fisher Scientific QEXactive Plus mass spectrometer. 
 Samples were dissolved in 200uL solvent A, centrifuged to remove TLC particles 
and transferred into glass LC-MS vials. 10 uL was injected using an ULTIMATE 4000 
system (Dionex) and chromatographed on a Waters CSH 2.1 x 100 mm C18 column 
according to the method described by Castro-Perez et al. (2010). Mass spectrometer 
settings were based on those published by Bird et al. (2011). The instrument was run at an 
140,000 resolution full scan followed by six lower resolution DDA scans on the six most 
intense peaks observed in the full scan. Data was interrogated using Lipid Search software 
(Thermo Fisher Scientific). Samples were analysed multiple times to allow statistically 
significant comparisons to be made. 
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3. HCV infection induces global Changes in the Host Cell Lipidome 
 
3.1 Introduction 
Chronic hepatitis C (CHC) can be considered to be both a viral and a metabolic 
disease. The hepatitis C virus (HCV) interacts with and changes the host's lipid 
metabolism to its advantage, supporting the virus lifecycle through changes in membrane 
transport and sorting, and in cell signalling. To examine HCV-induced changes in the lipid 
metabolism, cellular lipidomics must not only determine which lipids are present, but also 
the concentration of each lipid at each specific intracellular location in time and the lipid‘s 
interaction partners (van Meer 2005). A better understanding of the relationship between 
lipid metabolism and the key stages involved in the production of infectious HCV will 
improve our understanding of the pathophysiology of HCV infection and may provide new 
antiviral drug targets. 
There are basically two groups into which the lipids can be subdivided: non-polar 
or neutral lipids, like acylglycerols and wax esters; and polar lipids, which mostly consist 
of phospholipids (Makula et al. 1975). Lipids perform key functions in all living beings 
(Athenstaedt & Daum 2006). Neutral lipids mostly consist of triacylglycerols and steryl 
esters, and are considered to be hydrophobic molecules because they are deficient in 
charged groups (Devaux 1991). In eukaryotic cells, neutral lipids are the final form in 
which cholesterol and free long-chain fatty acids are stored when cells are exposed to 
excess amounts of nutrients. It is not possible to incorporate these storage lipids into 
biomembranes, so they are separated from the cytosolic environment in membrane-coated 
LDs or lipid particles (Walther & Farese 2009). 
 Phospholipids are an essential part of many processes in the body and comprise 
different membranes and layers of cells. Phospholipids have been classified into various 
groups according to their dimensions, geometry, amount of charge and organic structure. 
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Phospholipids of different classes help to build up the plasma sheath of the cells; their 
uneven distribution within the membrane can aid the performance of a number of 
functions. They also constitute the outer surface of the lipoproteins, which aids the transfer 
of neutral lipids around the body. They help to absorb lipids from the gut, following 
secretion into the bile. Phospholipids also help to monitor the function of various 
molecules, such as arachidonic acid, phosphatidate and inositol trisphosphate, and prompt 
them to function properly. 
Phospholipids are formed when two fatty acyl molecules are ester-linked to the sn-
1 and sn-2 positions of glycerol, leaving a phosphate residue at the sn-3 position (Figure 
3.1). This is the ―head position‖, which allows linking of the phospholipid head group via 
the phosphate residue. Because the head group is typically charged (hydrophilic), while the 
fatty acyl side chains are hydrophobic, this causes the phospholipid molecule to be polar, 
forming biological membranes and leading to compartmentalization of the cell. 
 
Structure and major classes of phospholipids 
http://lipidlibrary.aocs.org 
(PG) (PS) 
(PE) (PC) (PA) 
(PI) 
 
Figure 3.1 Structure and major classes of phospholipids (http://lipidlibrary.aocs.org) 
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Replication of HCV depends on the virus modulating lipid metabolism, thereby 
reconfiguring the endomembrane system. These alterations create an environment that is 
lipid-rich, and allows the virus to replicate efficiently. Analysis of the blood of an HCV-
infected patient reveals that the lipoviral particle biochemically closely resembles the 
VLDL particle (Bassendine et al. 2011). Host cell lipids are a major focus in the HCV life 
cycle, with the intracellular levels and composition of fatty acids, including cholesterol 
being  key factors in HCV RNA replication. 
 Liver steatosis, or fatty liver disease, occurs when there is an accumulation of LDs 
in hepatocytes. HCV interacts with the metabolic syndrome, resulting in insulin resistance 
and obesity in infected patients. HCV genotype 3 is associated with increased steatosis, 
while genotypes 1 and 4 are associated with insulin resistance and diabetes (Hui et al. 
2003; Cua et al. 2008). The results from these studies highlight the clinical importance of 
up-regulated lipid metabolism for HCV replication and offer the potential for new targets 
for antiviral therapy.  
The effects of HCV infection on lipid homeostasis and turnover in hepatic cells 
will be examined in this chapter, together with the redistribution of cellular lipids. The 
experimental outline is summarised in Figure 3.1.  
For these experiments, the JFH-1 HCV cell culture model was used, as this is the 
only HCV model that produces infectious virus particles in vitro (Wakita, Pietschmann, 
Kato, Date, Miyamoto, et al. 2005).  
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3.2 HCV infection and lipid extraction 
JFH1 is the first full-length HCV viral genome capable of replicating and 
producing intact virus in cell culture (Huh-7 cells). Huh-7 hepatoma cells were transfected 
(by electroporation) with full-length viral RNA (JFH1). Uninfected and JFH1-infected 
Huh-7 cells (2×10
6
 cells/flask) were cultured in 3 T150 cell culture flasks until >90% of 
cells were infected (typically 10-14 days). Infection was confirmed by the 
immunofluorescence of the fixed cells that grew on glass coverslips, using antibodies 
against HCV core and NS5A proteins.  
After media had been removed, the cells were harvested and adjusted with cells 
number (2 x 10
7 
cells). Total lipids from both Huh-7 and JFH-1 infected cells were 
extracted using a modified Bligh-Dyer protocol (Bligh & Dyer 1959) and the protein in all 
samples was measured as an internal control. Extracted lipids were subjected to separation 
by high-performance thin layer chromatography-automated multiple development 
(HPTLC-AMD) technologies (Churchward et al. 2008). This was followed by mass 
spectrometry analysis to identify alterations in the host cell lipidome that occurred in 
response to infection with HCV (JFH1). 
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Figure 3.2An overview of the experimental outline for lipidomic analysis of HCV      
infected Huh-7 cell line.  
 
3.3 Analysis of cellular lipid distribution by fluorescence microscopy 
As an initial approach, the cellular distribution of lipids following HCV infection 
was analysed using the JFH1 HCV cell culture model. HCV-infected and mock-infected 
cells were labelled for NS5A using specific antibodies. Neutral lipid was stained with 
BODIPY® 493/503 and nuclei was stained with 4'6-Diamidino-2-phenylindole (DAPI). 
The cells were examined using fluorescence microscopy to determine changes in the 
accumulation and distribution of intracellular lipids in response to the HCV infection. As 
expected, a significant accumulation of lipids were observed only in cells that stained 
positively for HCV NS5A (Figure 3.3) Interestingly, there was little co-localisation 
between lipids and NS5A. 
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Figure 3.3 Lipids accumulation in Huh-7 cells chronically infected with JFH1. 
Huh-7 cells were labeled with immunofluorescence, using antibodies against NS5A (red), 
BODIPY® (green) and DAPI (blue), before (A) and (B) after a minimum of 2 weeks 
infection. JFH1 infected Huh-7 cell show a significant cholesterol accumulation compared 
to uninfected cells. 
 
 
The observed increase in cellular lipid supports a role for lipids in forming a 
cellular niche for HCV replication. These data are consistent with previous reports of 
increased lipid accumulation in HCV-infected cells (Abid et al. 2005; Hofer et al. 2002). 
However, these studies only used microscopy to measure the number and size of LDs, and 
simple biochemical assays to show increased triglyceride content (Yamaguchi et al. 2005; 
Negro & Sanyal 2009). The change in the cellular content of other lipid species following 
HCV infection is not known; as such, detailed lipidomic analysis of the infected cells was 
performed using HP-TLC and mass spectrometry.  
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3.4 High-performance thin chromatography separation of lipids using automated 
multiple development (AMD) technology 
To further study lipid accumulation in HCV-infected Huh-7 cells, lipids from Huh-
7 cells that had been infected with JFH1 strain and mock Huh-7 cells were extracted, 
andseparation and quantification of the lipid and sterol composition was performed using 
HPTLC-AMD and a fluorescent detection method based on the classic cupric sulfate 
charring techniques. The optimized protocol yielded the reproducible detection of a wide 
range of phospholipids and neutral lipids with higher sensitivity than standard TLC 
protocols. 
The technique involved developing neutral and polar lipids with a reproducible 
stepwise elution gradient from polar to nonpolar using different solvent systems. An 
automatic TLC sampler was used because this offers fully automatic sample application 
for qualitative and quantitative analyses as well as for preparative separations. It is suitable 
for routine use and in studies involving high sample throughput in mass analysis. The 
whole system is fully automated and is software controlled to ensure reproducibility.  
Lipids were extracted using the modified Bligh and Dyer method for each sample, 
and were then subjected to HPTLC separation, using separate plates and solvents for 
neutral lipids and phospholipids. After development, separated lipid classes were detected 
by spraying plates uniformly with 10% cupric sulphate, placing them into a 145 °C oven 
for 10 minutes, and performing densitometric analysis of cupric-sulfate-charred plates 
using a Luminescent Image Analyser LAS-4000 (Fuji Film, Japan). 
 
3.5 Chronic hepatitis C infection induces global changes in host cell neutral lipid 
Using a high-resolution HPTLC, a global increase in neutral lipids in JFH1 (HCV) 
infected Huh-7 cells compared to the mock-infected Huh-7 cells was observed. This effect 
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was dose-dependent and consistent at two different loading volumes (5 and 10 µl). All 
major lipid classes present in the sample were well separated (Figure 3.4). 
 
 
Figure 3.4 HPTLC separation of neutral lipids in HCV infected hepatic cells.                                                                    
JFH1 (HCV) infected Huh-7 cells compared to uninfected Huh-7 using two different 
loading concentrations (5 and 10 µl). JFH1 (HCV) infected Huh-7 cells demonstrated a 
global increase in neutral lipids compared to mock infected Huh-7.  
 
3.5.1 Identification of the neutral lipids composition in the chronic hepatitis C 
infected cells 
Next, we analysed the effect of HCV infection on individual classes of neutral 
lipid, using commercial standards for monoacylglycerol (MAG), diacylglycerol (DAG), 
free cholesterol (FC), cardiolipin (Car), triacylglycerol (TAG), and cholesteryl esters 
(CE)(Figure 3.5).  
 
Chapter 3: HCV infection induces global Changes in the Host Cell Lipidome 
97 
 
 
 
Figure 3.5Identification of neutral lipid bands using purified standards. 
Purified standards for monoacylglycerol (MAG), diacylglycerol (DAG), free 
cholesterol (FC), cardiolipin (Car), triacylglycerol (TAG) and cholesteryl esters 
(CE) were used to characterize the specific effects of chronic hepatitis C infection 
on different neutral lipid classes 
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Following HPTLC, identified bands of neutral lipid species were scraped off to be 
analysed by mass spectrometry analysis (MS).The major neutral lipid species such as 
cholesteryl esters, triacylglycerol, free cholesterol, diacylglycerol and monoacylglycerol 
were first identified by HPTLC then all identified bands were scraped off for MS 
confirmation. Furthermore, some major bands with consistent changes between JFH1 
infected and mock Huh-7 cells that could not be identified by HPTLC were identified by 
MS as diacylglycerol species (Figure 3.6).  
 
Figure 3.6 Major neutral lipids bands after separation by HPTLC and confirmed 
with MS. 
 
Chapter 3: HCV infection induces global Changes in the Host Cell Lipidome 
99 
 
All major neutral lipid bands, either identified or unidentified which showed 
consistent change in JFH1 infected Huh-7 cells were cut out for MS analysis. Cholesteryl 
esters, triacylglycerol, and free cholesterol bands were reconfirmed by MS analy. 
 
3.5.2 The effect of HCV infection on neutral lipids 
To examine the effects of chronic HCV infection on neutral lipids in host 
cells,Huh-7 cells were transfected with JFH1 RNA, cultured until >90% of cells were 
infected (confirmed by IF), then lipids from JHF1 infected and mock Huh-7 cells were 
extracted and separated by HPTLC.  Densitometry was performed on the HPTLC plate for 
TAG, FC and CE bands 
HCV increases Triacylglycerol 
As expected we identified a significant increase in TAG in JFH1 (HCV) infected 
Huh-7 cells compared to mock infected Huh-7 (P=0.03) (Figure 3.7). This is consistent 
with accumulated data in the literature pointing to the role of triglycerides in HCV life 
cycle and clearance. 
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Figure 3.7Chronic hepatitis C infection induces increase ontriacylglycerol in the host 
cells.  
Triacylglycerol bands were identified against known standards and densitometric detection 
of cupric-sulfate-charred plates was carried out using Luminescent Image Analyser LAS-
4000.  Chronic JFH1 (HCV) infected Huh-7 cells has a significant higher levels of 
triacylglycerol compared to mock infected Huh-7. 
 
HCV increases cholesteryl esters  
After HPTLC separation, cholesteryl ester (CE) bands were identified using known 
standards. We observed a significant increase in cholesteryl esters in JFH1 (HCV) infected 
Huh-7 cells compared to mock infected Huh7 (P=0.02) (Figure 3.8). 
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Figure 3.8HCV infection induces increase oncholesteryl esters in the host cells.  
Cholesteryl esters bands were identified against known standards and compared between 
(JFH1 (HCV) infected Huh-7 cells and mock infected Huh-7).  Chronic JFH1 (HCV) 
infected Huh-7 cells has a significant higher levels of cholesteryl esters compared to mock 
infected Huh-7 (P= 0.02). 
 
HCV increases cellular free cholesterol 
Bands representing free cholesterol (FC) wereidentified using known standards.  
We observed a significant increase in FC in JFH1 (HCV) infected Huh-7 cells compared to 
mock infected Huh-7 (P=0.04) (Figure 3.9). 
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Figure 3.9 HCV induces increase onfree cholesterol in the host cells.  
Free cholesterol bands were identified against known standards and compared between 
JFH1 (HCV) infected Huh-7 cells and mock infected Huh-7.  Chronic JFH1 (HCV) 
infected Huh-7 cells has a significant higher level of free cholesterol compared to mock 
infected Huh-7. 
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3.6 HCV infection induces global changes in cell phospholipid composition 
The major components of cell membranes are phosphatidylcholine (PC) and 
phosphatidylethanolamine (PE), so we next investigated the effect of HCV infection on 
cell phospholipids. Consistent with the increased in neutral lipids in HCV infected cells, 
HPTLC lipidome analyses revealed a significant accumulation of several 
phosphatidylcholine (PC) and phosphatidylethanolamine (PE) species. Representative 
examples are presented in (Figure 3.10), showing global increase in phospholipids in JFH1 
(HCV)-infected Huh-7 cells compared to mock infected Huh-7. 
 
 
Figure 3.10HPTLC separations ofphospholipid classes.Phospholipids from JFH1 
infected Huh-7 cells (Infected) and mock-infected Huh-7 (Control) were separated by 
HPTLC using different loading concentrations (5 and 10 µl).  
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3.6.1 Identification of altered phospholipid species in HCV-infected cells 
Having demonstrated that the main neutral lipid classes were up-regulated in 
chronically JFH1-infected cells, we further sought to identify the effect that chronic HCV 
infection had on phospholipids. Whole cell lipid extracts were run on HPTLC plates using 
a protocol optimised for separating phospholipids. To identify bands, the samples were run 
in parallel with purified commercial standards for phosphatic acid (PA), 
phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylinositol (PI), 
phosphatidylglycerol (PG) and phosphatidylserine (PS) (Figure 3.11). 
 
Figure 3.11Identification of phospholipids species bands against known standards. 
Known standard bands for phosphatic acid (PA), phosphatidylcholine (PC), 
phosphatidylethanolamine (PE), phosphatidylinositol (PI), phosphatidylglycerol (PG) and 
phosphatidylserine (PS) were utilized to characterize the specific effects of chronic 
hepatitis C infection on phospholipids. 
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The major phospholipids species were identified by HPTLC and confirmed by mass 
spectrometry analysis. 
 
Figure 3.12Identification of phospholipids species bands against known standards.  
Huh-7 cells were infected with HCV (JFH1) for two weeks then total lipids was extracted 
and separated by HPTLC. PC, The most abundant phospholipids species as detected by 
HPTLC were PE, PI and PS respectively.  
 
 
 
 
 
 
 
 
 
Chapter 3: HCV infection induces global Changes in the Host Cell Lipidome 
106 
 
 
3.6.2 HCV induces a significant increase in global host phospholipids  
 
To examine the effects of chronic HCV infection on phospholipids in host cells, 
Huh-7 cells were transfected with JFH1 RNA, cultured until >90% of cells were infected 
(confirmed by IF), then lipids from JHF1-infected and mock-infected Huh-7 cells were 
extracted and separated using HPTLC. Densitometry was performed on the phospholipid 
bands. Figures 3.13 A and B demonstrate that PC and PE were significantly increased in 
JFH1 HCV-infected Huh-7 cells compared to mock-infected Huh-7, by approximately 
30% and 20% respectively. Furthermore, PI showed significant increase in JFH1-infected 
Huh-7 cells by approximately 20% (Figure 3.14A). In contrast, the apparent increase in PS 
in JFH-infected Huh-7 cells was not significant (Figure 3.14B). 
Together PC, PE and PS HPLTC findings indicate a role for lipid species in the viral life 
cycle. An increase of phospholipids suggests that host cell phospholipids play a crucial 
role in the formation of cytosolic LDs and modified membrane compartments for the 
promotion of viral replication and infectious virus assembly.   
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Figure 3.13 HCV induces increase onPC and PE in the host cells.  
PC and PE bands were identified against known standards and compared between 
(JFH1 (HCV) infected Huh-7 cells and mock infected Huh-7).  Chronic JFH1 
(HCV) infected Huh-7 cells has significant higher levels of PC (A) and PE (B) 
compared to mock infected. 
 
 
A 
B 
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Figure 3.14HCV induces increase on PC and PE in the host cells. 
PI and PS bands were identified against known standards and compared between 
(JFH1 (HCV) infected Huh-7 cells and mock infected Huh-7). (A) Chronic JFH1 
(HCV) infected Huh-7 cells has significant higher levels of PI. (B) a non-
significant higher levels of PS compared to mock infected Huh-7 (*p=0.3). 
 
 
A 
B 
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3.7 Mass spectrometry analysis supported the finding that chronic HCV infection 
induces global changes in the host cell lipidome 
To further characterize changes in lipid content, the detailed fatty acid composition of 
some lipid classes that showed significant increase in HCV-infected cells, such as TAG 
and PC, were analysed individually using mass spectrometry. This was initially performed 
directly on whole lipid extracts, using liquid chromatography and tandem mass 
spectrometry (LC-MS/MS). An alternative technique was to separate lipids by HP-TLC as 
above, and then analyse individual lipid species using mass spectrometry. Both of these 
techniques were available through established collaborations at the University ofWestern 
Sydney and University of New South Wales. 
The excellent sensitivity and molecular specificity offered by modern mass 
spectrometry has made it arguably the method of choice for lipid analysis. No other 
analytical method allows for both the simultaneous and differential detection of individual 
lipid variants and the acquisition of the detailed structural information that is required by 
the lipid researcher (Ellis et al. 2013). 
Generally, the typical methods used to analyse lipids can be divided into two 
categories: liquid chromatography (LC)- and mass spectrometry (MS)-based methods (Li 
et al. 2011), and shotgun lipidomics (Han & Gross 2005). LC-MS-based methods are 
limited as it is time consuming to perform the experiment and analyse the data. 
Additionally, the ionization efficiency of lipids may vary with elution order (where mobile 
phase compositions are different over time), creating challenges for quantitation studies 
(Han et al. 2012). In contrast, shotgun lipidomics, which is performed by direct infusion, is 
faster and may be more suitable for the purposes of analysing a large number of samples. 
However, shotgun lipidomics has a limited ability to detect nonpolar lipids due to the 
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overwhelming signal effect of polar lipids. Furthermore, downstream bioinformatics 
analysis is particularly challenging due to the large amount of data acquired. 
HPTLC-AMD technology was used to overcome the limitations of both the LC-
MS and shotgun MS methods. The HPTLC system represents a good alternative to 
conventional TLC and is a fast, inexpensive, robust and reliable method for lipid analysis. 
Additionally, HPTLC-AMD is capable of separating lipids that exhibit few differences in 
polarity and over a wide range of polarity. It is easier to compare the relative abundance of 
different species of the same class or subclass of lipids within samples when using the MS 
lipidomic approach, as the solution composition is constant during the analysis (Han et al. 
2012), overcoming one of the main challenges associated with the use of shotgun 
lipidomics.  
 
3.7.1 Mass spectrometry analysis shows that chronic HCV infection induces global 
changes in the fatty acid composition of triacylglycerol 
As can be seen in Figure 3.15, which is consistent with HTPLC data, there was a 
global increase in the fatty acid components of triacylglycerol in JFH1 HCV-infected Huh-
7 cells than there was in uninfected Huh-7. 
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Figure 3.15Mass Spectrometry lipidomic analysis of TAG fatty acids composition. 
Lipids were extracted from JFH1 infected Huh-7 and mock infected Huh-7cells and 
separated by HPTLC. TGA bands were scraped off for MS analysis.  
 
Representative examples are presented in (Figure 3.16) where the triacylglycerol 
species TAG 52:05, TAG 54:05, TAG 56:05 and TAG 60:12, exhibit increased abundance 
in the JFH1 (HCV) infected Huh-7 samples, relative to mock infected  samples. In 
contrast, the triacylglycerol species TAG 55:06, TAG 57:05, TAG 57:06 and TAG 58:06 
are shown to exhibit decreased abundances in the JFH1 (HCV) infected Huh-7 samples 
relative to mock-infected samples (Figure 3.17).  Overall, these changes suggest an 
intimate link between lipids and HCV life cycle. 
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Figure 3.16 Representative examples of triacylglycerol fatty acid chains differentially 
regulated during chronic HCV infection. 
The relative ion intensity is plotted for various TAG in the JFH1 infected Huh-7 and mock 
infected Huh-7 as a reference. Panels A-D (lipid species TAG 52:05, TAG 54:05, TAG 
56:05 and TAG 60:12) provide examples of triacylglycerol fatty acid chains exhibiting 
notable changes in abundance during chronic HCV infection.  
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Figure 3.17 Representative examples of triacylglycerol fatty acid chains differentially 
down regulated during chronic HCV infection. 
The relative ion intensity is plotted for various TAG in the JFH1 infected Huh-7 and mock 
(conditioned media) infected Huh-7 as the reference. Panels A-D (lipid species TAG 
55:06, TAG 57:05, TAG 57:06 and TAG 58:06) provide examples of triacylglycerol 
species exhibiting notable decrease in abundance during chronic HCV infection.  
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3.7.2 Mass Spectrometry Analysis shows that chronic HCV infection induces global 
Changes in the fatty acid composition of phosphatidylcholine  
In addition, as shown in Figure 3.18, consistent with HPTLC data there was a 
global increase in the fatty acid composition of phosphatidylcholine (PC) in JFH1 (HCV) 
infected Huh-7 cells compared to mock infected Huh-7.  
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Figure 3.18 Mass Spectrometry lipidomic analysis of PC fatty acids composition. 
Lipids were extracted from JFH1 infected Huh-7 and mock infected Huh-7cells and 
separated by HPTLC. PC bands were scraped off for MS analysis. PC; 
phosphstidylcholine. 
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3.8 Summary 
In summary, using two complementary approaches (high-resolution HPTLC and 
mass spectrometry) we demonstrated that infection of Huh-7 cells with JFH1 HCV induces 
global cellular changes in both neutral lipids and phospholipids. These findings provide 
useful insights into the metabolic reprogramming induced by chronic HCV infection aimed 
at benefiting both energetic and biosynthetic needs for supporting the viral life cycle.  
The increased abundance of some phospholipids potentially reflects their role as 
crucial constituents in the various structural entities that support viral replication, including 
the lipid droplet and membranous replicase compartments. In contrast, the decline of some 
species of other lipid classes (triacylglycerol) probably reflects their consumption 
following incorporation into lipoprotein-associated viral particles, and this potentially 
plays an important role in infectivity. However, the analysis of whole cell lipid extracts did 
not identify changes of lipid content in different cellular organelles. This level of detail is 
crucial to understanding the effects of HCV on cell lipid metabolism and is explored in 
more detail in Chapter 4, where cellular organelles were separated using centrifugal 
fractionation for individual lipid analysis. 
Identification of the metabolic pathways during HCV infection and the key 
enzymes mediating this effect could serve as candidates for novel antiviral targets against 
hepatitis C virus, offering higher barriers against drug resistances than current DAA drugs.  
 
In conclusion, this study of HCV-infected cells provides a valuable reference 
pertaining to the use of HPTLC and mass spectrometry to dissect the role of various host 
cell lipid species in the viral life cycle. The observations presented open the door to several 
new and exciting avenues of investigation, which should improve existing understanding 
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of HCV-associated pathogenesis and lay the groundwork for the development of novel 
antiviral therapies. 
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4. Lipidomic Analysis of Purified ER From HCV Infected Hepatocytes 
4.1 Introduction 
The previous chapter described how chronic HCV infection modulates global 
intracellular lipidomics to create an environment that aids RNA replication and the 
production of progeny virus particles. The complementary techniques of HP-TLC and 
mass spectrometry were employed. 
This chapter will describe the influence of HCV infection on lipidomic changes at 
the sub-cellular level. It is likely that changes in host lipid gene expression levels will 
cause variable effects in different fractions of the cell. Furthermore, measuring 
downstream metabolite concentrations in different fractions can determine the activities of 
metabolic pathways more accurately than just quantifying lipid enzyme concentrations or 
mRNA expression (Kell et al. 2005; TAN et al. 2009).  
Among the various subcellular compartments, the endoplasmic reticulum (ER) is a 
prime candidate for HCV infection. The ER plays a central role in HCV replication: 
following infection, viral RNA is translated at the ER, where viral proteins induce 
membrane modifications, giving rise to the ‗membranous web‘. This web acts as the 
platform for the synthesis of HCV RNA. Viral structural proteins are then packaged with 
RNA, assembled into ‗lipoviral‘ particles and exported through the ER-Golgi pathway 
(Gastaminza et al. 2008). Thus, understanding HCV/host lipid homeostasis and turnover in 
the ER should provide novel insights, over and above examining changes in the whole 
infected cell. 
These experiments commenced by optimising a protocol to isolate the ER 
subcellular fraction, using ultracentrifugation over a sucrose gradient (described in detail 
in the Methodology section, Chapter 2). The complementary techniques of HPTLC and 
mass spectrometry were then employed to define the lipid profiles in the purified ER of 
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JFH1-infected Huh-7 cells, compared to uninfected Huh-7. Three replicates for each 
sample were analysed and statistical analysis was performed to identify the main lipids 
with differential expression across conditions. A particular emphasis was placed on 
identifying the differences between HCV-infected and uninfected cells in the lipid classes 
that are known to be important for HCV replication, including neutral lipids and 
phospholipids.  
 
4.2 HCV infection induces diffuse changes in neutral lipids purified from host cell ER  
To examine how the lipid content of the ER organelle is impacted by chronic HCV 
infection, Huh-7 cells were transfected with HCV (JFH1) RNA, then cultured for two 
weeks until >90% of cells were infected, confirmed by immunofluorescence using anti-
NS5A protein. Cells were harvested and an equivalent number of cells (2 × 10
7 
cells) were 
used for each sample. The ER fraction was isolated using discontinuous sucrose gradient 
centrifugation. Validation of the purity of the ER fraction was determined by examining 
―house-keeper‖ (HK) protein markers using standard SDS-PAGE analysis (Figure 4.1). 
Lipid was extracted from the isolated ER fractions by a chloroform-methanol method then 
separated and quantified by HPTLC. To allow a valid comparison among samples, protein 
concentrations were measured post-lipid extraction and used to normalise the amount of 
lipid loaded onto each HPTLC lane.  
First, the effect that chronic HCV infection had on neutral lipids in the ER was 
examined. Commercial standards for the major neutral lipid classes were used to identify 
bands in ER extracts from both JFH1-infected Huh-7 and uninfected Huh-7 cells. All 
identified bands were scraped off and analysed by MS to further confirm their identity 
(data not shown). A dramatic increase in free cholesterol in ER from JFH1-infected Huh-7 
cells relative to uninfected Huh-7 cells was observed (Figure 4.2). In contrast, no 
significant change in triacylglycerol and cholesterol esters was exhibited. 
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Figure 4.1 Immunoblot analysis of subcellular marker proteins to verify the purity of 
isolated ER.                                                                                                             
Subcellular fractionation ofJHF1 infected and control Huh-7 cells was performed by 
discontinuous sucrose gradient centrifugation. Protein (20 µg) from each fraction was 
separated by 10% SDS PAGE and transferred onto PVDF membranes.Blotted proteins 
were probed for markers of ER (eIF2-α), nucleus (NF-β) and cytosol (AKT). 
 
 
Figure 4.2 HPTLC separation of neutral lipids extracted from ER.                              
ER fractions were isolated from JHF1 infected and control Huh-7 cellsby discontinuous 
sucrose gradient centrifugation, followed by lipid extraction and HPTLC analysis. ER 
from JFH1 infected Huh-7 cells demonstrated a dramatic increase in free cholesterol (FC) 
compared to uninfected Huh-7 cells (P<0.05).The other major neutral lipid classes 
(monoacylglycerol, diacylglycerol and tiyacylglycerol) showed some slight but not 
significant changes.  
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4.2.1 HCV-induced significant increase in free cholesterol (FC) in ER fraction 
Because of its key roles in HCV RNA replication and virus export, it was 
anticipated that more profound lipid changes would be observed in the ER of HCV-
infected cells than would be evident in whole cell extracts. To investigate, the changes 
observed in the neutral lipids in the whole cell were compared with those exhibited in 
purified ER (Figure 4.4). There was a significant difference in the lipid profile of purified 
ER, relative to the whole cells. In particular, the HCV-induced increase in free cholesterol 
(FC) was more profound in the ER than it was in the cell overall (Figure 4.5). This further 
suggests that the ER plays a crucial role in the HCV life cycle. 
 
 
 
Figure 4.4 Neutral lipid composition of purified ER from HCV infected cells, relative 
the whole cell.  
In ER fraction the effect of HCV infection on neutral lipids was more profound for FC, the 
relative increase in FC is more in ER than in whole cell. DAG, TAG and CE showed no 
significant difference between HCV infected and uninfected samples of ER fractions. FC; 
free cholesterol, DAG; diacylglycrol, TAG; triacylglycerol and CE; cholesterol esters   
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Figure 4.5 HCV increases free cholesterol in the ER of infected cells.                                                                                            
FC bands were identified against known standards (red oval) and densitometric detection 
of cupric-sulfate-charred plates was carried out using Luminescent Image Analyser LAS-
4000.  Chronic JFH1 (HCV) infected Huh-7 cells has a significant higher levels of FC 
compared to mock infected Huh-7 (**p<0.01). 
 
4.2.2 HCV infection induces diffuse Changes in the Host Cell purified ER 
phospholipids 
We next investigated the effect of chronic hepatitis C infection on phospholipids in ER. 
Consistent with the overall increase in neutral lipids we observed in purified ER from 
HCV infected cells, compared to uninfected cells, HPTLC lipidomic analysis revealed a 
significant up regulation of several phospholipid species (Fig 4.6). Using commercial 
phospholipid standards, the phospholipids classes, phosphatidic acid (PA), 
phophatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylinositol (PI),  
phosphatidylglycerol (PG) and phosphatidylserine (PS) were identified (Figure 4.6A). 
Densitometry analysis demonstrated that JFH1 infection resulted in a significant increase 
in phospholipid, including PC, PE, and PI (Figure 4.6B). 
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Figure 4.6 HCV increases phospholipids in the ER of infected cells.                                                                                                                 
Huh-7 cells were infected with HCV (JFH1) for two weeks then total lipid was extracted 
from purified ER fractions and separated by HPTLC. The major phospholipid classes PC, 
PE, PI, and PS were identified against known standards (A). Densitometric detection of 
cupric-sulfate-charred plates to characterize the specific effects of chronic hepatitis C 
A 
B 
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infection on phospholipids classes (B). There was a significant increase in PC, PE and PI.                                                                                                               
(PC, phosphatidylcholine; PS, phosphatidylserine; PI, phosphatidylinositol; PE, 
phosphatidylethanolamine.) (*p<0.05, **p<0.01) 
 
 
4.2.3 Comparison of the changes in the neutral and phospholipids composition in the 
purified ER from HCV-infected cells relative to the whole cell  
 
As described above, the hypothesis applied to the research was that HCV-induced 
lipid changes would be more profound in the ER organelle than they would be in the 
whole cell. Therefore, the relative changes in lipid content of purified ER fractions were 
compared with those of whole-cell extracts. As expected, the overall changes in neutral 
lipids (Figure 4.7A) and phospholipids (Figure 4.7B) were greater in the ER than they 
were in the whole cell. The most striking differences were the relatively greater HCV-
induced increase in phosphatidylcholine (150% vs. 30%, p <0.001) and free cholesterol 
(200% vs. 50 %, p <0.01) in ER. This suggests that chronic HCV infection causes the 
profound accumulation of phosphatidylcholine in the ER fraction. This emphasises the role 
of the ER in HVC replication, suggests ER is an attractive target for anti-viral therapies 
and reveals the vital role phosphatidylcholine plays in HCV replication in the ER. 
Modulation of the enzymes that control phosphatidylcholine pathways may represent 
novel host-targeted anti-HCV therapies. 
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Figure 4.7 Relative changes in major lipid classes in purified ER, compared to whole 
cell extracts, following HCV infection.                                           Comparison of the 
changes of the neutral lipids composition in the purified ER from chronic JFH1 infected 
cells relative the whole cell (A). Comparison of the changes of the phospholipids 
composition in the purified ER from chronic JFH1 infected cells relative the whole cell 
(B).                                                    
A 
B 
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4.2.4 HCV induces diffuse changes in the host cell purified ER lipid rafts 
Thus far, the research demonstrated the following: 1) The effect of HCV infection 
on lipids was more profound in the purified ER than it was on the whole cell; this was 
consistent with the vital role of the ER organelle in HCV replication; and 2) HCV infection 
induced a significant accumulation of several PC and PE species, which are essential 
components of cell membranes. Therefore, more detailed analysis of the effect that chronic 
HCV infection have on ER lipid rafts was performed. Recent studies suggest that the HCV 
replication complexes are formed on lipid rafts (which are detergent insoluble micro 
domains of intracellular vesicular membranes that are rich in cholesterol and sphingolipid). 
Lipid rafts are small platforms in the outer exoplasmic leaflet of the lipid bilayer, and 
consist of sphingolipids and cholesterol, which are connected to phospholipids and 
cholesterol in the inner cytoplasmic leaflet. These assemblies are fluid, but are more 
ordered and tightly packed than the surrounding bilayer. Lipid rafts were first discovered 
as a detergent-insoluble fraction (REF), and the concept of lipid rafts has changed our 
understanding of cell membrane organization. In mammalian cells, lipid rafts are first 
assembled in the Golgi complex (Simons & Ehehalt 2002), and are involved in cell 
signalling and intracellular trafficking (Helms & Zurzolo 2004). Some viruses utilize these 
subcellular membrane domains for cell entry, virion assembly, or budding (Chazal & 
Gerlier 2003; Salaün et al. 2004). Viruses can also perturb cell signalling pathways by 
interfering with proteins in lipid rafts (Krautkramer et al. 2004; Avota et al. 2004). 
Moreover, different studies have indicated that HCV replication is associated with ER lipid 
rafts (Shi et al. 2003; Aizaki et al. 2004). Therefore, lipidomic analysis of HCV–lipid raft 
interaction may have the potential to partially explain the abnormality of lipid metabolism 
that is associated with HCV infection. 
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4.2.4.1 Purification of lipid rafts from the ER of HCV-infected cells 
To study the effects of HCV on lipid rafts in the model, a protocol to purify ER-
lipid rafts was first established. Detergent-free buffer and discontinuous sucrose gradients 
were used (described in detail in Methods Section 2.4.3) that were adapted from a 
published protocol for total lipid raft isolation (Song et al. 1996). To allow the purification 
of ER-lipid rafts without the use of detergent, Triton -100 was replaced with sodium 
carbonate. The pellet resulting from ER isolation was resuspended in 2 ml of 0.5 M Na3Co 
and adjusted to sucrose gradient. All sucrose gradients were prepared in a detergent-free 
buffer. Validation of the purity of the ER-lipid rafts fraction was performed by examining 
―house-keeper‖ (HK) protein markers, Erlin-1 (endoplasmic reticulum lipid rafts protein) 
using standard SDS-PAGE analysis (Figure 4.8A). Erlin-1 is found in the detergent-
insoluble low-density fraction of cell lysates of many cell types, and was observed to be 
localized to the endoplasmic reticulum (ER) and highly enriched in detergent-resistant 
membranes (DRM) fractions. HCV infection was further confirmed by Western blot, using 
specific antibodies against NS5A protein (Figure 4.8B). The high level of NS5A protein in 
the ER-lipid rafts fraction (F4) was consistent with previous data, thus demonstrating that 
the membranous web, where HCV-RNA synthesis and replication take place in 
hepatocytes, is a lipid raft membrane structure (Gao et al. 2004; Aizaki et al. 2004). 
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Figure 4.8 (a) Detergent-free purification of ER-lipid rafts using discontinuous 
sucrose gradients.                                                                                
Protein extracts were analysed for the presence of Erlin-1 (lipid raft marker) and eIF2 α 
(ER marker) by western blot. The experiment was repeated three times independently with 
the same results. 
(b) Confirmation of HCV protein in the purified ER-lipid rafts.                                                                            
Total cellular protein was extracted from JFH1 infected cells. Protein was separated by gel 
electrophoresis, transferred to a PVDF membrane and examined by western blot. HCV 
NS5A protein was detected using specific antibodies.  
 
4.2.4.2 Identification of the neutral lipids composition in the purified ER-lipid rafts 
Next, the effect that HCV infection had on the composition of neutral lipids in ER-
lipid rafts was examined. JFH1 HCV-infected and uninfected Huh-7 cells were lysed, and 
ER-lipid rafts isolated, as per the process described above (4.3.1). Total lipids were 
extracted, and the neutral lipids were analysed using HPTLC. Using commercial standards, 
neutral lipid bands were identified in ER-Lipid raft extracts from both JFH1-infected Huh-
7 cells and uninfected Huh-7 cells (Figure 4.9). Free cholesterol (FC) was the most 
prominent neutral lipid class observed in ER-lipid rafts and appeared to be up-regulated in 
HCV-infected cells (Fig 4.9A). Densitometry analysis of HPTLC plates confirmed that 
HCV infection resulted in a significant increase in FC in ER-lipid rafts (Fig 4.9B). 
A 
B 
Chapter 4: Lipidomic Analysis of Purified ER From HCV Infected Hepatocytes 
 
129 
 
!
A B 
 
Figure 4.9 Identification of neutral lipids classes in ER-lipid rafts against known 
standards by HPTLC. 
ER-lipid rafts were isolated from HCV (JFH1) infected and uninfected Huh-7 cells, lipids 
extracted and analysed by HPTLC A) Commercial standards for FC, TAG and CE were 
used to characterize the specific effects of HCV infection on the composition of neutral 
lipids in ER-lipid rafts.B)Densitometry analysis demonstrated that JFH1 infection 
significantly increased FC in ER-lipid rafts.* demonstrates significant difference between 
Huh-7 and infected cells (p<0.05). 
 
 
 
4.2.4.3 The increase of FC in ER, as induced by HCV infection, is not global, but ER-
lipid rafts are specific  
After the fractionation and isolation of the ER organelle from the JHF1-infected 
and control Huh-7 cells, ER fraction was further fractionated to isolate lipid rafts using the 
protocol described in Chapter 2. Next, using the same protocol for ER-lipid rafts isolation, 
fractions were individually analysed to clarify whether FC up-regulation in the ER was 
specific to lipid rafts or ER global. All fractions obtained from each ER sample were 
analysed using HPTLC against commercial standards for FC. The ER-lipid rafts fraction 
(F2) exhibited in Figure 4.10 showed the highest band density, thus indicating that the 
increase of the level of FC in ER organelles in HCV infection is lipid rafts specific.  
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Figure 4.10 HPTLC separation of purified ER lipid rafts neutral lipids.                        
ER fractions isolated from JFH1 HCV infected and mock Huh-7 cells were further 
fractionated using discontinuous sucrose gradient into four fractions. Neutral lipids in all 
fractions were analysed by HPTLC. ER-lipid rafts Fraction (F2) from JFH1 infected cells 
showed dramatic increase in FC. F1, F2 , F3 and  F4 are ER fraction numbers. 
 
4.2.4.4 Comparative proteomics analysis of detergent-insoluble fractions by 2-D 
PAGE 
To identify novel candidate biomarkers for HCV infection, ER-lipid rafts isolated 
from JFH1-infected and uninfected Huh-7 cells were analysed as per the process described 
previously. The proteins from ER-lipid rafts fractions were precipitated with acetone, 10% 
trichloroacetic acid, 0.07% β-mercaptoethanol for 1 h at −20 °C, following centrifugation, 
pellets were washed with acetone, 0.07% β-mercaptoethanol. Changes in protein 
expression in ER-lipid rafts were analysed using two-dimensional polyacrylamide gel 
electrophoresis (2-D PAGE) (Figure 4.11).  
 Tens of protein spots were visualized on 2-DE gels, and differences in spot 
intensities were compared visually. No significant changes were induced by HCV 
infection on ER-lipid rafts proteins. 
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Figure 4.11 Two-dimensional polyacrylamide gel electrophoresis separation of ER-
lipid rafts proteins. Proteins from ER-lipid rafts fraction of JFH1 infected Huh-7 (A) and 
uninfected Huh-7 (B) cells were subjected to IEF in a 17-cm IPG strip spanning the pH 
range of 4-to-7. The strip containing focused proteins was transferred to an 18 x 20 cm 
SDS-PAGE gel (8-16%T) and subjected to electrophoresis. Proteins in the gel were stained 
with coomassie brilliant blue stain and the image shown was captured with a laser-based 
instrument. 
 
4.3Lipidomic analysis of LDs isolated from HCV-infected cells. 
Sections 4.1 and 4.2 confirmed that broad changes in lipid content were induced in 
the whole infected cell. Section 4.3 showed that this effect was more profound in the ER, 
the organelle that plays a crucial role in HCV replication and membrane formation.  
Next, there was a requirement for further detailed analyses of other sub-cellular 
compartments. In particular, studying cytoplasmic LDs (LDs) was deemed to be of 
potential significant value. The LD is an organelle that is used for the storage of neutral 
lipids. It dynamically moves through the cytoplasm, interacting with other organelles, 
especially the endoplasmic reticulum (ER) (Martin & Parton 2006; Blanchette-Mackie et 
al. 1995; Vock et al. 1996). These interactions are thought to facilitate the transport of 
lipids and proteins to other organelles throughout the cell.  
An association between the HCV capsid protein (Core) and the LDs has been 
reported, mediated by lipophilic interactions with two amphipathic helices in the core D2 
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domain (Boulant et al. 2006). The association of core with LDs is thought to form part of 
the assembly complex, and is essential for the production of infectious virus particles 
(Boulant et al. 2007; Miyanari et al. 2007). The envelope proteins E1 and E2 reside in the 
ER lumen, and the viral replicase is assumed to localize on ER-derived membranes in 
association with NS5A protein (Penin et al. 2004). 
Briefly, HCV core protein is cleaved from the viral polyprotein by cellular 
proteases, thereby producing the 191 amino-acid (aa) immature form of core. This form 
(MW 23 kDa) remains anchored to the ER. It is then cleaved by a signal peptide peptidase, 
which removes the signal peptide to generate the mature form of core (MW. 19–21 kDa), 
which is 173–179 aa long and is trafficked from the ER membrane to LDs (McLauchlan et 
al. 2002). The association of the mature core protein with LDs is directly related to the 
intracellular transport of this protein to the perinuclear area, the site of assembly of 
infectious HCV particles. HCV particles are then secreted through the VLDL-secretory 
pathway (Gastaminza et al. 2008; Chang et al. 2007). 
LDs have recently attracted considerable attention because of the link between the 
accumulation of LDs and human diseases such as obesity, atherosclerosis and HCV-
associated liver malfunctions. However, the actual role of LDs in the complexity of the 
HCV life cycle, especially in terms of HCV assembly and release, is still not clearly 
understood. Therefore, this research sought to clarify this issue by investigating the way 
HCV virus particles interact with LDs, as understanding this relationship may lead to the 
development of new therapeutic strategies that protect against HCV.  
First, a protocol to isolate LDs using methods adapted from published protocols 
was developed (Brasaemle & Wolins 2006). To measure the recovery efficiency and purity 
of LDs obtained using this protocol, equal volumes of the recovered fractions were 
analysed on a 12% SDS-PAGE, followed by immunoblotting with antibodies against 
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adipose differentiation-related protein (ADRP), a LD-resident protein found in most 
tissues (Strey et al. 2005) (Figure 4.12A ). The purity of the isolated LDs was assessed 
using the relative enrichment of ADRP and by considering the absence of markers that 
correspond to other cellular organelles (Figure 4.12B). 
 
 
 
 
 
 
Figure 4.12Sub cellular distribution of ADRP, analysed by sucrose-density-gradient 
centrifugation. A) Cells were solubilised with 1% Triton X-100, 0.5% DDM, 1% CHAPS 
or 1% Brij99 and separated on discontinuous sucrose density gradients. Fractions collected 
from the bottom of the gradient were analysed by western blotting.                                                                                         
B) Immunoblot analyses of sub cellular marker proteins ADRP (lipid droplet), AKT 
(cytosol) and NFKβ(nucleus), confirming the purity of the LD fraction.  
 
4.3.1 TAG content in LDs increased by HCV infection  
In order to study the effects of HCV infection on different classes of neutral lipids, 
LDs were isolated using discontinuous sucrose gradient (Section 2.4.4). The LDs fraction 
was isolated from both JFH1-infected Huh-7 cells and uninfected Huh-7, lipid was 
extracted then separated and quantified by HPTLC. The separated lipid bands were 
identified using commercial standards (Figure 4.13A). TAG was the most prominent 
among the neutral lipid classes and was significantly up-regulated in HCV-infected cells. 
Different bands with different lengths of fatty acyl chains were identified as TAG (Figure 
A B 
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4.13B). This finding was consistent with existing data pertaining to the role of triglycerides 
in the HCV life cycle (André et al. 2005; Negro 2010). 
 
 
!
Cholesterol esters 
Free Cholesterol  
 
 
 
Figure 4.13 Identification of neutral lipid bands against known standards.Commercial 
standards for FC, TAG  and CE were utilized to characterize the effects of HCV infection 
on the composition of neutral lipid classes in both Huh-7 cells (control) and HCV (JFH1) 
infected Huh-7 cells (infected) (A).Densitometry analysis demonstrated that HCV 
infection significantly increased TAG in LDs (B).        
* demonstrates significant difference between Huh-7 and infected cells. FC free 
cholesterol, TAG triacylglycerol and CE cholesterol esters. (*p<0.05). 
A 
B 
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4.3.2 HCV induces a significant increase in phospholipids in the purified LDs relative 
to the uninfected cells  
Next, the effect of HCV infection on the phospholipid composition of LDs was 
investigated. PC was the only detectable phospholipid class in lipid extracts from purified 
LD fractions. An accumulation of PC in LDs purified from HCV-infected cells relative to 
uninfected cells was observed; this effect was statistically significant, as shown in Figure 
4.14.  
!
**	
Phosphatidylcholine 
 
Figure 4.14 HPTLC analysis of phospholipids in LDs isolated from HCV infected and 
uninfected cells. 
Phosphatidylcholine bands were identified against known standards and compared 
between JFH1infected Huh-7 cells and mock infected Huh-7.Densitometry analysis 
showed purified lipid droplets from chronic JFH1 infected Huh-7 cells has a higher levels 
of Phosphatidylcholine compared to mock infected Huh-7. (**p<0.01) 
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Finally, the relative HCV-induced increases in PC levels in whole cells, ER 
fraction and LDs fraction was compared to determine whether the increase in PC is global, 
or more specific to some subcellular organelles. Figure 4.15A shows that ER fractions 
from HCV-infected cells contained a higher level of PC than whole cell extracts and LD 
fractions. On the other hand, there was no significant difference in PC increase between 
whole cell and LD fractions. Again, this emphasizes the vital role that ER plays in HCV 
replication and suggests that PC plays an important role in HCV replication in the ER. 
Another comparison was performed for the changes in PL and neutral lipid in the 
LDs were compared to the whole cells changes. The LDs neutral lipids analysis indicated 
that TAG was the predominant lipid class detected by HPTLC, with up to 40% significant 
increase in JFH1-infected Huh-7 cells LDs samples, compared to less than 20% increase in 
whole cell samples. Whereas, in the case of the PL analysis, PC was only detected among 
PL classes in LDs, with no significant difference in increase from the whole cell (Figure 
4.15B).  
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Figure 4.15 Relative increase of lipid classes in subcellular fractions.                                  
(A) Comparison of HCV-induced changes in the phosphatidylcholine composition  of 
whole cells, ER and LDs fractions in Huh-7 cells. (B) Comparison of the HCV-induced 
changes in the triacylglycerol (TAG) and phosphatidylcholine (PC) composition of 
purified LDs, relative to the whole cell. All lipids were extracted from chronically JFH1 
infected Huh-7 cells. (ns, non significant; * p<0.05, ** p<0.01 ). 
 
A 
B 
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4.3.3 Identification of DDX3 in the purified LDs from HCV-infected Huh-7 cells  
We sought to gain further insights into the effects of HCV on cellular LDs by 
comparing the protein content of purified LDs from JFH1 HCV-infected Huh-7 cells 
compared to uninfected Huh-7 cells. Protein was precipitated using cold acetone protocol 
and quantified using a BioRad colorimetric kit. One-dimensional protein gel 
electrophoresis (1-DE) of purified LDs was used to examine the protein composition of 
LD fractions. Three independent experiments were performed with very consistent results. 
Tens of protein bands were visualized on 1-DE gels using Coomassie stain, and 
differences in the intensity of the bands were compared visually. Bands with molecular 
masses of approximately 110, 90 73, and 66 kDa were more prominent in JFH1 HCV-
infected cells than they were in uninfected Huh-7 cells, suggesting possible roles in the 
HCV replication cycle. To identify the proteins, the bands were excised, digested with 
trypsin and analysed using mass spectrometry by TOF/TOF-MALDI- MS. The 110, 90 73, 
and 66 kDa protein bands were identified as human ATP dependant RNA helicase, 
DEAD-box RNA helicase (DDX3), and insulin-like growth factor 2 respectively (Figure 
4.16). 
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Figure 4.16One D gel protein electrophoresis (1-DGE) of purified lipid droplets.Lipid 
droplets were purified from HCV (JFH1) infected and uninfected Huh-7 cells and proteins 
extracted by acetone precipitation. Proteins from of each sample (20 μg total protein) were 
separated using a 12% SDS–polyacrylamide gel, and the gel was stained with Coomassie 
Brilliant Blue. Bands with increased intensity were excised and identified by MALDI-TOF 
mass spectrometry. The cellular proteins DEAD-box RNA helicase (DDX3), Human ATP 
dependant RNA helicase and Insulin like growth factor 2were increased in lipid droplets 
purified from JFH1 infected Huh-7 cells compared to uninfected Huh-7. 
 
The HCV-induced increase in DDX3 in LDs was confirmed using Western blot. As 
shown in Figure 4.16, there was strong labelling of DDX3 protein in LDs purified from 
JFH1 HCV-infected Huh-7 cells, which was undetectable in LDs from uninfected Huh-7 
(Figure 4.17A). This is consistent with recent reports that the cellular DEAD-box protein 
DDX3 is essential for HCV replication (Angus et al. 2010). Furthermore, the role of 
DDX3 in the life cycle of other viruses has been previously documented for human 
immunodeficiency virus-1 (HIV-1) (Yedavalli et al. 2004) and brome mosaic virus 
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(Noueiry et al. 2000). In contrast, DDX3 has been reported to exhibit antiviral activity 
against the hepatitis B virus (HBV), as it inhibits transcription following incorporation into 
virus nucleocapsids (Wang et al. 2009). Thus, there is increasing evidence that DDX3 is 
important in the life cycle of several diverse viruses. 
 
4.3.3.1 DDX3 interacts with CRM-1/exportin in shuttling of HCV core protein 
The data presented in Figure 4.16 indicates that HCV results in the accumulation of 
DDX3 protein in LDs, where HCV assembly takes place, suggesting that the interaction 
between DDX3 interaction and HCV core on LDs is potentially important for HCV 
replication. As such, understanding the viral strategies for manipulating or co-opting 
DDX3 in functional and molecular detail can provide valuable insights that can aid the 
development of strategies to therapeutically target DDX3. 
The data described above indicates that LDs are vital for HCV replication, this is 
consistent with the published data (Boulant et al. 2006; Miyanari et al. 2007) where HCV 
core accumulate DDX3 (Angus et al. 2010). To test this hypothesis, uninfected Huh-7 cells 
and JFH1 HCV-infected cells were treated with 10 nM leptomycin B (LMB, Sigma), a 
specific inhibitor of CRM-1/exportin, or mock treated. After 24 h, cells were harvested, 
LDs isolated and Western blots were performed, using specific antibodies against DDX3, 
ADRP and core protein. As shown in Figure 4.17B, leptomycin B significantly reduced the 
accumulation of DDX3 in purified LDs from chronic JFH1 (HCV).  
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Figure 4.17 Association of DDX3 with LDs in response to HCV-JFH1 infection.The 
LD fraction was collected from uninfected cells (Huh-7) or HCV-infected cells (JFH1) at 
12 days postinfection. (A) The results of Western blot analyses of DDX3 and the HCV 
core protein, as well as the LD marker ADRP are shown. (B) Protein extracts were 
evaluated for DDX3 compared ADRP after. The accumulation of DDX3 in the purified 
lipid droplets decreased significantly after treatment with leptomycin B as assessed by 
western blot. Confirmation of the infection of the purified LDs was done using antibodies 
against HCV core protein. This figure is a representative figure of three times 
independently, all yielded the same results. 
 
 
 
 
 
4.4 Summary 
A B 
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These findings collectively suggest that HCV infection impacts hepatic lipid 
metabolism broadly, with these changes being more evident in ER fractions and LDs.  In 
ER fraction, a significant difference in the lipid profile of purified ER, relative to the 
whole cells was observed. In particular, the HCV-induced increase FC. Moreover, the 
most prominent neutral lipid class seen in ER-lipid rafts, and appeared to be up-regulated 
in HCV-infected cells is FC. On the other hand, phospholipids analysis showed a 
significant increase in PC, PE, and PI classes in the ER fraction of HCV-infected cells. 
The most striking difference was the relatively greater HCV-induced increase in PC (150% 
vs. 30%, p<0.01) and free cholesterol (200% vs. 50 %, p<0.01) in the ER, compared to 
whole cell extracts. This suggests that chronic HCV infection results in the profound 
accumulation of PC in the ER fraction and emphasizes the role ER plays in HVC 
replication. Furthermore, it suggests that ER is an attractive target for anti-viral therapies 
and that PC plays a vital role in the HCV replication in the ER. The modulation of the 
enzymes that control PC pathways may represent novel host-targeted anti-HCV therapies. 
In LD fractions, TAG was the most prominent among neutral lipid classes and was 
significantly up-regulated in HCV-infected cells. For phospholipids, PC was the only 
detectable class by HPTLC in LDs with a significant up-regulation in infected cells.  
Lastly, proteomic analysis of ER-lipid rafts and LD fractions was performed. No 
significant change was induced by HCV infection on ER-lipid rafts proteins. However, 
DDX3 protein was the most significant up-regulated protein in LDs proteomic analysis. 
The treatment of HCV-infected cells with leptomycin B (CRM-1/exportin inhibitor) 
significantly reduced the accumulation of DDX3 in purified LDs from chronic JFH1, 
which suggests that targeting DDX3/CRM-1/exportin pathway in LDs represents a 
potential novel host-targeted agent against HCV. 
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HCV induced the accumulation of DDX3, a helicase that is important in the HCV 
life cycle. On the other hand, HCV also induced a shuttling protein, CRM-1/exportin. The 
research thus far has shown that both DDX3 and Exportin 1 interact together in the process 
of shuttling of HCV core protein between the nuclear and cytoplasmic compartments of 
the cell. Leptomycin B (a specific CRM-1/exportin) pre-treatment reduces HCV RNA. 
This suggests that targeting the DDX3/CRM-1/exportin pathway in LDs may result in a 
potential novel host-targeted agent that can protect against HCV. 
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5. PEMT a novel pathway for host-targeted agents against hepatitis C 
5.1 Introduction 
The previous two chapters described how chronic HCV infection modulates the 
global intracellular lipidome to create an environment that aids RNA replication and the 
production of progeny particles. This effect was more prominent in the endoplasmic 
reticulum (ER) and cytoplasmic LDs (LDs), where HCV protein translation, RNA 
replication and virus assembly take place. As well as the known effects on neutral lipids 
and cholesterol, HCV induced a significant accumulation of phosphatidylcholine (PC).  
PC and PE are the major phospholipids found in mammalian cell membranes (Kent 
1995; Li et al. 2006). In hepatocytes, PC is mainly synthesized from choline via the CDP-
choline pathway, phosphate cytidylyltransferase 1 alpha (PCYT1A), known also as 
CTP:phosphocholine cytidylyltransferase (CTα) is the rate-limiting enzyme in this 
pathway. PCYT1A facilitates the conversion of phosphocholine to CDP-choline, the 
addition of the phosphocholine moiety to diacylglycerol completes the synthesis of PC. 
The alternative phosphatidylethanolamine N-methyltransferase (PEMT) pathway accounts 
for 20-30% of total PC synthesis (Figure 5.1) (Bremer & Greenberg 1961). PEMT 
catalyses the synthesis of PC from PE, as shown in Figure 5.2A, by the stepwise transfer 
of methyl groups from S-adenosylmethionine (SAMe) to the amino head group of PE. This 
reaction consumes three molecules of SAMe for each molecule of PC being formed 
(Sundler & Akesson 1975). 
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Figure 5.1 Phosphatidylcholine biosynthesis pathways in human hepatocytes.PC, 
phosphatidylcholine; PEMT,phosphatidylethanolamineN-methyltransferase;CT, 
CTP:phosphocholine cytidylyltransferase; CPT,CDP-choline:1,2- diacylglycerol 
cholinephosphotransferase; CK, choline kinase; CT, CTP:phosphocholine 
cytidylyltransferase; cholinephosphotransferase; PEMT, phosphatidylethanolamine N-
methyltransferase; P-choline, phosphocholine; CDP-choline, cytidine diphosphate-
choline;PE, phosphatidylethanolamine; 
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Figure 5.2 S-Adenosyl methionine (SAMe) dependent methylation reactions. 
 Phosphatidylethanolamine N-methyltransferase (PEMT) pathway: PEMT catalyses the 
synthesis of phosphatidylcholine (PC) by sequential addition of methyl groups from SAMe 
to the amino head group of phosphatidylethanolamine (PE). 
 
According to this hypothesis, metabolic reprogramming could help HCV to 
establish and maintain persistent chronic infection, as inhibiting STAT1-induced ISG 
activation would reduce the effectiveness of an important early component of the anti-viral 
immune response, Type I interferon. Furthermore, this could help to explain the 
development of interferon resistance, which is frequently observed during HCV anti-viral 
therapy. To this end, a series of experiments was designed with the goal of investigating 
whether the inhibition of PEMT in HCV-infected cells: (1) affects lipid accumulation; and 
(2) enhances IFN-α induced expression of antiviral ISGs. 
 
5.2 HCV infection activates phosphatidylcholine (PC) biosynthesis pathways in Huh-
7 cells  
To examine the effect that HCV infection has on PCYT1A and PEMT expression, 
the key enzymes in PC biosynthesis, JFH1 HCV-infected and uninfected-Huh7 cells were 
seeded in 6-well plates, with 1 ×10
6
 cells per well, and incubated overnight at 37 °C. The 
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next day, the cells were subjected to RNA extraction, using the process described in 
Chapter 2 (Section 2.2.2.3). Real-time quantitative PCR analysis (qPCR) using PEMT or 
PCYT1A specific primers revealed significant up-regulation of expression for both 
enzymes in HCV-infected cells, compared to uninfected controls (Figure 5.3) 
 
A B 
*	
*	
 
Figure 5.3 PEMT and PCYT1A mRNA expression is increased in HCV infected 
Huh7 cells.  
Huh7 cells were transfected with HCV (JFH1) then cellular RNA was extracted and 
relative mRNA expression was quantified using qPCR for A) PCYT1A and B) PEMT.  * 
Significant change from uninfected control (p<0.05). 
 
 
Having confirmed up-regulation of PCYT1A and PEMT expression in JFH1-
infected cells, the next step was to investigate the effect of PCYT1A and PEMT inhibition 
on HCV replication. To test this, three small interfering RNAs (siRNA) that target 
different regions of PCYT1A or PEMT mRNA were transfected into JFH1-infected Huh-7 
cells to silence gene expression. In cells, siRNAs are produced by enzymatic cleavage of 
long dsRNAs by the RNase-III class endoribonuclease Dicer. The siRNAs associated with 
the RNA-induced silencing complex (RISC) in a process that was facilitated by Dicer. The 
siRNA-27 contained three Dicer-Substrate 27-mer duplexes targeting a specific gene that 
were selected from a predesigned set of duplexes from the RefSeq collection of Genbank. 
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OriGene‘s siRNA collection of 27-mer sites were chosen by a rational design algorithm 
that integrated both traditional 21-mer siRNA design rules as well as new 27-mer design 
criteria (Kim et al. 2005). The efficiency of PCYT1A and PEMT knockdown was 
confirmed using qPCR, as shown in Figure 5.4. Forty-eight hours post-transfection with 
siRNA, mRNA expression was reduced by approximately 90%. As such, this time point 
was selected for subsequent HCV infections. Two days following HCV infection, 
intracellular HCV RNA levels were determined using qPCR.  
In cells where ePYCT1A expression was knocked down, there was no significant 
reduction in HCV RNA levels, suggesting that PYCT1A is not important for HCV 
replication. In stark contrast, knockdown of PEMT resulted in more than a 50% decrease 
in infection, as quantified by qRT-PCR (Figure 5.5). This suggests that PEMT-dependent 
PC synthesis is important for HCV replication. 
 
 
 
***	**	
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Figure 5.4 siRNA mediated PCYT1 and PEMT knockdown efficiently reduces their 
expression.   
Treating Huh-7 cells with siRNA targeting (A) PCYT1 or (B) PEMT reduced gene 
expression by approximately 85% or 90% respectively at 48 hr.compared with scrambled 
controls (** p<0.01, ***p<0.001). 
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Figure 5.5 Effect of inhibiting PC synthesis on HCV infection. 
HCV (JFH1) infected Huh-7 cells were transfected with target specific siRNA, or 
scrambled RNA control (20nM/ml). HCV RNA was measured 48 h after transfection. 
Cells transfected with PCYT1A (CTTA) siRNA did not show any effect in HCV RNA 
levels (A). PEMT knockdown cells showed significant reduction in HCV RNA levels, 
compared to mock treated cells (B). (*p<0.05).  
 
To test whether reducing PEMT inhibited new HCV infection, infection assays 
were also performed PYCT1A or PEMT were knocked down using siRNA, as described 
above, with scrambled controls, then cells were infected with a JFH1-concentrated virus. 
After 48 hr, infected cells were labelled for virus protein using antibody against NS5A, 
and viral infectivity was determined through the use of a tissue culture infective dose 
(TCID50) calculation (Figure 5.6). Similar results were obtained and exhibited a 
significant reduction in infectivity of approximately 50% for cells that had been treated 
with PEMT siRNA, but not for those treated with PYCT1A siRNA. This suggests that 
PEMT is important for establishing HCV infection and ongoing RNA replication. 
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Figure 5.6 PEMT siRNA pre-treatment reduces HCV infection. 
To determine the effect of PEMT knockdown on HCV infection, Huh-7 cells were treated 
with 20 nM/ml PEMT siRNA or scrambled siRNA for 48 h followed by JFH1 infection. 
TCID50 analyses demonstrate that PEMT siRNA pre-treatment significantly reduced JFH1 
infection of Huh-7 cells (** p<0.01). 
 
 
5.3 PEMT protein level is increased in JFH1 HCV-infected cells 
Having confirmed that the expression of PEMT mRNA increases in HCV-infected cells; 
there was a requirement to measure the PEMT protein levels. Huh7 cells were infected 
with HCV (JFH1), the cells were then lysed and Western blotting was performed using 
anti-PEMT antibody, as described in Chapter 2 (Section 2.3.5). Western blot analysis of 
total cell lysates confirmed that PEMT protein levels were significantly elevated in JFH1-
infected Huh-7 cells than they were in uninfected cells (Figure 5.7). 
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Figure 5.7 Western blot analysis of PEMT protein levels in Huh7 and JFH1 infected 
cells. Densitometry analysis demonstrated that JFH1 infection significantly increase in 
PEMT levels. 
 
 
To further confirm the in vitro data obtained in cell lines, the expression of PEMT 
in human liver biopsies from patients infected with HCV genotype 1 and 3 was also 
investigated using qPCR. Due to the difficulties associated with obtaining normal liver 
biopsies as a control, liver biopsies from hepatitis B virus (HBV) infected patients were 
obtained as a control. Consistent with the in vitro findings, the HCV patientdemonstrated a 
significant increase in PEMT expression when compared with HBV patients (Figure 5.8), 
with the highest PEMT mRNA levels observed in HCV Genotype 3-infected patients, 
suggesting that HCV infection specifically induces PEMT expression. 
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Figure 5.8 Increased PEMT expression is specific for HCV infected patients.                                    
Relative hepatic PEMT mRNA expression in 88 patients with Chronic Hepatitis C 
(genotype 1 and 3) and 12 Hepatitis B patients (normalized to 18s). PEMT was 
significantly increased in HCV patients compared to HBV patients, and higher for HCV 
genotype 3 than genotype 1. (*p<0.05, ** p<0.01). 
 
 
5.3.1 PEMT pathway knockdown restores S-Adenosyl methionine (SAMe) levels to 
normal 
SAMe is the major biological methyl donor in hepatocytes, where it is involved in 
a range of methylation reactions (Borchardt & Wu 1974), including the methylation of 
activated STAT1 (Figure 5.9) (Kerri A. Mowen et al. 2001). 
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Figure 5.9 Methylation of activated STAT1 is catalysed by PRMT1 and requires 
SAMe. 
 
STAT1 is a member of the signal transducers and activators of transcription 
(STAT) family of transcription factors. It is involved in mediating up-regulation of genes 
in response to a signal from either Type I, Type II or Type III interferons. STAT1 is 
activated by phosphorylation of a single residue, Tyr-701, following binding of a number 
of cytokines to their cognate receptors, including interferons (IFNs), interleukin 6 (IL-6), 
and epidermal growth factor. Phosphorylation on the Tyr-701 residue of STAT1 is 
required for its nuclear translocation, dimerization, DNA binding and gene activation 
(Shuai et al. 1994; Shuai et al. 1993). IFN-α-induced gene transcription can be inhibited by 
the protein inhibitor of activated STAT1 (PIAS1), which adds a SUMO group to a 
conserved lysine residue of STAT1, inhibiting its ability to bind to STAT1 promoter 
elements (Liu et al. 1998). The binding of PIAS1 to STAT1 is affected by methylation of 
STAT1, which is regulated by protein arginine methyltransferase 1 (PRMT1) (Figure 5.9). 
Arginine methylation of STAT1 inhibits binding of PIAS, whereas demethylation of 
STAT1 enhances its association with PIAS1 (Duong et al. 2006; Kerri A. Mowen et al. 
2001). Duong et al. have shown that HCV induces hypomethylation of STAT1, resulting 
in increased binding of PIAS1 to STAT1, increased methylation of STAT1, decreased 
binding of STAT1 to promoter elements and ultimately down-regulation of ISG expression 
(Duong et al. 2004).  
Based on the findings of the current research and those outlined in published data, it 
can be hypothesized that:  
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1. HCV activation of the PEMT pathway in HCV-infected hepatocytes results in a 
high consumption of SAMe. 
2. Depletion of the level of SAMe can lead to decreased methylation of STAT1. 
3. Decreased STAT1 methylation results in decreased STAT1-DNA binding and a 
reduction in the induction of ISGs. 
To investigate this hypothesis, SAMe levels were measured in JFH-infected Huh-7 cells 48 
hours post transfection with PEMT siRNA (20 nM/ml) or scrambled siRNA, and 
compared to uninfected Huh-7 cells as a negative control. As expected, PEMT knockdown 
in JFH1-infected cells showed partial, but significant, restoration of SAMe towards the 
normal levels of the control cells (Figure 5.10). This suggests that activation of the PEMT 
pathway in JFH1-infected cells resulted in the increased methylation reactions of PE and 
the depletion of SAMe levels. 
 
 
 
*	 *	
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Figure 5.10 PEMT knockdown restores S-adenosylmethionine (SAMe) levels to the 
normal. 
Total protein was extracted from JFH1 infected Huh-7 treated or mock treated with 20 
nM/ml PEMT siRNA for 48 hr, then SAMe levels was quantified by commercial ELISA 
kit and compared to uninfected Huh7 cells as a control. (*p<0.05).  
 
 
5.3.2 PEMT pathway knockdown modulates interferon-stimulated gene expression 
Having confirmed that PEMT knockdown restored the SAMe levels in JFH1-
infected cells to nearly normal levels, there was a requirement to explore the impact that 
this had on ISG induction. As outlined in the introduction, IFN-α signals via the JAK-
STAT pathway to induce the expression of hundreds of genes, known as interferon-
stimulated genes (ISGs). The methylation status of STAT1 is an important determinant of 
ISG expression. The manipulation of STAT1 methylation had consequences on DNA 
binding of STAT1 and the induction of IFNα target genes (ISGs) (Duong et al. 2006; K A 
Mowen et al. 2001). A series of experiments was therefore designed to investigate whether 
PEMT knockdown enhances the expression of antiviral ISGs following treatment with 
IFN-α. 
For the purpose of these experiments, JFH1-infected Huh-7 cells were pre-treated 
with PEMT siRNA for 48 hr, or scrambled RNA control, then treated with 100 U/ml IFN-
α. The expression of key ISGs was then measured using qPCR. Selected well-characterised 
ISGs were chosen to determine whether PEMT knockdown affected the regulation of the 
antiviral response. The expression of ISGs over a 24 h period was examined at key time 
points (0 hr, 2 hr, 6 hr and 24 hr after IFN-α treatment). The results revealed that the 
PEMT knockdown significantly increased the IFN-induced expression of Viperin, 2‘5‘ 
oligoadenylate synthetase 3 (OAS3), and MX1, but had no significant effect on ISG15 
(Figure 5.11). 
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These findings suggest that PEMT functions beyond its recognized role as a 
compensatory pathway for PC biosynthesis and that, in contrast, PEMT activity is 
involved in many physiologic processes including the flux of lipid between liver and 
plasma and the delivery of essential fatty acids to blood and peripheral tissues via the liver-
derived lipoproteins. This is consistent with existing clinical data that shows that HCV 
G3a infection directly induces hepatic steatosis in humans. 
 
 
 
*	
*	
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Figure 5.11 PEMT knockdown pre-treatment variably effects interferon stimulated 
genes expression following interferon alpha treatment. 
JFH1 infected Huh-7 cells were pre-treated with PEMT siRNA for 48 hr, or scrambled 
RNA control, then treated with 100 U/ml IFN-α, and the expression of key ISGs measured 
by qPCR after 0, 2, 6, and 24 hr post INF-α. Significant up-regulation at early time points 
was observed in Viperin, OAS3, and MX1 in PEMT knockdown pre-treated cells, whereas 
ISG15 expression was not effected (*p<0.05, ** p<0.01).  
 
Chapter 5: PEMT a Novel Pathway for Host-targeted Agents Against Hepatitis C 
 
157 
 
 
 
 
To explore the mechanism of this effect, a Western blot analysis was performed to 
examine the effect of IFN-α and PEMT siRNA pre-treatment on STAT1 phosphorylation. 
JFH1-infected cells (>90% infection) were treated with PEMT siRNA (20 nM), or mock 
treated as a control. After 48 hr, the cells were treated with 100 U/ml IFN-α and were then 
lysed after 30 min and 2 hours, protein was extracted, and STAT1 phosphorylation was 
detected using Western blot. STAT1 phosphorylation was evident at 30 and 120 min post-
IFN-α treatment in both PEMT-kd and control cells, but was more prominent for PEMT-
kd cells(Figure 5.12A). Baseline STAT1 was also modestly elevated in PEMT-kd. 
Densitometry analysis confirmed that IFN-induced STAT1 phosphorylation was stronger 
in PEMT siRNA-treated cells than it was in the control cells (Figure 5.12B). 
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Figure 5.12 PEMT knockdown modulates STAT1 phosphorylation post interferon 
treatment.                                                                                                                            
JFH1 infected Huh-7 cells were mock treated or treated with 20 nM/ml PEMT siRNA for 
48 hr followed by 100 U/ml IFN-α treatment. (A) STAT1 and pSTAT1 Western blots were 
performed over 2 h post- IFN-α to examine cellular response. (B) PEMT knockdown 
significantly increased STAT1 phosphorylation following IFN-α treatment (* p<0.05). 
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5.3.3 PEMT knockdown enhances the anti-HCV activity of interferon-alpha 
To examine the effects of PEMT knockdown on IFN-α antiviral activity, JFH1 
HCV-infected Huh-7 cells were cells were transfected with PEMT siRNA, or scrambled 
RNA control; then, cells were treated with 100 U/ml IFN-α. HCV replication was 
determined at 0 hr, 2 hr, 6 hr and 24 hr by qPCR. PEMT knockdown significantly 
decreased viral replication compared to scrambled RNA control cells (Figure 5.13A). To 
examine the average reduction in viral replication, each treatment was normalized to 
baseline (0 hr) expression and compared. PEMT siRNA treated cells were the most 
sensitive to IFN-α treatment, exhibiting over 40% more sensitivity than scrambled RNA-
treated cells (Figure 5.13B). This suggests that PEMT sensitised cells to IFNon ISG 
expression. 
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Figure 5.13 PEMT knockdown act synergistically with interferon alpha to reduce 
HCV replication. 
JFH1 (HCV) infected Huh-7 cells were transfected with PEMT siRNA, or scrambled RNA 
control, for 24 h then cells were treated with 100 U/ml IFN-α. (A) HCV replication was 
determined at 0 hr, 2 hr, 6 hr and 24 hr by qPCR. In all time points, PEMT knockdown 
significantly decreased viral replication compared to control. (B) The average reduction in 
viral replication, each treatment was normalized to baseline (0 hr) expression and 
compared (* p<0.05, **p<0.01). 
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5.4 The PEMT enzyme controls hepatic intracellular lipids homeostasis and turnover  
SAMe is involved in mediating hepatic TG synthesis via the PEMT pathway 
(Figure 5.14). Currently, there is evidence that decreased content of SAMe is linked with 
the development of NAFLD in different experimental models of steatosis in rodents and 
humans (Lu & Mato 2012). This research has shown that chronic HCV infection is 
associated with increased cellular triglyceride and cholesterol content (Hourioux et al. 
2007; Negro & Sanyal 2009). As such, the hypothesis that PEMT knockdown with SAMe 
at normal levels will be reflected in decreased cellular triglyceride content in the JFH1 
HCV-infected Huh7 cells was developed. To test this hypothesis, the cellular distribution 
of triglyceride and cholesterol following PEMT knockdown was examined using 
immunofluorescence labelling. PEMT expression was knocked down in JFH1-infected 
Huh-7 cells using 20 nM PEMT siRNA and, 48 h later, cells were immune-labelled with 
NS5A antibodies and secondary 594 anti-Sheep IgG conjugated antibodies. BODIPY® 
493/503 was used to label the neutral lipids and DAPI was used to label the nucleus. 
PEMT knockdown cells were compared with both JFH1 cells that were treated with 
scrambled RNA and non-infected Huh7 cells.  
As expected, HCV-infected cells showed a significant increase in neutral lipid 
compared to uninfected cells (Fig 5.15, p<0.01). Consistent with the hypothesis, the PEMT 
knockdown led to a significant decrease in the accumulation of BODIPY®-stained neutral 
lipid in HCV-infected cells, but did not impact uninfected controls. These results suggest 
that PEMT and its target genes are intimately involved in the lipid metabolism of 
hepatocytes, especially in LD formation and the persistent infection of HCV. 
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Figure 5.14 Schematic representation of the role of SAMe in mediating TG synthesis 
via PEMT. PE, phosphatidylethanolamine; PC, phosphatidylcholine; PA, phosphatidic 
acid; CER, ceramide; SM, sphingomyelin; DG, diglycerides; FA, fatty acids; TG, 
triglycerides; LD, lipid droplets; PEMT, PE N-methyltransferase; PLD, phospholipase D; 
PAP, PA phosphatase; PLC, phospholipase C; SMS, sphingomyelin synthase; PLIN2, 
perilipin2. (Martínez-Uña et al. 2013). 
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Figure 5.15 Decrease in lipids accumulation in PEMT knocked down JFH1 infected 
Huh-7 cells. 
Huh7 cells were electroporated with 5µg of in vitro transcribed JFH-1 RNA. After 14 days 
JFH1 infected Huh7 cells were treated with PEMT siRNA or scrambled RNA. 48 hr post-
transfection, cells were fixed in methanol and labelled with sheep polyclonal anti-NS5A 
antiserum (anti NS5a) and red 594 antiSheep IgG conjugated secondary antibody, neutral 
lipids and nucleus were stained with BODIPY 493/503 or DAPI respectively, then 
examined by fluorescence microscopy.PEMT knocked down JFH1 infected cells showed a 
decrease in the accumulation of neutral lipid. For quantification of lipid abundance, images 
were captured and analyzed using Imaris software. **Significant difference from JFHI 
infected Huh7 cells (P < 0.01). 
  
 
5.4.1 The effect of PEMT-knockdown on intracellular lipid turnover  
Various studies have shown that HCV hijacks the host lipid machinery to facilitate 
its own replication, inducing lipogenesis, while reducing fatty acid secretion (Syed et al. 
2010). For example, HCV modulates lipid homeostasis by reducing oxidation and lipid 
export (Negro & Sanyal 2009b) and increasing lipogenesis via SREBP activation (Waris et 
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al. 2007b). Moreover, HCV downregulates very-low-density lipoprotein (VLDL) particle 
secretion by inhibiting the activity of microsomal triglyceride transfer protein (MTP) 
activity (Perlemuter et al. 2002) Therefore, the effect of PEMT knockdown on the 
expression of key lipid synthesis and trafficking genes was examined in order to develop 
an understanding of the mechanism of modulation of cell lipid content following PEMT 
knockdown in JFH1-infected cells. Huh-7 cells were infected with JFH1 then, after two 
weeks (when > 90 % of cells were infected), JFH1-infected and uninfected control cells 
were seeded in 6-well plates and incubated at 37 °C. 24 hours later, JFH1-infected cells 
were transfected with 20 nM/ml PEMT or scrambled RNA then, after 48 hr, cells were 
lysed, the total RNA was extracted and reverse transcribed to produce cDNA. The 
expression of key enzyme genes was measured using quantitative real-time PCR. Figure 
5.16 shows the expression of entry factors LDL-R (A), cholesterol synthesis transcription 
factor SREBP1 (B), VLDL pathway components MTP (C) and cholesterol transporters 
ABCA1 (D). 
SREBP-1c is the isoform of the sterol regulatory element-binding protein (SREBP) 
family that controls the biosynthesis of fatty acids and triglycerides in the liver (Brown & 
Goldstein 1997). The amount of (active) SREBP-1c protein in the nucleus is highly 
correlated with SREBP-1c mRNA levels. Therefore, mRNA expression of the SREBP-1c 
gene is the key regulatory step for its activity and ultimately determines hepatic 
lipogenesis. The expression of SREBP-1c was significantly up-regulated in HCV-infected 
cells (Waris et al. 2007b). As such, the expression of SERBP-1c mRNA in JHF1-infected 
cells transfected with 20 nM/ml PEMT siRNA, or mock transfected, was measured and 
compared to uninfected Huh-7 controls. SREBP-1c expression was increased in JFH1-
infected cells, but there was a significant down-regulation of the normal levels in PEMT 
knockdown observed in the JFH1-infected cells (Fig 5.16A). 
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Next, the expression of the two genes (MTP and ABCA1) involved in lipid 
trafficking was assessed. MTP was significantly down regulated in JFH1-infected cells 
compared to mock-infected cells; importantly, the JFH1-infected cells that were treated 
with PEMT siRNA elevated MTP expression to normal levels (Figure 5.16B). MTP 
protein transfers lipids from various donor lipid sites to acceptor sites and plays an 
essential role in transferring triglycerides to the ER lumen and thus in the formation of 
very low density lipoprotein (VLDL) (Raabe et al. 1999). HCV core protein interferes with 
the assembly of VLDL by decreasing the expression of MTP protein (Perlemuter et al. 
2002). 
Importantly, an increase in ABCA1 expression following PEMT knockdown in 
JFH1-infected cells was also demonstrated. These data are consistent with ABCA1 
positive regulation (Figure 5.16C). ABCA1 mediates the transport of phospholipids and 
cholesterol across cellular membranes and their export from cells by high-density 
lipoproteins (HDL) (Oram 2003). Interestingly, a recent study showed that the stimulation 
of ABCA1 expression inhibited HCV infection of both human primary hepatocytes and 
isolated human liver slices. 
Lastly, PEMT knockdown had no effect on LDL-R expression in JFH1-infected 
cells (Figure 5.16D). Low density lipoprotein receptor (LDL-R) is a cell surface receptor 
that is involved in the binding and uptake of HCV lipoviral particles that circulate in the 
blood (Koutsoudakis et al. 2006; Zeisel et al. 2011). The inhibition of LDL-R in HCV-
infected patients through the use of anti-LDLR has been shown to significantly reduce 
HCV endocytosis (Germi et al. 2002).  
The inhibition of PEMT in HCV-infected cells led to decreased lipogenesis via 
SREB1-c activity inhibition and enhanced intracellular lipids transport and export by 
increasing ABCA1 and MTP activities respectively. Taken together, these data suggest 
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that the effect of PEMT knockdown on lipid metabolism genes reflects the accumulation 
of lipids within infected cells.  
 
 
 
A B 
C D 
 
Figure 5.16 Representative sample (Three replicates) of gene expression responsible 
for lipids turnover. 
HCV (JFH1) infected Huh-7 cells were treated or mock treated with PEMT siRNA for 48 
h, RNA was extracted and SREBP-1c, MTP, ABCA1, and LDL-R mRNA were measured 
by qPCR. (A) Significant reduction in SREBP-1c expression with PEMT siRNA pre-
treatment compared to mock treated cells. (B and C) MTP and ABCA1 were significantly 
increased in JFH1 infected cells pre-treated with PEMT siRNA.  (D) PEMT knockdown 
had no effect in LDL-R expression in JFH1 infected cells. (* p<0.05, ** p<0.01).  
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5.4.2 PEMT pathway knockdown significantly reduced HCV replication through 
reduced DGAT1  
The diacylglycerol acyltransferase-1 (DGAT1) enzymes catalyse the final step in 
triglyceride biosynthesis and are essential in LD biogenesis (Yen et al. 2008). Herker et al. 
identified DGAT1 as a key factor for HCV infection, as it binds the HCV core protein and 
localizes core protein to DGAT1-generated LDs (Figure 5.17). The inhibition of DGAT1 
activity robustly inhibits HCV particle production, suggesting that assembly requires 
DGAT1-mediated LD formation (Herker et al. 2010). A subsequent study showed that 
DGAT1 is required for the development of hepatic steatosis in DGAT1 knockout mice 
(Harris et al. 2011). Recently, research has also indicated that, besides the core protein, 
NS5A protein is translocated from the ER onto LDs through the actions of DGAT1 
(Camus et al. 2013). 
To examine the impact of PEMT knockdown on DGAT1 expression, Huh-7 cells 
were electroporated with JFH1 RNA. Then, after two weeks, JFH1-infected cells and 
uninfected cells were seeded in 6-well plates. After 24 h incubation, JFH1-infected cells 
were transfected with PEMT siRNA or scrambled RNA for 48 h, the cells were lysed, the 
total RNA extracted, reverse transcribed to produce cDNA, and mRNA was quantified 
using qPCR. As expected, there was an up-regulation of DGAT1 expression in JFH1-
infected cells, but PEMT knockdown restored DGAT1 expression to control levels (Figure 
5.18). These results support the view that increased PEMT activity induces both TG 
synthesis and its accumulation into newly formed LDs. 
Because phosphatidylcholine is required for the formation of LDs, there is a 
potential that the loss of PEMT activity interferes with triglyceride turnover and reduces 
cellular lipid droplet levels, thereby resulting in a reduction the production of infectious 
particles. Consistent with this hypothesis, the results of this study indicate that the flux 
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from PE to PC is stimulated in the HCV-infected cells via PEMT pathway, and that this 
produces a marked increase in DG and TG. 
 
Figure 5. 17 DGAT1 is necessary for HCV particle assembly at lipid droplets.                           
HCV core association with lipid droplets depends on DGAT1.  Inhibition of DGAT1 
prevents HCV core protein from accessing lipid droplets (Herker et al. 2010). 
*	 *	
 
Figure 5.18  Real-time RT-PCR  analysis of DGAT1 expression.                                                                        
RNA isolated from Huh-7 cells or from of Huh-7 cells electroporated   with JFH1 RNA 
and treated with PEMT inhibitor (20nM) or scrambled RNA. Results are   expressed as 
DGAT1 RNA copy numbers per   1 μg total cellular RNA normalized to GAPDHRNA   
(intracellular) at day 2-post transfection (*p< 0.05). 
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5.5 Correlation of PEMT expression and steatosis in HCV-infected patients  
 
It has been reported that the severity of steatosis is associated with the progression 
of hepatic fibrosis and hepatocellular carcinoma in chronic hepatitis C (CHC) (Kurosaki et 
al. 2010). Moreover, of the CHC patients who are infected with HCV genotype 2, those 
with hepatic steatosis are more resistant to interferon therapy (Kurosaki et al. 2010). The 
mechanism by which hepatocyte steatosis plays a role in IFN resistance is still unclear. 
Previous sections of this chapter described the increased expression of the PEMT 
enzyme in HCV-infected hepatic cells and confirmed the impact that PEMT knockdown 
had on HCV replication, lipid accumulation and interferon signalling. Therefore, the last 
section of this chapter investigates the association between PEMT expression and the 
severity of steatosis in HCV infection. To investigate how HCV infection may influence 
PEMT expression in the liver, PEMT expression was measured in liver biopsies from three 
independent HCV cohorts, using three different techniques: Microarrays, RNA high 
throughput sequencing (RNA-Seq) and real-time qPCR. 
All liver biopsies samples were collected from HCV genotype 1-infected patients. 
A total of 26 samples for RNA-Seq, 22 for microarray analysis and 37 for qPCR were 
used. Ethics approval was obtained from the Human Research Ethics Committees of 
Sydney West Area Health Service and the University of Sydney. All subjects provided 
written informed consent (HREC2002/12/ 4.9(1564) prior to the research. 
PEMT expression was positively correlated with steatosis severity in HCV patients 
in all three cohorts (Figures 5.19 a, b, and c). Gene microarray, RNA-seq and qPCR 
analysis consistently exhibited higher PEMT levels in patients who suffered from 
moderate-to-severe steatosis than those with mild-to-moderate steatosis.  
In a similar manner, the extent to which hepatic PEMT expression correlates with 
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plasma HCV RNA levels was assessed. As was the case with steatosis, there was a positive 
correlation between HCV RNA levels and PEMT expression in the three independent 
cohorts, using the three different techniques (Figure 5.20).  
Following this, the correlation between liver fibrosis and PEMT expression in 
HCV-infected patients was assessed. Liver biopsy samples were divided into high 
(METAVIR or Scheuer fibrosis score ×2) or low fibrosis (METAVIR or Scheuer fibrosis 
score p1). In contrast to the positive correlation between steatosis and PEMT expression in 
the liver, the opposite effect was observed with fibrosis. As demonstrated in Figure 5.21, 
PEMT expression was negatively correlated with fibrosis severity in HCV-infected 
patients in all three cohorts. 
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Fig. 5.19 Analysis of PEMT expression level in low versus high steatosis liver biopsy 
samples.    Panel (a) performed by RNA-Seq (n 1⁄4 26), panel (b) by microarray (n 1⁄4 22) and 
panel (c) qPCR (n 1⁄4 37). High fibrosis samples exhibit higher MT expression by all three 
methods. 
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Figure 5.20 Correlation between HCV RNA levels and PEMT expression in 
hepatocytes. Panel (a) performed by RNA-Seq (n 1⁄4 26), panel (b) by microarray (n 1⁄4 22) and 
panel (c) qPCR (n 1⁄4 37). High fibrosis samples exhibit higher MT expression by all three 
methods.  
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Fig. 5.21 Correlation between hepatic fibrosis in HCV infected patients and PEMT 
expression. Independent comparisons RNA-Seq  (A) and microarray (B) of expression of 
PEMT in HCV-infected liver biopsies. 
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5.6 Summary 
In summary, based on the in vitro and in vivo data gathered through this research, 
HCV infection increases the expression of PEMT in hepatocytes. Furthermore, inhibiting 
PEMT activity using PEMT siRNA led to two important observations: 
 1. Inhibiting PEMT reduced HCV infection in vitro, most likely by altering the synthesis 
and simultaneously enhancing the secretion of lipids. HCV-infected cells have increased 
expression of genes involved in lipogenesis (SREB1-c ABCA1 and LDL-R), and more 
intracellular lipid. 
 2. PEMT siRNA pre-treatment enhanced the sensitivity of HCV-infected cells to IFN-α 
treatment, as demonstrated by the increased STAT1 phosphorylation, the increased ISG 
induction and, most importantly, the reduction in HCV RNA.  
The researchers hypothesize that this improved response to IFN-α may be due to increased 
intrahepatocellular concentrations of SAMe, which restore STAT1 methylation and 
improve IFNα signalling. This suggests that PEMT inhibitors may be useful as a result of 
their ability to improve treatment response in patients with chronic HCV infection who are 
refractory to treatment with IFN-α.  
3. Finally, the research revealed that PEMT expression is elevated in patient‘s CHC and is 
coupled with elevated HCV RNA levels and more severe steatosis. The relationship 
between HCV viral load and PEMT suggests the possibility of a causative interplay 
between the virus and PC metabolism, which will need to be further examined.
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6. Final Discussion  
6.1 Study aims  
The original aim of this project was to examine, in detail, hepatitis C virus-induced 
lipid changes in whole cells and sub-cellular organelles, and explore the implications for 
novel anti-host targeted HCV therapies. Upon finding that HCV induced the significant 
accumulation of several phosphatidylcholine (PC) species, the research sought to assess 
the effect of silencing the enzymes responsible for the activation of this pathway 
(PCYT1A and PEMT) on HCV replication and the antiviral effects of IFN. The results 
indicated that the PEMT pathway is involved in HCV replication and probably HCV-
induced interferon resistance, in mechanisms mainly related to methylation and partially 
independent of changing PC levels. The lipid-modifying effects of PEMT knockdown 
were examined in more detail to further understand how the PEMT pathway may 
contribute to HCV-induced metabolic reprogramming. 
6.2 Findings and significance 
The results of this study demonstrated, for the first time, that PEMT enzyme 
knockdown can increase the sensitivity of Huh-7 cells to IFN-α treatment, resulting in 
reduced HCV replication in vitro and reduced HCV-associated lipid accumulation. 
The research demonstrated that the use of two complementary approaches (high-
resolution HPTLC and mass spectrometry) on the JFH1 HCV infection of Huh-7 hepatoma 
cells induces global changes in the cell lipidome, affecting both neutral lipids and 
phospholipids. The clinically derived JFH1 strain and its derivatives are the only HCV 
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strains that reproduce the entire virus life cyclein vitro, and only replicate efficiently in the 
Huh-7 cell line, which is why this model was selected for the in vitro studies. 
Chapter 3 described HCV-induced global changes in the content of cell lipids. 
These findings provide useful insights into the metabolic reprogramming induced by 
chronic HCV infection, and how this benefits both the energetic and biosynthetic needs of 
the viral life cycle. The increased abundance of certain phospholipids (PC, PE, and PI) 
potentially reflects their role as crucial constituents in the various structural entities 
supporting viral replication, including the lipid droplet and membranous replicase 
compartments. In contrast, a major change in other lipid classes (triacylglycerol) was 
expected; however, only minor changes were observed. This probably reflects their 
consumption during incorporation into lipoprotein-associated viral particles, reflecting 
potentially important roles in infectivity.  
However, the detail of these changes at the subcellular level was not known, so this 
was examined further. Of the various subcellular compartments, the endoplasmic 
reticulum (ER) is a prime candidate for HCV infection. The ER plays a central role in 
HCV replication: following infection, viral RNA is translated at the ER, where viral 
proteins induce membrane modifications, giving rise to the ‗membranous web‘. This web 
acts as the platform for the synthesis of HCV RNA. Virus structural proteins are then 
packaged with RNA at the interface between ER and cytoplasmic LDs (Herker et al. 
2010), assembled into ‗lipoviral‘ particles in the ER and exported through the ER-Golgi 
pathway (Gastaminza et al. 2008). Thus, understanding of HCV/host lipid homeostasis and 
turnover in the ER should provide novel insights, over and above examining changes in the 
whole infected cell. This research incorporated the hypothesis that HCV-induced lipid 
changes would be more profound in the ER organelle than they would be in the whole cell. 
Consistent with this, dramatically greater changes in both neutral lipids and phospholipids 
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in the ER we observed in comparison to the whole cell. The most striking difference was 
the relatively greater HCV-induced increase in phosphatidylcholine (150% vs. 30%, p 
<0.001) and free cholesterol (200% vs. 50 %, p <0.01) in the ER, compared to whole cell 
extracts. This emphasizes the importance of the ER in the HCV life cycle. Further studies 
are required to explore this in depth both in terms of HCV and perhaps also for viruses that 
affect cellular lipid. 
In the view of the findings, more detailed analysis of the effect of chronic HCV 
infection on ER lipid rafts was performed. Recent studies suggest that the HCV replication 
complexes are formed on lipid rafts, which are detergent-insoluble micro domains of 
intracellular vesicular membranes. 
Lipid rafts are small platforms in the outer exoplasmic leaflet of the lipid bilayer, 
composed of sphingolipids and cholesterol, which are connected to phospholipids and 
cholesterol in the inner cytoplasmic leaflet. These assemblies are fluid, but more ordered 
and tightly packed than the surrounding lipid bilayer. Lipid rafts were first discovered as a 
detergent-insoluble fraction, and the concept of lipid rafts has changed our understanding 
of cell membrane organization. In mammalian cells, lipid rafts are first assembled in the 
Golgi complex (Simons & Ehehalt 2002), and are involved in cell signalling and 
intracellular trafficking (Helms & Zurzolo 2004). Some viruses utilize these sub-cellular 
membrane domains for cell entry, virion assembly or budding (Chazal & Gerlier 2003; 
Salaün et al. 2004). Viruses can also perturb cell signalling pathways by interfering with 
proteins in lipid rafts (Krautkramer et al. 2004; Avota et al. 2004). Moreover, several 
studies have shown that HCV replication is associated with ER lipid rafts (Shi et al. 2003; 
Aizaki et al. 2004). Therefore, lipidomic analysis of HCV-lipid raft interactions may help 
to explain the abnormalities of lipid metabolism that is associated with HCV infection. 
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Interestingly, after isolating the ER-lipid rafts and analysing each fraction 
individually, it was elucidated that the HCV-induced increase in free cholesterol levels in 
the ER was lipid raft specific. This was evidenced by the fact that the ER-lipid raft fraction 
in the HCV-infected cells exhibited the highest cholesterol band density when analysed 
using HPTLC and commercial standards to identify free cholesterol.  
Next, it was important to perform further detailed lipid analyses of other sub-
cellular compartments, particularly cytoplasmic LDs (LDs). LDs are organelles that are 
used for the storage of neutral lipids within hepatocytes. They dynamically move through 
the cytoplasm, interacting with other organelles, especially the endoplasmic reticulum 
(ER) (Martin & Parton 2006; Blanchette-Mackie et al. 1995; Vock et al. 1996). These 
interactions are thought to facilitate the transport of lipids and proteins to other organelles 
throughout the cell.  
LDs have recently attracted considerable attention because of the link between the 
accumulation of LDs and human diseases such as obesity, atherosclerosis and HCV-
associated liver malfunctions. Additionally, the size and neutral lipids content of LDs 
increases in Huh7 cells transfected with HCV genotype 3a (Piodi et al. 2008). However, 
the actual role of LDs in the complexity of the HCV life cycle, especially HCV assembly 
and release, is still poorly understood. This research sought to clarify this issue by 
investigating how the HCV virus particles interact with LDs, with the ultimate aim of 
identifying new therapeutic strategies that can protect against HCV.  
Notably, the results indicated that triacylglycerol was the most prominent neutral 
lipid class in LDs and was significantly up-regulated in HCV-infected cells (Figure 4.13). 
This finding is consistent with data published in existing literature, which highlights the 
important role of triglycerides in the HCV life cycle (André et al. 2005; Negro 2010b). 
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Phospholipid was also higher in LDs extracted from HCV-infected cells than it was in 
those extracted from naive cells (Section 4.4.2). 
To provide deeper insights into the effect that HCV have on LDs, the protein 
content of purified LD from JFH1 HCV-infected Huh-7 cells was compared with LDS 
from uninfected Huh-7s. Using protein gel electrophoresis and Western blot, an HCV-
induced increase in DEAD-box RNA helicase (DDX3) in LDs was observed. This finding 
was consistent with that of previous studies (Ariumi et al. 2007; Oshiumi et al. 2010). 
However, work by Li et al. identified interactions between the HCV 3‘UTR and DDX3, 
which contributed to lipogenesis by stimulating SREBP-1c (Li et al. 2013). This data 
suggests that the interaction between DDX3 and HCV core on LDs is potentially important 
in the replication of HCV. Understanding the viral strategies for manipulating or co-opting 
DDX3 could provide valuable insights that could benefit the development of strategies for 
preventing HCV by targeting DDX3. Interestingly, there is accumulating data in existing 
literature that indicates DDX3 is also important in the life cycle of several other viruses, 
including human immunodeficiency virus-1 (HIV-1) (Yedavalli et al. 2004) and brome 
mosaic virus (Noueiry et al. 2000). 
This research also included the hypothesis that the interaction between DDX3 and 
HCV core is required for the process of shuttling HCV core protein between the cellular 
compartments (a vital step in the life cycle of HCV) and mediated by CRM-1/exportin. To 
test this hypothesis, the effect of leptomycin B (LMB, Sigma), a specific inhibitor of 
CRM-1/exportin, on DDX3 was investigated using Western blot. Notably, leptomycin B 
significantly reduced the accumulation of DDX3 in purified LDs from cells infected with 
HCV (JFH1).  
Collectively, this data suggests that targeting the DDRX3/CRM-1/exportin 
pathway may result in a novel host-targeted agent that prevents HCV. Generally, host 
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targeted therapies for HCV have a higher genetic barrier to resistance than direct acting 
antivirals (DAA), which target variable virus proteins. This makes them attractive 
candidates when used as part of a combination, as oral antiviral therapies in the future. 
Finally, the research sought to compare the relative HCV-induced increases in PC 
levels in whole cells, ER fraction and LD fraction, to determine whether the increase in PC 
is global, or more specific to some sub-cellular organelles. The results revealed that ER-
specific fractions from HCV-infected cells contained a higher level of PC than whole cell 
extracts and LD fractions. On the other hand, there was no significant difference in PC 
increase between whole cell and LD fractions. Again, this emphasizes the vital role ER 
plays in HCV replication.   
Another comparison was performed for the changes in PL and neutral lipid in LDs 
compared to the whole cells changes. After analysing the neutral lipid content of LD using 
HPTLC, TAG was the predominant lipid class detected, with up to 40% increase in LDs 
from JFH1-infected Huh-7 cells, compared to less than 20% increase in whole cell lysates. 
Similarly, during the PL analysis of LDs, PC was the only PL detected, with significant 
increase that was similar to that found in the whole cell. This reflects the importance of the 
LDs organelle in the HCV life cycle.  
Based on these findings, a hypothesis that HCV infection induces wide metabolic 
reprogramming, resulting in the accumulation of PC species in the ER, through effects on 
the choline pathway (through CTP enzyme) and methylation pathway (PEMT enzyme) 
was developed. Effects on PEMT may be particularly significant as they could lead to 
higher rates of consumption of SAMe, the major biological methyl donor, which may 
ultimately induce interferon resistance and lipid accumulation. The roles of SAMe in 
steatosis and interferon signalling are well established (Duong et al. 2006; Lu & Mato 
2012). 
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Chapter 5 described a series of experiments that were designed to investigate 
whether inhibition of PEMT in HCV-infected cells: (1) affected lipid accumulation; and 
(2) enhanced IFN-α-induced expression of antiviral ISGs. 
In the cell culture model implemented, HCV infection increased the expression of 
PEMT in Huh-7 cells (Figure 5.3). Consistent with this, PEMT expression was elevated in 
patients who had chronic hepatitis C (CHH), particularly in those with genotype 3 
infection. This is associated with elevated HCV RNA levels and more severe steatosis 
(Figure 5.8).  
Inhibiting PEMT activity using PEMT siRNA led to two important observations:  
1. Inhibiting PEMT reduced HCV infection in vitro, most likely by altering the synthesis 
and simultaneously enhancing the secretion of lipids. HCV-infected cells have increased 
expression of genes involved in lipogenesis (SREB1-c, ABCA1 and LDL-R), and more 
intracellular lipid (Figure 5.16). Consistent with this, in human liver biopsies from three 
independent cohorts using three different techniques (microarray, RNA-Seq and RT-PCR), 
the hepatic expression of PEMT mRNA correlated with the degree of hepatic steatosis 
(Figure 5.19). Furthermore, the hepatic expression of PEMT was higher in patients who 
were infected with genotype 3 than it was in those infected with genotype 1 (Figure 5.8). 
These findings are consistent with the well-described direct steatogenic effect of HCV 
genotype 3 (Adinolfi et al. 2001). 
 2. PEMT siRNA pre-treatment enhanced the extent to which HCV-infected cells were 
sensitive to IFN-α treatment, as demonstrated by increased STAT1 phosphorylation, 
increased ISG induction and, most importantly, the reduction in HCV RNA levels and 
infectivity (Figure 5.11). 
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This improved response to IFN-α may be due to the increased intracellular 
concentrations of SAMe, restoring STAT1 methylation and improving IFNα signalling. 
PEMT catalyses the synthesis of PC by the sequential addition of methyl groups from 
SAMe to the amino head group of phosphatidylethanolamine (PE). Methylation of 
activated STAT1 is catalysed by PRMT1 and requires SAMe (Figure 6.1A). 
Thus, silencing the PEMT pathway should prevent the consumption of SAMe in 
the synthesis of PC, a process that is enhanced by HCV infection. This should lead to 
restored STAT1 methylation, decreased STAT1 association with the inhibitory protein 
PIAS1, activation of STAT1 binding to DNA and, consequently, increased IFN sensitivity 
and decreased HCV replication (Figure 6.1B), partially independent of decreased levels of 
PC, as the latter can be compensated by the PCYT1 pathway. In support of this hypothesis, 
silencing of PCYT1, the enzyme responsible for the majority of PC synthesis had no 
significant effect on HCV replication or infectivity (Figure 5.5). This suggests that the 
effect of PEMT silencing on HCV replication is mainly related to altered methylation 
STAT1 and is independent of PC levels. 
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Figure 6.1 Schematic diagrams to explain the effect of PEMT inhibition on INF 
signaling in HCV infected cell. 
HCV induces an upregulation PEMTleads to higher consumption of SAMeand decreased 
methylation of STAT1 byprotein arginine methyltransferase 1 (PRMT-1) enzyme inhibits 
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the enzymatic activity of protein arginine methyltransferase 1 (PRMT-1) resulting in 
hypomethylated STAT1 associates with the inhibitory proteinPIAS1 (protein inhibitor of 
activated STAT1) leading to inhibition of STAT1-DNA binding and,therefore, reduced 
transcriptional activation of IFN target genes activation (A). 
Silencing the PEMT pathway should prevent the consumption of SAMe in the synthesis of 
PC, a process which is enhanced by HCV infection. This should lead to restored STAT1 
methylation, decreased STAT1 association with the inhibitory protein PIAS1, activation of 
STAT1 binding to DNA and, consequently, increased IFN sensitivity and decreased HCV 
replication (B). form(Duong et al. 2006) with modification. 
 
 
 
Taken in combination, the data presented in this research suggests that PEMT inhibitors 
may be useful in patients who are suffering from chronic HCV infection. They not only 
have the potential to improve the treatment response of those who are refractory to IFN-α, 
but may also improve many of the HCV-associated sequels, including hepatic steatosis. 
The possible importance of the PEMT pathway in other HCV-related complications (e.g., 
liver fibrosis and HCV-associated HCC) deserves further investigation. 
6.3 Future directions 
The results of this thesis suggest that reversing the metabolic reprogramming 
induced by HCV infection is an effective novel treatment strategy that deserves further 
investigation. Until now, there have been no robust therapies developed to target HCV-
associated consequences such as steatosis and fibrosis. Understanding and correcting 
HCV-induced metabolic reprogramming and its deleterious consequences could open the 
door for future novel therapies. 
 The results associated with the use of HCV as a model are encouraging and could 
inform future studies involving other viruses that are known to be dependent on cell lipids, 
such as HIV. Furthermore, the results of this study may also have implications for other 
fatty liver diseases (e.g., NAFLD). Indeed, several candidate gene studies on mice have 
emphasised the role of the PEMT pathway in hepatic steatosis due to NAFLD (Lu & Mato 
2012). 
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6.4 Conclusion 
In conclusion, the use of an HCV cell culture model in this study provided a valuable 
example of the importance of dissecting the role of various host cell lipid species in the 
virus life cycle. The research demonstrated HCV-induced global changes in cell lipids and 
highlighted the fact that the effect was more profound in the ER fraction, particularly for 
PC and cholesterol. HCV increased hepatic PEMT expression in vitro and in vivo, 
increasing consumption of SAMe and resulting in hepatic lipid accumulation and 
interferon resistance. PEMT knockdown in the model reversed HCV-induced metabolic 
reprogramming, with reduced lipid accumulation, improved interferon sensitivity and 
decreased HCV replication. The observations made in this study open the door to several 
new and exciting avenues of investigation. These should further improve understanding of 
HCV-associated pathogenesis, and hopefully lead to the development of novel antiviral 
therapies, not only for HCV, but also for other viruses that interact with cell lipid pathway
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